var title_f22_16_22784="Anal fissure and ulcer Crohns";
var content_f22_16_22784=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perianal Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 194px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADCAWwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3yRvmAI4qC4IwNpOatSbj2BqrP94DGOfWvmZp2Z68NytMoXBJyT71UkBDEBsAdandwzMvAHpWbLznbIQa45+R1wTJH+cjaRnrxVK9w0bLGMt0waXcVVjHkknioVdlRtw5PG4VzSaOuKsZt1GyKjFssazri2WYgDPzfe461u3HyxqqnLemKqsjCMEbfy6VOiNeYw7/AE6NGUEHAHQNxWW2nwiCR5IlG45BPP5V0l2MN8yqyjqCaybsrKTGGAAHBNbRZDsc9LJFBcfvVVQgySfSsPWrozhzHGYrVuCzr97/AHV6109xbRwyAs2GYZPAxWBqwtoElub502gcBjwPoO9dUJRT7nLUTexyN7HaGLYqBSASFCF5H9uOlUbWCC0juLy8twk7nZFGOgwB0989TWpPPLdL5kZSyt9p5ZdrFfYds+9cjr2ptczxWthGfLUeXnB4B7Z7Zruo803yr5nFOCj7zJLFPtNw4tn/AHB2+dInVs5J/wAB7VuKqMnlw58ovtjLnn3I9uKboFglnGlvF8oZsHd1bHUn6/yq1r9ylpAyQFDKCTkjA29z7Af0rOpVc58sTop01CF5HMw/uLq7gmVmKyFQ2eMdv8atXduhiW0aRYw7KHdzwBnBP9azLOGRlku5vMWRyznK9vf/AD2qaWO4voreGFGM8xPljsRk9K63H3lqVRS5W2UbyFbPU7q2U8RSsARyCOxHsRW9oWp/ZXBt22MGDZHc9/0xXJzxm0P74nzSTz9DjpVu1uEjIctjnbn1/Ctq1LnQsFWVOWp3WvQx6zpxCbd7qSAT+Yrz3Ri0N1LbXbsoh3MsbdN1dBpuri2lIJ3qe57Voaxolnr0K3Vg4gvgOp6P7Gs6M/Y3hLZndj6Sr8tanq4/iv62N/QgZYozGc5Gcnp061dum6KzHzB1Pp9K5Xw5Hq9uXt7i38oKM73bgfTHWrGr6tDaKI1m3zMPnbd29zWU6d3od8MbFQVyxql2pgcI3yAgDHdvWuZuL3cNp+4MAkenWqV3qhuVHlHhf61nG7UR4OTJnGK0p4drVnnV8dCWz0OmXVIPJt1DcBCMA85rQ0+9Fy4YnhRtLYz9P8+9cIquHMrZHbFdDo16IjkK24jrjge9KvQSV46k0KyqO0tDt9Ou5k3zKB5EO0Ic5+b6fj/KtOTWjNJIAFLEYy3Q4HX/AOtXBPqbtdStJtYkcqowufXj0rQsGe4gP7wblBJODl81xum46nVJpOx6DYXS2KJHAC7LGxO5upP8ua6SwXytPWIuXlkXcc9SvQY9K8vsWuDG6M0iySsEQevGc/hmu/sb65jtXzGv2aNdrTHBb0xWsLPc46mmiNTxAZXs7a2jMEfmlTIjOT+7HJ49OMfjWVfSiLQ3WeUxKAWG0bcD2qAst5Nc3cW2MKgjjLZJbuQPSuX1+8aUfZpJDtZivoAMEj/9dOUkcri9WXZdVfT9Fj86XZI7NI6E5IfHHH5ViS+IIrq1EsrqHiwqk9yOOfY1n35L2Es8DPJJIoG4jIXjBqjYaTPvENthwFGXIyM0+eNrnO6UpaImbXWguDJYMzN1WRGw6HPBBHNepeBvjPr1gBZeKbOe+tlAC3UYHnKP9ofxfXr9a890/SPse9L2P55GASRB09s1u2+lTxp80TyHPyODkj6+tP28VsZfU533PofQPiV4b1RFVdSijl7xzfI36111vqFldxg29zDIO21wa+YLfQjPjKEvjcuR+n1q/Z6Bn545ZklLZJVypH5U/ryjubRwE5H0wswU8tVS6YGTcCK8OtItXiKxRahfHb93EpNdDZajrUKjffNLg42sAcU/7Sh1Rf8AZs1s0emM+0daj80BwR61xdrreqPkbYyB1yKupqd3Jt+RPerWY0jN5fVT1O+tJw6Dmrqycetef2mrXMUmGAIzwfWt+DXFMYz1rppY+lLqctbA1F0Hum1R1zVOdGyMg5rVbbkAVSuFbPB4rhqU9DWnPUxLoMjbyPbis24bMmB3ravFYRsoOe9UPKHyu3QV5VZa2R6NOXUpxICW64/nTGjYDA5GavOpQYwME9aidclckAZ61ytGinqZ8u5c7VznjkVWlT92ASQvqK05Iy7Eq3PTpVWcLznIx0qWmaKRg30DMDs+VAOvrWXdB2YtnCqOhXrW7cxLkLuPPPPaqVyGf5DtwKqJocPq324PIV2MByHPA+mKyW0Qoxu9WkFxchSYoQflGfb1rsLi1++0smHI/hX/ABrCvLYC3uADtjAPzZyze2fSumD7GU433OIaE3t9cRqUkkVOCWyqNnkn1IHQdqz4rb/SvLgJmSFiWc9WY8ZP+e9dHLDHY2pgs123jjG5h93P8R9TWRrDxWuy1TbGmw5ZzzI39STXXCTfuox5UtWTNc27XZnkbJ2s2xeuOnb1yK5W6dtWud4ZzbIyxZHVuTx9P/rVo+Q8dgGkJWafDS56pF6U/RogdLmkjiGDnYMdMnjHv0/Kt4WppyW+xMk5vlMnUxPE6rbbnSRfl4yWx7ewJp1u0k8DKshUBNiHBGMen4itbWbNbRo8k+cihQRwUOAfzOKx0DW0wgUky/e3bccHrxW0JKUFbc6I03GTT2Zz+oRNGhSRxI3rnPv/AFrP3tjqa6W6tBGu/wAvfuzkHoBWTJbSW8oIUbnHynHqP516NKqmjysXhZxleJViuGjOQfu84PIrQh1uaB28tiqkngcYzVBbVyfl/Sk+zN6HHrVyjTluYQniKfwmxc+KL2aIIZWxt2k9yPesWa4klJLMefeh4GGAATQLeQ4wp5OPpTjGEdiKtSvU0kRhm6An8KtWcF1PdCK3ikmnfICxruY9+MVYt9PbzFBZSSMhQevFdToukwyqgnLxgEfcbDZ/z3rKtiYU1c1oYOU9zmrSC7BEgiLt0UE5A/CrUdteQzB2jLIcggnAyRXr2neGLVEP2eFEwchOp2+pP+FUfEmju0RCxKAgPCL19K8+eOXVHtYbLrtK553p/nrdCXCtIo24bofrXX+HxFJO8PkbZMHAfO4eoHaucVfKYjHI61vaZG97tZZfKbvITnGOmampNy2R7X9nwUb31OnsLaO1uIJ3JOVbCH7wOcc10Ukxhhc/IAqjKjnBx1NcJLqZfV1t7plM6xFWOcKWzlcfhXQxXdpI0YaQsrjLcY/A/wAq5as+R2OP2Dt7xMdQaOFFlcZ3YPZQp4rNMKzatcJtPlkABj9ODV0fvbsRmMlGHyjqCM/zqSS2ktZl83B3DGSPvgdvrWPtnIwdBWsZEemLb3bI0ZCTZDBc/Kff61p2emizuFLIQhG3zVPDem4Vav8AS5lgW5s5csPm8pjkMO4zVrT5bkxIrxJJCRg88r7GndsSpJGnb6YbiMB9nlnFXbWyez5aJiM4+X09ataZFKoX5N8XY+n+NdFGIXQAjKgYyRS5WJySZh2kDbtrYB9D2q/b2irc5VWIPB9K2YrCIKQmG3DkdcVZhtwp8uJQWA+7jgCq9kyXWXQyPIZWwqlSDwfWr9tbIMjoTV5LZkTdNgjPK4pqhWYHAGGwM+lT7KzE6t9ERwWmx/u/L7Gp4Y1BIC7V7GpSVAGwjHf2qISoqN39Kfs0jPnbJGjXb7U5toOEHA96rSTPgBvxNQvNlv8A61S7dCdTvnguF24jVh3KtVLUrO7aJngj5HRAclq6MjjpTSBtH1r6eWGhJWZ87HEOLvY4u9srq0eJp2LpMOSB9w+lI0QKYIAArqNV/wCPN+ARkdfrWBMrbMhc+iivEx2HjSqWjsejRrupG7Mu92nb61VdUAznJ6c1pyrzggD61AIVKkFFHfrXlShdnXGaRlyFlQ+UCc+3Sq7nLZYYx2zWi68ZXOO/FUJ7beWfeRms+V2NlJX1Mq7Te5Z03Y4C5xWNNOHcoJDEV/hYcH8a6C4R0GHUbPXvWZfDzIEXCALnsOaq1tzeLObuw3zSNGXfOOvGKr6tbvLbKflJlIAUHgetak0Ijhk3jMPcAnNczrV4qQy2vlvG5GQ5U4VfWtYK7FJ2MS9uoZHllI3TlykYXoFHG7FcprNsXnVkBd96rvYZLZ4x7cA8VvzW1tbwRq7k3MzDdg9FHRfaovLiW6Z2U/ZIWO1s5LPwOPoOn1rqhLld0ZON7Iw9fjlgso5HP+kyMN5xxx/D7gf410mnWCQ2SNIVZgmV3HADYGOPbmmPZG/1ODz9pjjLMkR6DsGP+HtV+6R2tI1UFYgp3SL3IHb68c0TnoomtKnq5GIIEnuHludsvmncFI7A4/yKytTsfIuzKilSF5z/ABfSuovmllvosRqixR7QqrjH4fTH51nTxorySM4abjdkZRD6fQDH406crHXFJ7mVDBiyK3EhXcd4yAeeM7qh1WwJtor5JJWeLJYEclSMcD055rTu7iKaUSWUIvdgJLCM7fl+uAakXTri/hiEaXCxxgGdmbeqZPGMAADOAAa64XT5tjmqy5o8q1OVXQXlgTyXjZWboG+ZRnuOuDxirq6Z9lINwrFiNpUj5dvTj8q6sWtrHHBBbpFEyrtkkTJLHPJyc81UubQu6s7mXAI2le30onVb2ZVLD8urOdl02KKPG2MAckAEbh/Wqltpokm2qERWyfmP3f8AH2rqGspyrAQgoM4dmxg+mT3qzYaO9zxFBjC7t7enrk0KpIzqwTOctLIxqGeNSVOM7e3t/jXWeGNImnEkltvZBjGFyOnfjr+Vblj4TaSRbONHa78vfgYx75J/oK9I0zSU0dBbQzRRq4G5c55x2yeD7niq5HPc5l7j0Of0bT5pLbKW8jBQcv5eOMZP/wCurk+nRPpM0jxkBhgMQcetd7pN9YtaW1tqdq8VxcvhIIlD+aMdT2ApmvTW11pklvdSRqXYlApI2DoMjpjAxUywKa5ubob08ZLnSt1PlnUtMuLjUpUsLaSZlyQsSFiyqMlsDPYEmqNle3FvGUhlKxlgxjPRjjH8ia9ttdHufD6XxFlb3stwCLVmkZTG5BUnKkEqVLZHsOex8bvtOlsZpYLxVjkQ8g1FnCKUtz6mlWhWk3HZW+ZpeIvD9zBYWmpCGa2myuI3TaWB7jPXnFQWV7sKtcIsqlvnQHnFdfo3jqe48LLoeteXqNiI2RGnXMkPy4XYx7A4P4VmaXo0HiOznuNK+zwa7bD97YbipukxnfGp74BJFbVaMasU4nlVqs6TftFa7LFjdRO6eUGS2U5RXbJXnoTXQieK4gQtEXAOX5zx61yVq8ltCxMSmJmAkR1IZfTjtW3Y3S70dWzu9UIP0IHB/CvLnBx2OZTjezOgs7WFS0kMzrjs3I5+tWbdMz5VYy2MFBwR9PWoLSRlyFAZXGcg/wA6vQPGZlyuVPQjrmoUmJl22SGGQgSfOTkDOBj0xW3bHYgDoxI5BxxWeRbyMpcfMOMOO/1rWtphAqgyJsxxleR7Guum76M5qkmbtkjmEOBGuR0Aq15iovVc9yB/Ssj7Y0UKNCVk7YzULakqnEiFHbg8VvKajocnK5O5dluA7bl3EjjFRSSBV3HOfQis83sWRtDlv901HLcEsd27PtXI6hsolxbvrlgPWoLm6XaMj5RWe9zH0yQv06VlX+pFOM5XvWTk27Gij1NW81JYYt4fAxzk5Fc3c+K7dJSpnK47VxHirxN9nR8SFTzx2ryLUvE00t2zK7kfWuihhZ1tjmrYiFLRn6U0hNLSYr6k+aKOpANDyCfm6+lZDAZ4P4Vs35G3G7nPT1rLlUnkdK8nHxvO534d2iZ9yigk4GaiKDy/rV2VTjkfL61BNGmCVIB9a8qVPc7FIzJl3YCnA7471WnRSO+B2q3cnYw+bj0HeoFkik5XbvHBDdRWKir2Z0RbsZVxDuQsDuz/AAmsXVXWJMFfmJxgDOK3tQBgLMzlw33VA5rm71J5kYxKUlPfGSB7VLjZ2OiD6mHc6g0DyLHHLMQRw2AAfrXNav8Ab9QY+YIoUH8KfMzd+tdDfQxQ2x3yAzDlnZvmz/Kuc8m8LmViSjkhUHVh6k9hThZGklc5x4/M81Qp3oMIzHOCff8AWren28cEcUVysjNGFeLkbd27qf1/GtAaWzNCMh4SS0nP3sdvp6mrF9aM1mksbKIkxtOcFvUj2xkZquZvRAo9WU7WAF/PAYtc9M/wr6/zqzeSxRqLNGLFeQpGARjjP+e1OQTmya65aaRgqLjauOwH+NUNIuI5Indg8lwHKySZGAAegP8AWhJvU2T5dCtvMtzKsTB1jX73dv7zVQniTULiOxiSQ2gPmzMeGcZ4U/U/pV+R0+3SRwoVy27avc/3RWzaaE9oTdGMFnbfJu6D0ArohHl95Cc2/d6HK+JNYstJ04RyqAIx+7iTADt6cdh+lN+GmrjxB58F5IqTRvuKLwpUng4746fgPWu11jwJB4nSFtQtPK3fu4GT5ZD/ALWew46GuTv/AIXeKfhlrNl4htrc6vpETA3C2w/erEfvK6c9s/MMgEAnFehQoQq03/McNfE1aFWL+x5HbT6KzNClup27txfHy5/pUsvhhpY/3CtLcOxCInzZ9ff1r0CWfSrzR4LrTZBLaXcSzJhwPkIyOW9e/HbFZOk6ibaGcS2yTSs6sGaTZjHQZHaonQUHaR6FOrKceaCMnT/BkHlRsqR/aJhnMuAFCjLcc4/rVfU1tdHiivL2cIwwIlMZY4znhR1pmveNil1N5jxqTxsjOdoHYH0rhr/Xr+SaDUL5C9n5hWBZF+U45IA7j1/CsnUgnaB10Mvq1XzVNEeoad4l0V2lvbbUA+oSr8yOoV/UgJ1Aq+sc1xDAJJoLZmxKW3AyPu5PC9PxNeM2ltYeIdSijQtbySqUXA375jnYoBxtU8DJJxiqS6jq2ham9gJpoSs3kyRhslTnBAI6iqVVtarQuplcY3cJarXU+hrbUbXSpGuZJYY3VAokkxmNcfwryea8217VYZbia7juJLyWeQpCmdoUeuM+tVLnywqpNcGWXHLENyfUGqtxbXKJI9sU2qOi/K/1Ga1qVW1y2OKlhUnz3Op0kwLYSTXpR77aWaV5mA9lCjiuU1vT7O/0+8vY28xkBL5BJHHA6c5/pSW7o1uwvZI1kXPDEnJ98c1lJLOLeeC1lZIHBaRS2Aea53V7nTCMoNuLMPRm23JingYwABkfGdo9D7V6Dp2k6fqdvNJ5MMdzbqGSVcgrk9sHJHriuH0SKVrpkd8JHna/B57/AIe1a+oQ3NlJHdI6NGTyUHA+o7VLrNPQWITnHlb0JPFmivYSK2jyi2LKpltZWLBj/fXPY+35VQ0++kRvJaMwXCn7pJA+oPSuggvRfW3lSzmR0G1TuzhfQfrWZDZjzWt1x9qhB2seQw7ZrOdSMlseS6E4Sumb1nc3D3IAjGSBgB8H8q3NruwcAY4x9a5rR7W4uUYQFvtKfNIn3GX/AD7V01lAC7RSSSlozycE59wa55RNY1GjXtJX+QzgAY6Z/kK2Ibq1WMYkJUcdKz9OtbJ2VIt8rJ6uTj1rditn6JEyxgDGCta0zOc+4y6ZGt96xF9w4YECqoYNH5i4GeRzmtdIFZB5iLuHXODTZYAT+6I+b1XpVVFciM1sYxldjvkGBnp/WonnYgqoIz0FaTWzbW805wfwqo8RBCxIOTyeuK5JaGykmUJcqMLhmI6elcvrshWN8NjA5JrqZIHVCTyx6sfSud161aS3YYDMcn6VKlqNnz941v2adowx71xtdL41iKak4IwATWNFbExqxH3hnpX1GF5YUUz5/F3dRn6i0nP60tNz8vBxXacJTvOXAxzjrVOVMLzzmrNwymbrlunNQnBxuz9a86vaUmddO6SKjIfXgVWmX5OQOvQCrrLgMQTz0qrOGK/Lyc5ya4ZxsdUHcoyRRyDJGD24qnPYpKhVVCuP4u4rTlVdn7wEEDtVUK+G+YbfvYIrF00+hvGTWzMG4s5Y1YGUAYPKrz+BrDlt7eAvsuZndlJY5z+VdZcg9ZHQlhwF54rFvbmCLKxJKWAJwE6/nWUqSWx0wm2cbeab505d4ZAgOQrHk1Qms2uycN5eOpUccdf0robnzruaIS3C2nmYOzgtj3Pb8Kp3JjQyiXYLdW2xqpwGx/TNQoHRzGA0KTpDtRvK3ECMcGT2P+z3qa7hl+0J5SxMxXGzHCj1HbArUtLZ1tnu7hXkY5wAMAL9O9SwQlbfzwuJZIwNrH7q54H9afJbUakYEtrE0Ra/kKwRrxCMgY75Pp61U0yNfsM8qxvbWsjsykAZOegGfw/Ott4LRywm+S0hIaWQN/rTnhSP7ueTVXTydS1K2Em5ITIZvLwfujJ3D8cY71rCkEqnYk0vwhFa3CXDIHmcZd2/vHqxHY+mK7OHT0RoheMhUEMUwcquPvH3NXrXTp1RJbdAr5BDS5/DC8nPTtVmS5stLgeW7uFD8MysA8mfUgnaPxP4V3QoN7mKm3oiKSCG6uorm1DW0CAAszbQR7D1+mTUN5q1nZAvfXf7hQcbnCFsdMZy36CvPvGvjC61CTytK/cog2hmlLsfct0/AACvMdSt9SuJhPNN5hQ53Ek4PrzTniFB2genhsulUSc3b8z07xF480SARiyWAshciCNQsSknOeOXOckk9zXBat4surlcQ3KRKQWYR5J/E1yc1vK86xtl3bgZP+NU4YAMtjrWE26msmevRoRoWjCN/U0Hu2kk3tkk+veres61qGsyQvfzl0gQRQxABUiQdlUcD+ves5Bxgdalgid8qi7jgn8KjbRHfbmalLoFtKUlBLADoc88Vf0kC51O1TLAtMvUjnnjmi00S4nuEjkeOHcwVi5+5z1NdhpWl22mQ7DZNdl3+W8xlTjIwO1NRu7mNauoxcd2zZeZZJAsdmkIRthZSCQRwcnof84qrexvEwlihkOBy78H6/Sp5tUWOSBi6rIy48tEI3e3JqGeeW6XKiPYTuKk8/TrWk7M8lR5WYkzqbdkZSHPzZ4HbrUKJLb2DRCTcZB0Zev+c1ant2mkZnA2ngHPGPrQ6IfIMh/dKcHjiuNqxc432K0Fldh+MbfQDAIratYWSDaTuLcEYqAyxwPmKQujDaTWgk6eUrHb5o64HOPSspWMmrFH+zYnkcCUQXA+6Qv3qkisSL3zZNoHGWxkA4xz7GtmR7Vx5kcKySSDG3FT21nDiNpZ1Xcux4yOF9KS7HLUjbUu3FlasqbGC3G0OpDYJOOx6/hWpDZSSWam7by2/wCegPUe9RWoM5WzeNJVUfKQcn6g10WmNAsS28mTgYPmDn6GuiKUnqcE24jbSKHy1ilhEZxjLdD+NbttarFtMa8kfwniktokaSNR88WCDGRnHpir0dlGSwi81O5XOFzXRTw+tzlqVCFmKEqYiSehA4/OqczsHIEZHXJB6Vom2UtggqR1yT0qOaLZjGSo7GpqwdiINXMh1VsCQ5BPemTGOLgbRjnOauXK9Mx4HbHaqFwCQEKjmuGcWjqj7xRclnJJUIc4FY2r2nmI3z9RW3L8uMrnjqRVG+wkZy2QelZWNbWPnL4h6LI15+6GSfQUaN4PurnToZJBhtuCMelevR+Hf7U1De6grnniu8sPC8MVqi+WvHtXr4eUnTUX0PExclKfuntRPHJxUfGB609jwOO9QzMEidiMgCvdvZXZwRVzLnmL3Drgfex+FBfOSWzxxVfdyG5AFI023JOAM8CvC9rdtt7no8nYlO0YyTnp1qGQqc4b8M1WuJ1DZU/MevNUJ7w+Y5ONo9fWolVSNI02yzcOw7qUHYnmq/mud3Hy/wAqzLnUMnaWAb3HGKSO6LxkxuD9f6e9RGd2bclkTXsc7gJHKqsOA2AD/OqF7CR81xfJs6Y4BJ6f5xUdzqkcZXzbJ5Bgj5cMQfcdawdQ1i24R9NvxcyYxFFGAzHsOOn1OKvR7fqUvd3LA0pFumlddxILBF+Utn+8evNUm0/+1njUoptrXLOsPRnHRR6+5/CprW0vmYS6i4t7c4As0k3lV/2iByT3ANSahrthb3Edqt5BAgX7g25/ToK0jSS3E6jZJa2/nW/mX6bFHCqeFT6+p/Sue1+62LFHYnMpBCyE4VRkZx/eb3rH8T+LLW7kFtpd6Lu6c7EVI2cN7AkgY+n4mq+g2lzb3DzaxdwrMFB2wHzHReyhfuqPfNNwWyLhJyeh0ek6Lf3sqy3dvFbWrH5fNbzHl7/Knb8fxrrdPs4rELYQuC7ku4jZWlbPPzv0QAHoK4e413T4EDTXEssgXhYpccejNjrz0H50+Tx/awaTs07RxFa+ZiUIzHGehJ7k4OMnsaqFSnA7oYGtUs0rnd+IdZ+yWTwGRHZwCEQkIR6nu/1JxXl3iLUbnUJsrtG3IRTjCj0AHAqvffEnaZkFjb84wJEGV/Eda5O88VNMZGCrubkbUC8+9TWxCl8J7OCy2VLeOpqvL5Yd5SqgcnHArldY1i2VWSJC8n/TM8fn0rOvbuW5ZmuHMhPYngfhVELlskcetYpX+I7pQcdI7jbm+eYkCHn3NSalBe2sVpFNFFDI8YnEkcu8yI3K5wSAR6cH1ot1VN+V+Y9G9Kc2MjA5+laKSWiRk6E5q8piaY5kfZN8snUH1rbsZzZSxsuYpo33pImM8jofUdP19ax7e1mmnUQRu8hIAwM8k4ArYudK1G3jLXNpIhUlSCOQR1/Ksqj1ujuw1lHkqb/mdNa6tb3W0alD++bpMhCliT1PYCu48IaCFZJr2dTbycpGp49Bv6YzjrXjdu8UVzA92DLBwXSOTBK+mexr0fQvEDWfh0SG5ttS0dcLc2RUx3dupbGQcYbtyD36DmtqEle8zix+HfLal1/rTt+HqbGvaDFa6jdukTx5I/dMoZgCOWJBIHbHrzXM3elMrJtlnWXcco+Rkdvatm98QfY57WbRdRFxZXeXijLsWXkgLICOGFRRapdTo0jOs4cEMrLyop1HCTOGEasUuY56eSS2Mqsy7gP73AP0qPT5HmhJnjchTySeD7CtyQ20m9p08sE/w44plssAjKbcsTxuPJFckopbM2bK32YNaBhnOSyEDqKW3sQbjdsJOPmVSRVua2K27JCVK9VUnmqhkMVx5UKu84H3W42j1J9PpWUosxaRctbd47lpbe6kHIBWQbgB3rdtbaJ5Ns0afvOTIOn61h2RmhumectIknB2AYB7V0WnqxCOrFvm+ZCOcUkY1FobWm2oaURTPGQg+SUDHHv710unWkkztICjvGdqh+/uDXORyQTny2V4WzgbhwfxroLeG6sliML+cm7Lhjggex/xrspJX2PLrp/M6PTow1w4kj2zx85Na6qGJGcfXvWTDdRMFl3sCB3HUVpbxJDHJsV04YHPT3r1KSSVkeTVTbuTNagBi2PrWXdQHYzFlOD1FazXcOdpbJPAwMCq935WwrgYA7U6tOLWhFOUk9Tmp0CqMHIz1qpMwCnHzHNbN9CrhUU7W9jWTLEkLFkXcRwTnNeRWptM9KnJNGcwX5g/8QOB71kS2r3dwqJ0rduFV0wmQe+a0tD05V+cjk+tY0KHPIWKrckLLqGkaOlvEoA6VuR2wVcZq1FCAAMGrCoAMV7UaSSPGvc2XINUNVkCWwXJBdgPqO9XieBxz61g61ODdCMNuCD7o7GtsZU9nSbFQjzSRAWPPA2jtVaeXaOTnHrUdxPsRiDye1ZF/f8Alxk5Unp+NfPSn2PTjC5Ne3MSKSzAE/pWRJeKgIIY7uc47VnXd0rTrJMVC+uap3VzGGGHV42OFfPX1FRyvdm6stC/c3gJCuoKf7Izx/Ss2YvHKJLW7YQ+nXP0NVrmU204Maqyt0D55+gz+lY82o3UczizZHweIkg4Oe24n863VNvoS6iRvwzTxxgmYhj8xEjnkep9qZNdMiMUM9zOxwTEwjznn5c9vXrWBNLekNLqTJbMO0Z3DoevPWsnVhGCDFPcicqRGsKtvYnqS2Tj8e2a6IQUVdsxcnN+6jdv9TtgZYbtBA4AygkyxHuc5/OuXubewjuJJktIkWTkmSUKz+27qB67fzq1YW6uhhjhjRMByRKG3Ec8knk9eBU8uhW5nM1paNNFC4Pmygk7c8sUye+egzwKPbp6RN44Z7zKFveXrwCHQNFQlsKWWLJb/gTDp+NY2tawul4gZPP1kZE8UZzHGOMAkcbhznr26V6Td3EfhvQ5ZZ3jnu2jykERDIikZHO7I5YH9Oa4Kw0S2uLNrq4uIoW3M8hYlmcnnHfqaJ+7puz0cJCLd3pFHDMtzeTlpwS7HknoPp7Valaeztnt0un8mRgzRqcZIzgkfia39fNpaSBbKTexUZcrtwcc8Z6e9cu5aR5peWI4B9M96x16n0uGnGS93Yr7ssR1NWZIowI/KlaQlAWGzG1u49/rUCqAeK2NBEaX8Uk2wIhzl+g96U5WR3RXWRUt9PzIBdxzRq6ExkADLds57VQmiJdsAhM8KTkgV23izXrLUZEWzgSNFjCjae2McnAyfU1j32jXsR0yG4eGOK+Akt8zKwUMQMsR07damnOT3ItFxTmrN9DFtbUzx3L+dAghUNsllCM+TjCg9TUYHzfMOa1dS0G90+2a4mg3WomaAXKHMbMCQQD9Vb8jVeBkjlhlht/MMQDSLKQ6MQfTA46cc/WtXIilG+qd0dD8OdKm1jXhbwW0t1tAmkhVwisqkZ3ZI4Feoatqei2Gn+IoroRSXItkW2h6u7sxyVPTaMc46g14nY6lc6ZqAutIuJrWZQQskTFWwRg/gaV5bu5M1zKZJieZHIJ5PAzjpUczS06k1cI69S8naKtt3vf/AIBVuCr3MjIoCk5wB0p9rPLaXSSwvtdSGBxkcc81C0m4nAyxq5YW7TXSI3GwbiAMk0m7I63axtJdyX1p5r2sSyAu0jj5d7liwbaMAYzgADFa4uVtZYpJMYK7ZAScZ+oqnFbx+RMmwyl8N8vXkD06cjpU0CExkXKNvbhs9B6cetZOetzzKvK3obOYmjLLtbPQnPFSRWaNG4X5nQHknp7Vl29ikKktK25egOelasUqmEIWSJ/uq3riqUmcslbYmkS2FtHJC6wzKMc8DNU3mWUSEhSVO6Rhyc9KvRTwvA4KN5uMFWUbT+NVoooJNQM+SibQGDDhvqfSpbvsznuWrMLfwDyULQL1YetaNi08VykTLmPpvl6Ae+P51Ci+QTJGzRRZ5VTuU/l/hV7TLaWb99bmMMTg7+Mj3oV7mMmrGjptxMTIPs0sig4IR1b8RXT6dPPJCoiicx9NrAZHtXMaZDNb3UpuPlGcgxjK10dnPvkYQIzqvJPQE100WcFZXNiHaBhiq7hgqalAeEgRTJ5fUqCePwrPlkEkSljtlX+A84/GmyXBhKhVUsR97PFdHtVHVnJ7Ns2UvYNojaXLZwOKjmvUClVcAnvmsQz5yTt3A9cdT7UxLnG7gbs/nWUsSxxwyvc2JbiJo1IkJY9AO1VXcdskt/DVM3OCW24z1qeKUFCwA38Y3d6ydXmepap8qFSFmb5sA54HtXS6bEBGvArm1nJdSzAHsBXT6XKHjGK6sK1zHBjU9GaSpxTljyO9OTpUo4FeokecTXMywxFnYJxgE9zXJ3VwWld2OXY8nFa2rSPfSJDbAsFOWJGMN0p1hpKwlZLgB5B93/ZrhxKniZ8sdl1NqTjSjd7nNz2t3cRSGJdn93eCc1w/iWLU9Liaa8tzc2n8bwjLJ7leuPp+Ve1iOPecABqq3unQ3MbLIikEY4rOWAtH3XqaxxWup4L9o+024e0kS4gccZ6GormQSBlmeOJCMbG4OO3Favjfwm/hfVv7Ysbfz9If/j8tx1T/AKaL/UDrV6wm0ySKKSxe2GQGDJGHLZHrXDyuLs9DqjLn2OXstEkL+bZyXBjI+Y7l4x1GT/SrkGnXXlKEv7WFeW3S/MxHsCa7N0tJbYuJRMy8fKnyk/UCqqRWt0itOIVRV27EGcnPJ6Ebj6/Wt7JaMqML9DireXTri4YTamGdQQu/K7uM8D/Jpl29hazJcxQ4hkjKzJ5ZEhPcLlhtHTtjuOwrtL0xyOZrlLMWK8NHgl5DjJHyjr789a4rVrXU7m4v7XT4FjtGZXnhmO9UTrtZeu7kd196HFdWdFPToYd7rNhp+vRtpIuEt/LjIk8vLRlsEvg/exkDHQ+/Gelsbm+/s3UI4tPgR5xs/tC4nWJjkkkKCeDzx6/pXC2cNlHe3FvLCsUTOZBg5CMAQMFuByCOK666stNvoRawWkUAGSWhy7N75Of0AqI8sep225oq6OX8QWN3PM0scU6W7OCyNJvzg4yWFQXTulp5aNs4xkiuwsdMkubZbdbi7gtk58tiXbA9c8DPpVOKzS1neBjvDAhCUDbCR6+vHf8AKmld7jc3FNJHnD6ReXYnuhA8sUMZy49c8D3rPWKYQXLSxMAu0YZgpVieDg8twD09a9n0qxWK6SaKFzCY9jm4iO1jjnHP9axvEuiRCNb2by/JTIjfjHPRV5yfpVzjpdG+CxkqMuWWzPLNpTqOak+YqFP3TzXZWukC9kLNEGiJ+UYxk/hWR4oi0bQg639yLe5Khkt0BeQjscdAPckVzQ5qjsos9/8AtHD04805WRj2ACXsaywxyhvl2SllX5hgEkEHjIP4V097p2mx2FtaxzzXV3bsYpPs6ZRXJcABj13MFIzjA9elcFo02o+KNfg0vw9alp5m/wBZLztXu7Y4AH4/rX1N4Q+EemaLGlzNfSaowjxMk4Cq7EYzn+EdcV2LCVWtjzZ55hHK8ZN28tG+2v8AXmeT2PhrUTZ3Vj4ktLpJEdUgLSgPEyspcbeeqMcFuM55q/o3gSW1uLmd44ZbZ8iFZX/eKpPDccFscenNfQF3p+mWsMgFnFHGq7OG3YPH654rnH2MjtEixlXWRYvubuCP5ZxRPB62lLTsc0M4nUTcVb+vXQ+f/wDhEb+W7vkWKGExMxUyy7Aw56ZH88VFb+HNVuI4pA8MCMyoFV9uPQnH555Ne0zW8dzvuJId9s6gKrDGWOAG/wDrd6ieODD4VVAGVI75x+eKx9lZWbO5ZrN6WPJ/+EZ8mUlYmQRBQ7M24bu7E9hViwsFF6ZpcEy5KlGz3AwT616K9mxWQMGETrhymCHJHGc1zv2QIwmMYCspR1xjB46/iPwqZUktwWMlPRsxhFClzLPFCyOoxswcMv8Aj6VowLFKvmxBeTncOc1owWZZUmAWRV4Jzzj6f55psdiJW+0adG6AHLYGVI6cjqPrWTi1oZyqp9SCe0klHls0RDDbxk4/Gqt8s1pbIzxxzR/xBT8x9xx+la0JleRldViI/iPKn8aelpIkZc4eJxlwg3L9cf4Vk3YylOxm6XPBcxPFbbYyEzkjAI+h71NLavbvDIZPMVieNoqm+nyGZzp6IWHJAcgD6qev50kdhdNJI0k8yMFUFBwvrxjp/wDWpXM3OzNEyQo6bZDA4PJCgD8RVnR3kmuWjtGVzjLNkbcZxn3/AArKt2lgTYbWGdWcbjKDuPPckVdS3uJ7lLpYYoolk2II325HQk4HTPaqjruYTklsddBJcwEh5YZXfjyhHg5z25rRiWdk3sYIJPQ8muf07T/MuJXmYvKhH3ZCuAf51twxybcxwc5/iP8Ak1qpHHPyZaSVw4XkuTgdxUdxM+CWcZz3qrLeeU+wlQ3Q84I/Cq1xKXQGMZ3f5zWU6jKjHUmmmdHY+aM4wOOlOSd/LJJ5zz2NZ0e7fyPlPr3qZrpUDNKQqgclq5XUN+VF+1BT7x37T/F0FSyXBjT51IUnAxUuk6ZqWpRq8EQjtnHEsw28eoXqf0q/eeCkeALNqV1k8/u9q/lwa6YUas1zRWhyzxFGMrTlqc7NftC3zc4HTNdL4X1XzSELL7c1xOufD7U45TJZeIbloD1jkjUt+Df/AFqd4Z0G60e8EstzPPnqXfj8hV0uelPUzxEqNan7rPa4JMgelWh0rF027EkS84OK1UkyvJFfQ05qSPn2rMswxLEuFHJOSe5NS4oorpjFJWRm3caygjBGaryQNj91IVPo3IqyRx71GWO0/KQaynFN6lJvoYOuJcNbSRz2v2iIjBMXPH+6a8Y0LxFBoXiabwxIoWCSTdZNNGRtDZzGeePmzjg19Ak5781xvjjwnpvia1miuYYl1CNd9tdquJInHKkEc4z1FedXoNSU07nXSq2VmijNBbhImntjFIeVkjDHn0JABrE1qy+0WwfTYUgSBi0kwh/Me/510Nlbs9lbCeNml2Lks2fmxz0565qQ6bLcR3FtaBEVn5doyqgYGdueTmjk5lZI6oz5Xds88eO71FYVuJ1ilik2iIMVU4HruLEd8DH1rQj0xLRUs7WKadmJeRyu0uxOScdT+NdZNpWn6PYfZ4Y/N1CRGMb/AHeT1YnsB+PYVkW+la3b28kyx2kgYEyDc+8L7Z498cVjKg72Wp0RrrfZHl/i62j/ALSjnjZnMHzbQoGz1GPrg59zXewRpHpkJnkWOdl8yU7cde2c5Paquv2l1eeHr9fso3wkSFmjG9ueVBzwMZ457VdsNKK2Lag8sUMFqm/y3GN2B0J/vdfxrNUrM6PbJ+Q63jhBmitozK5+YMuQBjqT7f4msbU3LTxxxW4Cocl/+enXO09AO2a6Vp4prCFZlkiYqWSBF6j1JH3vx6Vn22n3ep3EMUgSBAwzGMkAH3/z1qnF6JGkZdZFDde6v5nktHaWqIAwUfJCnpk8Z6e59utVDpn9r6pFGku9Y0C+fO+QM+h9T7YrpL9IWD6Rby/Z7GNsyyFMFyPTAqW8tIIFt4rGFoz5ZzuX53HYnPTpV8rfxBGXbTscj4p1HSvDapLqM3kWcOFYpGW81xnCxgH5unrgYOfWvO/FHgzxD8QrG81yS2h0sWqAafYSqBPODjiRsjZ8vIB7ntnNe5xWEE+nCJ7XE4mDrKyB9pUEnGTjIz/Ktjwba2yi8lEYkkL8Sud5bCKCB0A59OtddCNn5s5MT78WpPRdP1OM+EHw5s/AeiQ3M2bjXLmMSXDiEkKMg7FOPujPXuefQDu5ZbuGRreOVYjcAkBxt2k9MfjXSGbbbqW3I+4BwDuIHpWbPp0pkkuLOcJITtdpSXdh7Ht+HpXTOLexx0ppLla0MsN5okXcAsJb94y8nPOMHnqMZ70y5tbfUkSOOJmts5kcfxH+6PTrgn8Kl1AT+W8VoVFyItqbgGJYnrn1A6E8UWhjlbEp/cD/AFUZwjoQOh7e9ZJWVjq5mlzI5iKP7FI0TNmCOdQA68DJBA9wOx61BqVpOz5RY28wfICuM/8A1+tbt7ZmSSU4cWsi7ZU4LEg8FSfQ1kFriVlt5olWPJAJcggDuARwfauacUtGdcKjbujFuWvbONopNpRWJHAyD6Y4/wDrVnwvOsUt3K0U1q7YkRxtaNv720c47V1F4FEDxXpBjIzHKF4kA9f7p+tZqrZlFjhkRo3PI3BhzXLOKT0ZrGrdbGXah7DU3Fr9neG8UN5ZJCnnBI/T/CnXZWC6CTWklvKTtLrwp59R/WrMmkwG5ZFPlbTuEJYgMfVGH3W9xT1hHmiOSSScM+0ySEb0PfPrj8Kyaexoql3cqXmnXKOqrK8cij+LDq3tUiRXNtGR+6lUj5olypB/2c5rbuIns5LdQytbSqQXGRsYdMjtn19qrX8zWRhLIXhdgrvnjBPGDjFZThbUzVaUtzBkjB2SrAGkkYBVXnA9c8flTLm2eC4WYXE7g4Dh+QpHtjOOtbN3b2qXrMY34VWRvL68nnI6VdtoLe8LAks45HPbPJz6+1RZrbcUqqeplRxG7jhldz5LjAK4GSPT0rTtbKJ7pEa3Plj+LgYPrirKaNB53zGZ0JzgH7v4DitZ4Zo1RItrouQWA2kfhWkU7anPOr0RGbZMb1mCNGOSV+8vXB9/enx2bTMJAzqrc7B/D/8AXq7bWqozSS/NIO4YufyFWE4ZS3mLzgBuP0H9a6ORWuzl9o1sY9zYfKcYZcVj3FuAdvCnp16fhXWXESohO773otUpI142FMZz83WuGvFXN6dVnMS27JEzEkqByzcfU1seCPDkmpTpqurJ/oS82tu4+/8A9NGHp6D8at22nC/vo4JOYi2XUnggdvoa7uMBQsagAAdAK1wWEjOXtJbL8zLF42UV7OO7HMcLxj2qlLuZjwOtXZePuDP1qsWB+vevWmruzZ5SdihcruQqRk1kvak84BFbd0BjI61TT5wOeeh9q5px1NozsinZzvCxA6Vrw6iQnQmqvkgyKpH6VMYkXgAYp01JbMiVmdhRRRXuHGIaaSM4NPqN0zyKloaGvGr9SK5Pxg13pNlLqtpiZLdCZYDwWX1B9R1rqumQawvEk4jtpUkwYpEZCD7iuXEqLg2zelfmRmWMztaqwIVSoxhSTmtGFL6QnDRRq2PmaMlun1xniqOm2o+zQrM5chQAvQDA9P8AGtuFJQQQ4K/3T/jXPSv1Omo0noZN7ZLFcwsD587nLOxO7P5f4AU7VxJHaobmRYd7fejG5h/ifwrWm+0lD9mWNXIxmToPy5qjNayNOG1GdpTt+SG3i2p+fJJ/EVu4qzsSp7XOeAjkRUuHaVmfftXhiqnP8+Pxqk1pLLiO7itowJiY4MliSecsfbrx1ro47c28zNaW0S8bQJDnC+pPc9OKzrmP7HeJdXkhknm+XPPPcKgHP/6qxlC250wqdjP1PT4WVREwYoCXlnBIj47KMVVa2uLCT7PA8s11jfJI4VY42YZ2+pYAj2relE2rh0htzbRocKXH7wt/eI/xqWCxtlg8i4kEhUASHOcHvx0JoVO7ujSNZpWZy1roqW8EF7++vLt5vLCeack+ueBz9O1WZ0uWl8obZGdxHtJ3lSCBgEAE96uX9+1tdGFYlkSK4TylTl0GOQfbGTjrTNZmMFrGYGMdzPhfOljLKwzyBj+I+px9amys0jb2jumxwiN8i6a7bEhYkxrwspP94Dkr+OOOc1vac4sR83l7Og4CBBjnHGBisrSkM86NM4LQHazhiNzKCNoP1IGK17C+kv8AULm0dfLit02SEFSrM3OO/bqTzzXVBWt3OWrO+nQt27tPbrcZ2sBgPwCOep9BWe99JcXCLA0gEagsVGS2frxRd2vkWN6mmIbWbcSDEMCQ+rc88nr1rCtNQRruK1hO+5IdiXkAiU8Dd65DZHrmic7NIVOCd2jZvCY5opBmJgAfV3xzk06VYntBJFAVSRTkZyPU8f5NUdJUyXf2i7JlkDbUkkk4zgZwo+7yce9Puru3sdRWScLF5jEKzfKp9M560lPS/QvW/KuhSs55re+kmuv30O0hOgI/3ux9M4rI1Cdb+7MgcI6ZYSGTbgZ6Een1rU1y3d4yWufKHTazDaQecDpx+NUIbW3udMWLfEJVYmV42+Qnt05z9c1yz5r8vQ3jOPx9TMttRgy1hOVe6cjYwIKhT6H0BHPpSS6Yitt8iP5m3kBQQSD1B64zVTUNO827CwAIyERpJLJjcW++BkYPBAwai1CW7s5ZbZ4rw6eh2xzsmWYcZyqjtyCfocGueVra9C+f3tOpsT7rm7ghMBMh4GW9B0AxUE0CRTr5zMhJ2+Yo7ds+tM8PfZLeW4kWSZFdNgkbDbwex9OtXrZXkvpHglM1tvMe+RM7eMYUj73v+FZW5teo3Pk06DljMsyzTSrcW8qmNgRtMbDgH2qvbJbyObXUfL2qGIZxhWUdc1sTxIk0aSM5KKCibflkP90j1+tRz2SNJ9puo4dh5+zuobDfUck57dKclYx57mZb2NwhjlsFRrcEKIpupTPAHcA8Yye/StE2xSYb4dkpz8m/Cgegq1YRxrOfs9qvkN95Qv8AF+PoP51aNvHO4aOBAFzhnXaW9wPSjlutCHN31I7O334DOYz2AkLY/Gri2EbKYlYOc5yWJ/A89ParNpCFh3K2w9wBkf4mrIQkgHGB9ea2jBW1MXN30K6wbEA2LgccHA/Ko5Cf+egAA4wOamQbC4lOVz8uBxVG4zyej7sgdcVnVnaOhUINshuGZSVfPTIzVMHzGYkLgDgjtVm4lVx8/U8ZI5/nVSVo1AVVBUda82q9bnXCOljY8MwoL13B/wCWfY+proY8/aWHtXM+Gp1GovH0DJ0PrXS8i4G305r08HL91G3c8zFJqq7krjdxnHrUUiIQSO1PlOMA9CcGoScMcHjNdys3qc5Sl+WTDenBrOZ/KvWUE4ddwA9e9aOoAFAR1XnjrWNezBJIHH97GfrXNU7FxNaDoDnPNTEhuckVUg+UDbjH1qyDjt+tUttAvY6yiikr127HJYM0jtgUjZ5qMkngmlqykhY/u5PJJrmfHMAl0W4C5D7DjFdIOKwPFv8AyDpOPT+dc1dfumjejpURTsRILaLaF3beSx6VsWseAeeO4HFZUDbIRtGMgY960rWTOcYwPU9a4qVkzqqJs0EAxkDB7Go7iJ2IZZWAHBUAcmo1fchzkD1FSqFIGwlu+c9a7YyUkczTRn3FrIZNoBAKgGYN830Gen1rNvNPjuQsKxkP0aUD5vovf8f51vSBzkLt/GqUm+FpGUF5DwNx6+30qJpFwkzmLSC7TVZYoLxTtO0bF2jbzjJHcYxgfpVm4tSJ4kcE4O77Q+dq+p25xn68fWtlADKskzIJsbVjAwB379T71nPDayapcPJvklVgPLILAH6dB9ay0S+Z0KTb+RQsdL/0+a8RtlswwhUAGYnqzd+mf6dKfc3EiStBFIHhjP3NpLcn7oHcke9aFzPOdo01InnDgyiZ/liHOeRnn2rOljij1KUXcNrHdPHuaQ8lR0GCcdfb3qrJLQak29SjJp80wmi/0mGaQkr5c2I4UznBKnrgk+5q3aQ2dlpMemxag6OjnfMSFkJJyR7sferdxBGrG5W4mkPlg/Z4cKrY/X260hliurWFo0k02ZBuSKS2UZPquev5/WrSQue9i1fiexsR9mh2rGB95uwHBPPPfNcO2tNFeRT3ukEX2ZGVkBCOCOXJxgL064/E812dub+7jkdiYcqFR4ojj3JBzg/jistNLkm1KeW4aSMzrtw6ZLLjgY6cHnBpVFJtOJpScUmnuY/h6fUE0bbKJFluC0jOVEjSbgCM4yF64A7Ac1paZb2i2wubp1urgsFM0xKt9Fz/AEFLpJaa1sYrX908KD7QDwu7HQdh/e59q3CkUNypjh2TsNrXBO7A9Rnov5VEYN2dy5ytocteXJa8jjtrSUxFtzzPD2PAC5659aZqsnlNLbwaeLd5RgDACn0ZgCc4PNat7payxm51Pe0u1REiNwWyccDGTzWVqWgNeu9xqd1OFG1Y1jwV993GTjtXPUhKxSnFtGXp+nW32+1tbK/a41AMT5oO7yh1YkDIHfAzW5NDevcRwyXnlQxHzZEc5yM8cnP5dv0p1iz6ZYiDTpfL/vJGilj9W/xFRahc3BviVOd4yARgLj19qwlKMI+Y/elIrXOn2c08UkdrFLO5J5QFm9yx659M1p6Zp8CWCi2dExh3VTlSx5OR2NQ2wYpHvxuGQSufzqwoWNE2uVOenasY1Vq2EovZCXMD+a29A8e3C9CAOpH+fSmWyhL0MN6KIwAG59e56DpVk3Hyg795BOTjAFVLp3m8tpSirnBVR970qJTSd0VGD2Zdt2M581nHlqeNwxu/+tWgLhACrFAvTr2rKt+F3fOcDgcVahdNpO0gnuwBNbU5kTgXkmR0A84kqfuJzj8qfJOMqSSpHHzIf5GqgnHzIGY+oJ6j8MUiyspxwD0BXFbc19EZ8hNKxeTMYbPQjgdKzrh1VihcqRwVJ/8Ar1O4DZwu7/eY/jUEu8MRFgN2+XH/AOuolHmNIaGfI6LMNrEleu1M1UkmILH52xyS2BWnLGXABcl++496pSwMpJkwD2KiuSdBvY6FMrRXstrcxzooBQ5Gc813+mXsWoQLPA/DDkE8qfQ1561tvHc5G4+uKWye5sJ91rJJHKwx8uCMe9OhN0HrsZYigqyut0elyEk8HIqORwq5Oa4i51zV8hI5VU92Ma5rmr5dQml86XU7nzSThxIRgd+BxXbPGwv7qZxwwU3uz0xpwGJ6isLVSTE6odzDlfqK4+HVdbsxtN2t8vZJ1GR/wIc/nV+DxJE/y6ha3FrJ3P30/Mc/pUOtGfUHhpQ6HUadfh1GW5IBrTikYJ2I9a4RL2FZM28qyQnk46r+HXFbNtqkfkr+9U/jV06ltJGFSFtj1mkoo717jdziI36HB5PvUROFGSM+1SSfeNRN0FFtCiJ5grc9KwfE0m+0ZVOcsvH/AAIVr3HC9K5nWJg0kMf3g0qj8M1yV3aLRtRXvpl2Fl8sEjLduOlWouV5wB6etQQpjLAY7c9cVZVflCgHOe/pXHCNzqky1CRkhTz656VNuIXBI3eoqsGKjg7iKlJYjK9a64q2hzydxHOS2HwOgqGTMZ+Us7AY6c0P5h7jjt0qKRiyY3EEdQv+NKT0KiiFstsLPIQW6ZAxSOiRH96/y9w3T2qZAhjGMZU7R2qvebW+dxwnA/HvWL0Vy09bCQtIbiVonjKlvlVx0HvSXDsbry5kURhN3nYDbvbPX9KpXLW7RlZBK4b0zlsfSqstjBNEQLYDoSc5b9an2tlZF8t9WSapJvCX1qhe5QhTF3dewGDgVqQW6a7aoupRYiGG8hiwZG9Sc9fp+dZ6RQCIwFn2E5O7B57c08XjabdHdcP9n4BJGSrn19u1b06ivzS26kyTatHc1bO12tJAA4hU8NvLZ+uTmm3lnGx/csyGP5gxZjtOOvWsG316KSVmhLw8/vAD1Geo/wDrVXu/ED75ReRsLNshZIGLEDHfvn6VvGrTkio0qnNcn0zQrK1mvFiumEczecxJ53n727k4P+FXNYHnWuwy+WpIBcH5ZR33f41ylrq5N5K1l5bJcZLO5wHI4yB+n5Ul7fxs7pKzLDHHuMeeCfb+g71zupBRasdn1ed02zaj1mQXMb3MPmW0bFYzkFmJGCQvBPHAP1rP1W5/tJW+VrS3ToB97H+e9YEeqNcO8l1E6RnmNBkEj1P+RTUuHmDM0TI+f3aF88ep968+viHbluVGhrdI2/tEEZSbY7sRtBBOMDuatedG6GSREGRhv/r1hRmQbVdARjkkA1NDMGOGUDdgZAAzXFKq3uaKjbY0GvI4htR8j0DZpv2vzSxOwjsR2qoskZJVwGLdTSQjYSAu1eTWE567myppLYueaGUgOSSc46Um/wCXGCDn61WZy4AXBx1xxmpoyTDkrg49c1mpMp6E8dz8uMjdjoasecRGcEHA7GsonIK9zxjrSq00Q2oFOeOTWkZslwNNrna3O09KtRShxnr7+tZUiMq72ILjuPSnwSHZg9D3H9a6Y1LGLjdXRrRyb2ba67vcdKeD82HBJPBNZxJWBiOfU561KjvJCo3/ADHnaD1+tdEaqZk49i66kPGjKRu6L7U0wZJBJB6fSkAwynBB6DnNSlpGbaCpX2zxWykupk5OxH9jXZsCNvzxxxTjZhUYgLuIxx3qbcVKbcbjzjHJqV3GCSp3dNvfNDhFk88jNa2IcZw2eCfT6VWk08MNwXfk8joPyrWkIzuOMsQOD0pGVAhY5znqD1NT7KJXtGjGltEWEoyD1UHvVf7EpYCYoVPRP/r1tGMM42sgIXJ/w5qEKjOTIh4GQc4pOkUpszH0yIvkQhuMZ7flUa6RGyjAjUemM1txHedu/aMcgjiomXJyko2/Sq9kifadz0t/4voKQfcT60UV7h4yGy/eP4VE1FFN7AU7jpXGat/yErX/AK6iiiuPFbHRQ+I20JDcEir0Xb6f1oorKmbSHD/WGnMTxRRW0TNkJJ3NzSQc7s880UVn1L6FdiRK2Dj6fSoLz76/Uf0oorGexcdxr8Fz34qqpOx+aKKye5rHYzr5iLdyCQQMg56c1W1OWQ6MxMj5aM5OTzyaKKcRvdHNsSNVgQE7AowvYZzn+VacbsjsqsVXngHAooqsMdi6GHYMw8TXWCRu2k4PXIbOaj8UsfsduMnDyIrf7QyeD60UU6nwv5nQviXyJdVYgQ4JGWx+GDVyQbXKrwo6AdKKK8yr1H1Q5STGoJOM/wBajkAAbHHXpRRXJIuO5LbkmJSSSc1YhJ2S89QP5UUVLCQsABhfI6mkQ/u2ooqBdSdP9aPp/SpcDOcDJooq4mbEm4j49P61XyQowSOKKKsI7F6DlQTycU+IAKcDGTRRW9Myl1LqdJT3AGPapXJCtgnjGKKK6Ec7HHiTjipJh++FFFbdCVuTSDiYdsj+tVX+7jsBxRRWj3M0QuABkDnZn9adbkmObJJ+tFFEdy5bDGJxJyeGGKag+UUUVoiHsf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Perineum in a woman with Crohn's disease shows a large posterior ulcer (arrow) with anterior edematous fissure (arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alain Bitton, MD, FRCPC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_16_22784=[""].join("\n");
var outline_f22_16_22784=null;
var title_f22_16_22785="Mature cystic teratoma Gross";
var content_f22_16_22785=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mature cystic teratoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mediastinal cystic mass filled with cheesy, sebum-like material and hair, forming a \"hair-ball.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_16_22785=[""].join("\n");
var outline_f22_16_22785=null;
var title_f22_16_22786="Leukocytoclastic vasculitis - lower leg";
var content_f22_16_22786=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leukocytoclastic vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous petechiae are present on the lower leg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_16_22786=[""].join("\n");
var outline_f22_16_22786=null;
var title_f22_16_22787="Hexaminolevulinate: Patient drug information";
var content_f22_16_22787=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hexaminolevulinate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/11/9395?source=see_link\">",
"     see \"Hexaminolevulinate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10503149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cysview&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F11248393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2954144",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with a light test to check for bladder cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F12990501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2954141",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hexaminolevulinate, aminolevulinic acid, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2954142",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood in the urine or porphyria.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2954143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been given BCG or a cancer drug in the bladder within the past 3 months.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F11248398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F11248396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697898",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bladder irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F12990504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F11248395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696026",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into the bladder.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2954145",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will need to keep this drug in your bladder for at least 1 hour, but not more than 3 hours.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F12990502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F11248397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F11248399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16073 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-85249D4AE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_16_22787=[""].join("\n");
var outline_f22_16_22787=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503149\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11248393\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990501\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11248398\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11248396\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990504\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11248395\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990502\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11248397\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11248399\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/11/9395?source=related_link\">",
"      Hexaminolevulinate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_16_22788="Hirsutism and acne in CAH";
var content_f22_16_22788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hirsutism in an 18-year-old woman with late-onset congenital adrenal hyperplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clinical features are similar to those of polycystic ovary syndrome: acne, hirsutism, menstrual irregularities, and obesity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd ed. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_16_22788=[""].join("\n");
var outline_f22_16_22788=null;
var title_f22_16_22789="Emergency thoracotomy pericardiotomy";
var content_f22_16_22789=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Emergency thoracotomy showing pericardiotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Forceps grasping cut surface of the pericardium. Scissors pointing at the left phrenic nerve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_16_22789=[""].join("\n");
var outline_f22_16_22789=null;
var title_f22_16_22790="Smoke inhalation";
var content_f22_16_22790=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Smoke inhalation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/16/22790/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/16/22790/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/16/22790/contributors\">",
"     Charles A Hales, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/16/22790/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/16/22790/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/16/22790/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/16/22790/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/16/22790/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoke inhalation is the leading cause of death due to fires [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/1\">",
"     1",
"    </a>",
"    ]. It causes three types of injuries: thermal injury to the upper airways, chemical injury to the tracheobronchial tree, and systemic poisoning due to carbon monoxide",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cyanide. The clinical manifestations, evaluation, and management of smoke inhalation are reviewed here. The emergency care of thermal burns is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2020367\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deaths from fires and burns are the third leading cause of fatal injuries at home, accounting for approximately 2600 deaths and 13,000 injuries in the United States during 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/2\">",
"     2",
"    </a>",
"    ]. The majority of the deaths were due to smoke inhalation, among which, up to 80 percent were attributable to carbon monoxide poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Among patients with inhalational and cutaneous injuries who die, it is estimated that 77 percent of the deaths are related to pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2020436\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient presents with smoke inhalation, immediate assessment of the patient&rsquo;s airway, breathing, and circulation is indicated. This should take only a few seconds to perform. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intubation is justified if any of the following signs are present: stridor, use of accessory respiratory muscles, respiratory distress, hypoventilation, deep burns to the face or neck, or blistering or edema of the oropharynx. If these findings are absent, the oropharynx should be examined, followed by laryngoscopy if there is erythema. Although some centers routinely perform bronchoscopy rather than laryngoscopy, we believe that laryngoscopy is preferable to bronchoscopy because thermal injuries tend to be limited to the supraglottic airways and the appearance of the subglottic airways does not definitively affect management or predict the need for ventilator support [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/3,9,10\">",
"     3,9,10",
"    </a>",
"    ]. An exception is that we routinely perform bronchoscopy instead of laryngoscopy if there is a history of inhalation of superheated particles or steam, since thermal injury may involve the lower respiratory tract in these situations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upper airway edema or blistering seen during laryngoscopic exam should prompt intubation. These findings indicate that the upper airway is at risk for developing severe edema, which may compromise the patency of the airway. Intubation with a large lumen endotracheal tube is preferable to facilitate optimal management of secretions [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/12\">",
"       12",
"      </a>",
"      ]. Humidified oxygen may help avoid inspissation.",
"     </li>",
"     <li>",
"      In contrast, in the absence of upper airway edema or blistering, close observation for 24 hours is reasonable, particularly if serial laryngoscopies are performed [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/13\">",
"       13",
"      </a>",
"      ]. Upper airway edema will usually manifest within 24 hours of the exposure if it is going to occur. During the period of observation, the threshold for intubation should remain low because the asphyxiation due to upper airway edema is a common and potentially lethal complication of thermal injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who do not require intubation should receive supplemental oxygen at a fraction of inspired oxygen (FiO",
"    <sub>",
"     2",
"    </sub>",
"    ) of 100 percent. The only exceptions are patients who have a history of chronic obstructive pulmonary disease (COPD) with carbon dioxide retention. The purpose of the high concentration of supplemental oxygen is to quickly reverse tissue hypoxia and to displace carbon monoxide and cyanide from protein binding sites. The tissue hypoxia is multifactorial, including the inspiration of air with an FiO",
"    <sub>",
"     2",
"    </sub>",
"    of less than 0.15 during the fire (fire consumes ambient oxygen) and the impaired delivery and utilization of oxygen by the tissues due to carbon monoxide and cyanide poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/11,14\">",
"     11,14",
"    </a>",
"    ]. Tissue hypoxia can quickly lead to death.",
"   </p>",
"   <p>",
"    An arterial blood gas should be sent for co-oximeter measurement of the oxyhemoglobin saturation, carboxyhemoglobin concentration, and methemoglobin concentration. The reason for measuring the oxyhemoglobin saturation via co-oximetry is that standard pulse oximetry may be misleading because it cannot distinguish oxyhemoglobin from carboxyhemoglobin. Standard laboratory studies should also be sent, including a lactate level and a toxicology screen. The latter recognizes that many fires result from impaired judgment due to drugs or alcohol.",
"   </p>",
"   <p>",
"    A targeted history and physical examination should be performed next:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surface burns on the neck and face, as well as carbonaceous sputum, suggest thermal injury to the upper airways, but cannot predict the extent of injury [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/12\">",
"       12",
"      </a>",
"      ]. As mentioned above, the major risk from a thermal injury is upper airway edema, which typically develops during the first 24 hours.",
"     </li>",
"     <li>",
"      Bronchorrhea or bronchospasm (ie, wheezing, cough, dyspnea, prolonged expiratory time) suggest direct toxin damage to the bronchial mucosa. In contrast to the upper airway manifestations of thermal injury, direct toxin damage has lower airway manifestations that typically appear 12 to 36 hours after the exposure. Aerosolized bronchodilators may be beneficial in this setting.",
"      <br/>",
"      <br/>",
"      Direct toxin damage is caused by the lower molecular weight constituents of smoke because of their pH, ability to form free radicals, and ability to reach the distal airways and alveoli. Examples include acrolein, formaldehyde, chlorine, phosgene, perfluoroisobutylene, sulfur dioxide, nitric oxide, and nitrogen dioxide. These compounds tend to cause acute neutrophilic airway inflammation, which may result in disruption of mucociliary transport, increased alveolocapillary permeability, impaired lymphatic flow, worsened",
"      <span class=\"nowrap\">",
"       V/Q",
"      </span>",
"      matching, and an increased susceptibility to respiratory infections [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/15-18\">",
"       15-18",
"      </a>",
"      ]. If bronchoscopy were performed, it would reveal erythema, edema, and ulceration of the airways, frequently in association with carbonaceous debris [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other risk factors for respiratory complications that are detectable by history or physical examination include loss of consciousness, death of another victim, facial burns or soot in the nares or mouth, and wheezes or crackles on examination. Respiratory complications are also more common following closed space fires than after fires in the open.",
"   </p>",
"   <p>",
"    Chest radiography should be performed as part of the assessment for occult trauma, as well as evidence of aspiration. It is important to realize that the chest radiograph is a poor predictor of inhalation injury because of its low sensitivity (ie, most patients with inhalation injury have a normal chest radiograph at presentation) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/15\">",
"     15",
"    </a>",
"    ]. In contrast, the presence of pulmonary opacities upon initial evaluation has been implicated as a marker of severe injury and a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Corticosteroids do not appear to confer any benefit following smoke inhalation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/20\">",
"     20",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2027110\">",
"    <span class=\"h1\">",
"     SUBSEQUENT MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subsequent management of the patient with smoke inhalation consists of monitoring the patient for the development of upper airway compromise due to thermal injury (ie, stridor, use of accessory respiratory muscles, respiratory distress, hypoxemia, hypoventilation), as well as the development of lower airway sequelae due to direct toxin damage (ie, bronchorrhea, wheezing, cough, dyspnea, prolonged expiratory time). The former tends to occur within 24 hours of exposure and is managed by intubation until the upper airway edema subsides, which generally occurs in three to five days. The latter tends to occur within 12 to 36 hours, is managed by aerosolized bronchodilators, and has a variable duration.",
"   </p>",
"   <p>",
"    For patients who are intubated, the endotracheal tube should be left in place until resolution of the upper airway edema has been documented. Changing the endotracheal tube and failed extubation requiring reintubation are dangerous in the presence of upper airway edema and should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/21\">",
"     21",
"    </a>",
"    ]. Assessment of the airway for patency prior to extubation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38183?source=see_link&amp;anchor=H4#H4\">",
"     \"Extubation management\", section on 'Airway patency'",
"    </a>",
"    .) The issue of tracheostomy is also reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11945?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of tracheostomy\", section on 'Timing of tracheostomy'",
"    </a>",
"    .) However, it should be kept in mind that tracheostomy in the setting of anterior neck burns should be delayed until five to seven days after skin grafting [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional aspects of subsequent management are focused on monitoring for the development of pneumonia or atelectasis, and the treatment of carbon monoxide and cyanide poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Carbon monoxide poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbon monoxide (CO) poisoning should be presumed in all patients who present following smoke inhalation until it is excluded by a normal carboxyhemoglobin level, even if the patients don&rsquo;t manifest the usual findings of headache, nausea, malaise, altered cognition, dyspnea, angina, seizures, coma, cardiac dysrhythmias, heart failure, or bright \"cherry red\" lips. Standard pulse oximetry (SpO",
"    <sub>",
"     2",
"    </sub>",
"    )",
"    <strong>",
"     CANNOT",
"    </strong>",
"    screen for CO exposure, as it does not differentiate carboxyhemoglobin from oxyhemoglobin. Carboxyhemoglobin level is measured from a blood gas sample, using co-oximetry. Nonsmokers may have up to 3 percent carboxyhemoglobin at baseline; smokers may have levels of 10 to 15 percent. Levels above these respective values are consistent with CO poisoning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link&amp;anchor=H9#H9\">",
"     \"Carbon monoxide poisoning\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial approach to presumed CO poisoning involves administering supplemental oxygen at a fraction of inspired oxygen (FiO",
"    <sub>",
"     2",
"    </sub>",
"    ) of 100 percent and then assessing whether hyperbaric oxygen (HBO) therapy is indicated. The purpose of both supplemental oxygen and HBO therapy is to displace CO from hemoglobin and other proteins, after which it can be expelled through the lungs. The management of CO poisoning, including the indications for HBO therapy, is discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef60672 \" href=\"UTD.htm?38/41/39580\">",
"     table 1",
"    </a>",
"    ). &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link&amp;anchor=H10#H10\">",
"     \"Carbon monoxide poisoning\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cyanide poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrogen cyanide is a byproduct of the burning of certain compounds (eg, polyurethane, acrylonitrile, nylon, wool, and cotton). It inhibits aerobic metabolism and can rapidly result in death. Cyanide poisoning is nearly impossible to confirm during the initial hours following smoke inhalation because cyanide levels cannot be measured soon enough to be clinically useful and the symptoms and signs (eg, coma, central apnea, cardiac dysfunction, severe lactic acidosis, high mixed venous oxygen (O",
"    <sub>",
"     2",
"    </sub>",
"    ), low arteriovenous O",
"    <sub>",
"     2",
"    </sub>",
"    content difference) are nonspecific and may be due to cyanide poisoning or an alternative inhaled toxin. The evaluation and diagnosis of cyanide poisoning is discussed separately (",
"    <a class=\"graphic graphic_table graphicRef65052 \" href=\"UTD.htm?25/15/25853\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/18/7466?source=see_link&amp;anchor=H9#H9\">",
"     \"Cyanide poisoning\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For these reasons, we maintain a low threshold to empirically treat cyanide toxicity. In addition to administration of high flow oxygen, the treatment of cyanide poisoning includes decontamination and use of antidotes (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    PLUS",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"     hydroxocobalamin",
"    </a>",
"    ) and is described in detail separately (",
"    <a class=\"graphic graphic_table graphicRef65052 \" href=\"UTD.htm?25/15/25853\">",
"     table 2",
"    </a>",
"    ). As hydroxocobalamin may interfere with co-oximetry, blood gas samples for co-oximetry testing are ideally obtained prior to administration of hydroxocobalamin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/18/7466?source=see_link&amp;anchor=H17#H17\">",
"     \"Cyanide poisoning\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     LATER TREATMENT CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If severe injury to the tracheobronchial tree has occurred, the necrotic epithelium will begin to slough three to four days after the exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/13\">",
"     13",
"    </a>",
"    ]. The increase in secretions puts the patient at high risk for obstruction of distal airways, atelectasis, and the rapid development of a bronchopneumonia. The risk for pneumonia is also increased because of the impaired function of alveolar macrophages, polymorphonuclear leukocytes, and mucociliary clearance mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Management of this phase consists of chest physiotherapy and postural drainage. Intubation and bronchoscopy may be necessary to control secretions. The secretions should diminish within 7 to 10 days if a pulmonary infection doesn&rsquo;t develop.",
"   </p>",
"   <p>",
"    Acute respiratory distress syndrome (ARDS) may also develop several days after the exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/19\">",
"     19",
"    </a>",
"    ]. The presentation, diagnosis, and management of ARDS caused by smoke inhalation are the same as that for ARDS due to other etiologies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients may also demonstrate marked hypermetabolism during this period [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/13\">",
"     13",
"    </a>",
"    ]. The increased production of carbon dioxide requires a high minute ventilation to maintain a normal acid-base status, which may require ventilatory support. Use of low respiratory quotient enteral formulas for nutritional support may decrease carbon dioxide production, making it easier for the patient to keep up with the respiratory demands of the hypermetabolic state. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2027324\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients do not suffer long-term respiratory impairment following smoke inhalation. In a study of 23 patients with a history of significant smoke inhalation, there were no changes in spirometry, nonspecific airway hyperresponsiveness, or cardiac or pulmonary variables, when measured during maximal exertion approximately four years after the exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/27\">",
"     27",
"    </a>",
"    ]. Rare long-term sequelae include tracheal stenosis, bronchiectasis, interstitial fibrosis, reactive airways dysfunction syndrome, and bronchiolitis obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22790/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], although most of these cases appear to have followed severe chemical bronchitis or nosocomial pneumonia at the time of injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/28/8650?source=see_link\">",
"     \"Reactive airways dysfunction syndrome and irritant-induced asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link\">",
"     \"Bronchiolitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2020444\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When a patient presents with known or suspected smoke inhalation, the patient&rsquo;s airway, breathing, and circulation should be immediately assessed. If indicated, cardiopulmonary resuscitation should be performed as described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"       \"Advanced cardiac life support (ACLS) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intubation is justified if any of the following signs are present: stridor, use of accessory respiratory muscles, significant respiratory distress, hypoxemia, hypoventilation, deep burns to the face or neck, or blistering or edema of the oropharynx. If these findings are absent, the oropharynx should be examined and laryngoscopy performed if erythema is seen. Laryngoscopic detection of upper airway edema or blistering should prompt intubation, whereas close observation for 24 hours (preferably with serial laryngoscopies) is reasonable if there is no upper airway edema or blistering. (See",
"      <a class=\"local\" href=\"#H2020436\">",
"       'Initial management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who do not require mechanical ventilation should receive supplemental oxygen using a fraction of inspired oxygen (FiO",
"      <sub>",
"       2",
"      </sub>",
"      ) of 100 percent. An arterial blood gas should be sent for co-oximeter measurement of oxyhemoglobin saturation, carboxyhemoglobin concentration, and methemoglobin concentration. Standard laboratory studies should also be sent, including a lactate level and toxicology screen. A targeted history and physical examination should be performed next, followed by chest radiography. (See",
"      <a class=\"local\" href=\"#H2020436\">",
"       'Initial management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subsequent management of the patient with smoke inhalation consists of monitoring the patient for the development of upper airway compromise due to thermal injury (ie, stridor, use of accessory respiratory muscles, respiratory distress, hypoxemia, hypoventilation), as well as the development of lower airway sequelae due to direct toxin damage (ie, bronchorrhea, wheezing, cough, dyspnea, prolonged expiratory time). The former tends to occur within 24 hours of exposure and is managed by intubation until the upper edema subsides, while the latter tends to occur within 12 to 36 hours and is managed by aerosolized bronchodilators. (See",
"      <a class=\"local\" href=\"#H2027110\">",
"       'Subsequent management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carbon monoxide (CO) poisoning should be presumed in any patient who presents following smoke inhalation until it is excluded by a normal carboxyhemoglobin level. The initial approach to presumed CO poisoning involves administering supplemental oxygen at a fraction of inspired oxygen (FiO",
"      <sub>",
"       2",
"      </sub>",
"      ) of 100 percent, followed by assessing whether hyperbaric oxygen (HBO) therapy is indicated. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Carbon monoxide poisoning'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link&amp;anchor=H10#H10\">",
"       \"Carbon monoxide poisoning\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinical suspicion for cyanide poisoning should similarly be high. We initiate treatment for cyanide poisoning in any patient being treated for smoke inhalation with an unexplained lactic acidosis, low arterial carbon dioxide tension (PaCO",
"      <sub>",
"       2",
"      </sub>",
"      ), or declining PaCO",
"      <sub>",
"       2",
"      </sub>",
"      . If these measurements are unavailable, treatment is initiated in the presence of a depressed level of consciousness, cardiac arrest, or cardiac decompensation. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Cyanide poisoning'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/18/7466?source=see_link&amp;anchor=H17#H17\">",
"       \"Cyanide poisoning\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Potential complications occurring three to four days after the exposure include increased secretions, obstruction of distal airways, atelectasis, bronchopneumonia, acute respiratory distress syndrome (ARDS), and hypermetabolism. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Later treatment considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients do not suffer long-term respiratory impairment following smoke inhalation. (See",
"      <a class=\"local\" href=\"#H2027324\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.cdc.gov/HomeandRecreationalSafety/Fire-Prevention/fires-factsheet.html (Accessed on May 27, 2011).",
"    </li>",
"    <li>",
"     file://www.cdc.gov/ncipc/factsheets/fire.htm (Accessed on August 27, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/3\">",
"      Haponik EF, Crapo RO, Herndon DN, et al. Smoke inhalation. Am Rev Respir Dis 1988; 138:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/4\">",
"      Ernst A, Zibrak JD. Carbon monoxide poisoning. N Engl J Med 1998; 339:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/5\">",
"      Raub JA, Mathieu-Nolf M, Hampson NB, Thom SR. Carbon monoxide poisoning--a public health perspective. Toxicology 2000; 145:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/6\">",
"      Ryan CM, Schoenfeld DA, Thorpe WP, et al. Objective estimates of the probability of death from burn injuries. N Engl J Med 1998; 338:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/7\">",
"      Darling GE, Keresteci MA, Iba&ntilde;ez D, et al. Pulmonary complications in inhalation injuries with associated cutaneous burn. J Trauma 1996; 40:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/8\">",
"      Kao CC, Garner WL. Acute burns. Plast Reconstr Surg 2000; 105:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/9\">",
"      Bingham HG, Gallagher TJ, Powell MD. Early bronchoscopy as a predictor of ventilatory support for burned patients. J Trauma 1987; 27:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/10\">",
"      American Burn Association. Inhalation injury: diagnosis. J Am Coll Surg 2003; 196:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/11\">",
"      Weiss SM, Lakshminarayan S. Acute inhalation injury. Clin Chest Med 1994; 15:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/12\">",
"      Clark WR Jr. Smoke inhalation: diagnosis and treatment. World J Surg 1992; 16:24.",
"     </a>",
"    </li>",
"    <li>",
"     Textbook of Critical Care, 3rd ed, Ayres SM, Grenvik A, Holbrook PR, Shoemaker WC (Eds), WB Saunders, 1995.",
"    </li>",
"    <li>",
"     Principles of Critical Care, Hall JB, Schmidt GA, Wood LD (Eds), McGraw-Hill, New York 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/15\">",
"      Pruitt BA Jr, Cioffi WG, Shimazu T, et al. Evaluation and management of patients with inhalation injury. J Trauma 1990; 30:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/16\">",
"      Demling RH. Smoke inhalation injury. New Horiz 1993; 1:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/17\">",
"      Herndon DN, Traber DL, Niehaus GD, et al. The pathophysiology of smoke inhalation injury in a sheep model. J Trauma 1984; 24:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/18\">",
"      Stollery DE, Jones RL, King EG. Deadspace ventilation: a significant factor in respiratory failure after thermal inhalation. Crit Care Med 1987; 15:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/19\">",
"      Masan&egrave;s MJ, Legendre C, Lioret N, et al. Using bronchoscopy and biopsy to diagnose early inhalation injury. Macroscopic and histologic findings. Chest 1995; 107:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/20\">",
"      Robinson NB, Hudson LD, Riem M, et al. Steroid therapy following isolated smoke inhalation injury. J Trauma 1982; 22:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/21\">",
"      Heimbach DM, Waeckerle JF. Inhalation injuries. Ann Emerg Med 1988; 17:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/22\">",
"      Langford RM, Armstrong RF. Algorithm for managing injury from smoke inhalation. BMJ 1989; 299:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/23\">",
"      Pamidi PV, DeAbreu M, Kim D, Mansouri S. Hydroxocobalamin and cyanocobalamin interference on co-oximetry based hemoglobin measurements. Clin Chim Acta 2009; 401:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/24\">",
"      Lee J, Mukai D, Kreuter K, et al. Potential interference by hydroxocobalamin on cooximetry hemoglobin measurements during cyanide and smoke inhalation treatments. Ann Emerg Med 2007; 49:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/25\">",
"      Herlihy JP, Vermeulen MW, Joseph PM, Hales CA. Impaired alveolar macrophage function in smoke inhalation injury. J Cell Physiol 1995; 163:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/26\">",
"      Nguyen TT, Gilpin DA, Meyer NA, Herndon DN. Current treatment of severely burned patients. Ann Surg 1996; 223:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/27\">",
"      Bourbeau J, Lacasse Y, Rouleau MY, Boucher S. Combined smoke inhalation and body surface burns injury does not necessarily imply long-term respiratory health consequences. Eur Respir J 1996; 9:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/28\">",
"      Tasaka S, Kanazawa M, Mori M, et al. Long-term course of bronchiectasis and bronchiolitis obliterans as late complication of smoke inhalation. Respiration 1995; 62:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22790/abstract/29\">",
"      Slutzker AD, Kinn R, Said SI. Bronchiectasis and progressive respiratory failure following smoke inhalation. Chest 1989; 95:1349.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1596 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-C6403DFCA4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_16_22790=[""].join("\n");
var outline_f22_16_22790=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2020444\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2020367\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2020436\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2027110\">",
"      SUBSEQUENT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cyanide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      LATER TREATMENT CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2027324\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2020444\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1596\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1596|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/41/39580\" title=\"table 1\">",
"      Carbon monoxide poisoning - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/15/25853\" title=\"table 2\">",
"      Cyanide poisoning - Rapid overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=related_link\">",
"      Bronchiolitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=related_link\">",
"      Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/18/7466?source=related_link\">",
"      Cyanide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38183?source=related_link\">",
"      Extubation management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11945?source=related_link\">",
"      Overview of tracheostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/28/8650?source=related_link\">",
"      Reactive airways dysfunction syndrome and irritant-induced asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_16_22791="Focal nodular hyperplasia";
var content_f22_16_22791=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Focal nodular hyperplasia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/16/22791/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/16/22791/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/16/22791/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/16/22791/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/16/22791/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/16/22791/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/16/22791/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal nodular hyperplasia (FNH) is the most common non-malignant hepatic tumor that is not of vascular origin. In one autopsy series of 96,625 patients, 8 percent of non-hemangiomatous lesions were FNH, representing 66 percent of all benign non-hemangiomatous lesions seen between 1918 and 1982 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/1\">",
"     1",
"    </a>",
"    ]. In a more recent series of 549 patients referred for MRI evaluation, 188 of 805 benign lesions (23 percent) were FNH. Of the non-hemangiomatous benign lesions, 86 percent were FNH [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FNH is seen in both sexes and throughout the age spectrum, although it is found predominantly in women (in a ratio of 8 or 9:1) between the ages of 20 and 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/3\">",
"     3",
"    </a>",
"    ]. FNH comprises up to 2 percent of liver tumors in children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will focus on the pathogenesis, clinical manifestations and management of FNH. An approach to patients presenting with a focal liver lesion is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=see_link\">",
"     \"Approach to the patient with a focal liver lesion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;FNH has various labels: solitary hyperplastic nodule, hepatic hamartoma, focal cirrhosis, hamartomatous cholangiohepatoma, and hepatic pseudotumor. This profusion of terms epitomizes the confusion surrounding our understanding of the pathogenesis of the many conditions in which nodules of benign appearing hepatocytes are found. The International Working Party of the World Congresses of Gastroenterology proposed a standardized nomenclature in 1994, which placed FNH in the group of regenerative nodules, as opposed to dysplastic or neoplastic nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/5\">",
"     5",
"    </a>",
"    ]. This fits well with our current understanding of the pathogenesis of FNH. The contention that this lesion is non-neoplastic has been bolstered by the reported polyclonal origin of the hepatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/6\">",
"     6",
"    </a>",
"    ], although this is disputed by others [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previously considered to be a hamartoma, a neoplasm, a response to ischemia or other injury, or a focal area of regeneration, FNH is now generally accepted to be a hyperplastic (regenerative) response to hyperperfusion by the characteristic anomalous arteries found in the center of these nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/3,8,9\">",
"     3,8,9",
"    </a>",
"    ]. Whether vascular injury is also involved is less clear, but FNH is occasionally supplied primarily by portal venous blood due to thrombosis of the anomalous central artery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association of FNH with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/11\">",
"     11",
"    </a>",
"    ]) and hepatic hemangiomas strengthens the hypothesis that FNH is a congenital vascular anomaly. Two pathology studies found cavernous hemangiomas in 6.5 and 2.3 percent of patients with FNH [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/12,13\">",
"     12,13",
"    </a>",
"    ] and an imaging study, using ultrasound and dynamic CT, found that 23 percent of FNH patients had associated hemangiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/14\">",
"     14",
"    </a>",
"    ]. Multiple FNH lesions have also been noted in association with hemihypertrophy and vascular malformations (Klippel-Tr&eacute;naunay-Weber syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/15\">",
"     15",
"    </a>",
"    ]. FNH with similar clinical and radiographic features has been documented in identical twins supporting a role of congenital vascular anomalies in its pathogenesis and a possible genetic predisposition to the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;FNH is most often solitary (80 to 95 percent), and usually less than 5 cm in diameter. Only 3 percent are larger than 10 cm, although FNH as large as 19 cm have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/1,12,17\">",
"     1,12,17",
"    </a>",
"    ]. It has a sharp margin with no capsule and may be pedunculated. The characteristic finding is the presence of a central stellate scar (",
"    <a class=\"graphic graphic_picture graphicRef54209 \" href=\"UTD.htm?12/7/12404\">",
"     picture 1",
"    </a>",
"    ) containing an inappropriately large artery with multiple branches radiating through the fibrous septa to the periphery. These branches divide the mass into multiple small nodules or cords of normal appearing hepatocytes (",
"    <a class=\"graphic graphic_picture graphicRef66952 \" href=\"UTD.htm?35/7/35957\">",
"     picture 2",
"    </a>",
"    ). The scar-like tissues within FNH nodules are composed of abnormally large portal tracts including large feeding arteries, portal veins, and bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The arteries drain into adjacent hepatic veins. This radiating, branching pattern produces the spoke and wheel image typically seen on angiography. Although normal bile ducts are absent, bile ductules derived from hepatocyte metaplasia are usually prominent, traveling along the fibrous septa (",
"    <a class=\"graphic graphic_picture graphicRef52949 \" href=\"UTD.htm?31/22/32101\">",
"     picture 3",
"    </a>",
"    ). Sinusoids and Kupffer cells are typically present, distinguishing it from hepatocellular adenoma (HA), which usually lacks bile ducts and Kupffer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/1,12,13,17,18\">",
"     1,12,13,17,18",
"    </a>",
"    ]. The minimal microscopic criteria for the diagnosis of classical FNH are nodular architecture, abnormal vessels, and proliferation of bile ductules [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/12\">",
"     12",
"    </a>",
"    ]. Lymphocyte infiltration, canalicular bile plugs, copper deposition, and feathery degeneration of hepatocytes may suggest cholestasis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inactive cirrhosis. Irregular intimal fibrosis or hypertrophy of the media may be seen in large arteries and veins, at times even occluding the lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/12,13,18\">",
"     12,13,18",
"    </a>",
"    ]. When present, portal veins are dilated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stenotic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Non-classical variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-classical forms of FNH lack either the typical nodular architecture or vascular malformations, but always contain bile ductular proliferation. They almost always lack the characteristic central scar [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/12\">",
"     12",
"    </a>",
"    ]. Three variants have been recognized:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common of these, the telangiectatic type, often presents with multiple FNH. In addition to the lack of a central scar, the mass is characterized by the absence of nodular architecture and the presence of single, quite regular plates of hepatocytes separated by sinusoids fed directly by anomalous arteries [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/12,19\">",
"       12,19",
"      </a>",
"      ]. The risk of bleeding appears to be similar to the risk observed in patients with a hepatic adenoma [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A mixed hyperplastic and adenomatous form may be difficult to distinguish from HA due to its subtle vascular and bile ductular findings [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/12,19\">",
"       12,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third histologic variant consisting of FNH with cytologic atypia resembling dysplasia of large cell type has been proposed [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A comprehensive pathological study of 305 lesions failed to identify a macroscopic central stellate scar in 50 percent and noted non-classical histology in 20 percent of the lesions, most showing a telangiectatic variant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/12\">",
"     12",
"    </a>",
"    ]. The surprisingly high number of lesions without a central scar was almost exclusively due to the large number of masses that had non-classical histology. Ninety-five percent of those with non-classical histology did not have a scar, whereas only 18 percent of those with classical histology lacked a scar [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/12\">",
"     12",
"    </a>",
"    ]. The overall prevalence and clinical significance of these variants remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of FNH is usually made by demonstrating its characteristic features on imaging tests and excluding other lesions. The latter can typically be accomplished by assessment of the context in which FNH is detected and by obtaining specific radiologic and laboratory testing (",
"    <a class=\"graphic graphic_table graphicRef53705 \" href=\"UTD.htm?36/60/37837\">",
"     table 1",
"    </a>",
"    ). The differential diagnosis includes hepatic adenoma, hepatocellular carcinoma, fibrolamellar carcinoma, cirrhosis, large regenerative nodules, hemangioma, and hypervascular metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=see_link\">",
"     \"Approach to the patient with a focal liver lesion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of reports have found that symptoms or signs directly attributable to FNH are infrequent. Two-thirds to three-fourths of patients are identified incidentally [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/17\">",
"     17",
"    </a>",
"    ], with the mass noted at the time of surgery, on an abdominal imaging study, or at autopsy. Unlike hepatic adenomas, FNH rarely presents with acute onset of hemorrhage, necrosis, or infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, symptomatic presentations have been described. In one series, for example, abdominal discomfort or a palpable liver mass was observed in 25 percent of 41 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/23\">",
"     23",
"    </a>",
"    ]. Another series that included 168 patients found that 60 percent had abdominal pain and 4 percent had an abdominal mass [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/12\">",
"     12",
"    </a>",
"    ]. The high number of symptomatic patients in the second report probably reflects selection bias since all of the patients were identified from pathology specimens obtained at the time of surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver tests are most often normal although minor elevations in aspartate and alanine aminotransferase, alkaline phosphatase and gamma glutamyl transpeptidase levels may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/12,13,23\">",
"     12,13,23",
"    </a>",
"    ]. The alpha-fetoprotein is normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Imaging tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A confident diagnosis can usually be made through a combination of imaging modalities; tissue diagnosis is usually not required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although often first identified on ultrasound examination, FNH is variably hyper, hypo, or isoechoic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/23\">",
"     23",
"    </a>",
"    ] and US is able to identify the central scar in only 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/24\">",
"     24",
"    </a>",
"    ]. The ultrasound characteristics are difficult to distinguish from an adenoma or malignant lesions. Power Doppler ultrasound may help differentiate the arterial flow in FNH from the venous flow in HA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/23,25,26\">",
"     23,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H211315113\">",
"    <span class=\"h4\">",
"     Contrast-enhanced ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have described improved characterization of focal liver lesions using contrast-enhanced ultrasonography compared with standard ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. While the approach is not approved in the United States, it is available in other countries. Test characteristics compared with other imaging modalities remain incompletely defined, although emerging data suggest its ability for differentiation among solid liver lesions is comparable with MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;A properly timed dynamic, triphasic, helical CT scan performed without contrast, and with contrast during the hepatic arterial and portal venous phases, will often be highly suggestive of the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The lesion may be hypo or isodense on non-contrast imaging with the central scar identified in one-third of patients. The lesion becomes hyperdense during the hepatic arterial phase due to the arterial origin of its blood supply (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75658 \" href=\"UTD.htm?1/59/1974\">",
"     image 1",
"    </a>",
"    ). FNH is generally isodense during the portal venous phase, although the central scar may become hyperdense as contrast diffuses into the scar. While characteristic of FNH, a central scar may be present in the fibrolamellar variant of HCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Technetium sulfur colloid scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;A characteristic of FNH is that it usually contains Kupffer cells. Thus, 80 percent of lesions will show active uptake of technetium sulfur colloid on nuclear medicine scanning (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76940 \" href=\"UTD.htm?41/36/42573\">",
"     image 2",
"    </a>",
"    ), whereas HA, which lack Kupffer cells, generally will not [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/31,33-35\">",
"     31,33-35",
"    </a>",
"    ]. One study suggested that the presence of a \"hot spot\" on sulfur colloid scanning was comparable to or more sensitive for the diagnosis of FNH than CT or MRI (92 versus 84 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/36\">",
"     36",
"    </a>",
"    ]. Unfortunately, because occasional HA will also show uptake, a positive nuclear medicine scan is not sufficient for a definitive diagnosis of FNH. In many centers, nuclear imaging has been largely replaced by Gd-BOPTA-enhanced MRI or dynamic multi-phase CT angiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=see_link\">",
"     \"Approach to the patient with a focal liver lesion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be little to distinguish FNH from normal liver on standard MRI, since it is composed of the same elements as normal liver. An isointense lesion is noted on T1-weighted images, while an isointense to slightly hyperintense mass appears on T2-weighted images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51338 \" href=\"UTD.htm?43/45/44759\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64152 \" href=\"UTD.htm?26/30/27119\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/37\">",
"     37",
"    </a>",
"    ]. The scar typically shows high signal intensity on T2-weighted images due to vessels or edema in the scar (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64152 \" href=\"UTD.htm?26/30/27119\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/38\">",
"     38",
"    </a>",
"    ]. Gadolinium infusion produces rapid enhancement of the FNH mass due to its arterial blood supply, producing a hyperintense lesion on early films (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51338 \" href=\"UTD.htm?43/45/44759\">",
"     image 3",
"    </a>",
"    ). On delayed images it becomes more isointense with respect to normal liver. The central scar enhances on delayed imaging as contrast gradually diffuses into the fibrous center of the mass [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. In one study, gadolinium enhanced MRI had a sensitivity and specificity of 70 and 98 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A relatively new MR contrast agent has been introduced into clinical use. Unlike currently used gadolinium-based contrast agents for MRI, this agent, a Gd-BOPTA chelate of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/45/25301?source=see_link\">",
"     Gadobenate Dimeglumine",
"    </a>",
"    , has a dual route of elimination, through both renal and hepatobiliary excretion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58438 \" href=\"UTD.htm?38/3/38960\">",
"     image 5",
"    </a>",
"    ). Thus, it can be useful for distinguishing hepatic adenomas from focal nodular hyperplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=see_link\">",
"     \"Approach to the patient with a focal liver lesion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although angiography may reveal the diagnostic \"spoked wheel\" appearance of FNH, its use is rarely indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/31,34,35\">",
"     31,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94740971\">",
"    <span class=\"h1\">",
"     ROLE OF ORAL CONTRACEPTIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;FNH was first described in the early 1900s, long before the advent of oral contraceptives (OCPs). It is seen in men and children who do not use OCPs and its incidence remained steady after the introduction of OCPs in 1960, in sharp contrast to the dramatic rise in the incidence of HA with the widespread use of OCPs. Thus use of OCPs is not required for the development of FNH [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, FNH may be responsive to estrogens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients taking OCPs tend to have larger, more vascular tumors, have more symptoms, and reports of hemorrhage or rupture in patients with FNH have all occurred in patients taking OCPs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. However, the magnitude of the risk associated with OCPs is uncertain. In a study of 216 women with FNH, use of OCPs did not appear to influence the size or number of FNH lesions or size changes (which were rare) during follow-up for an average of two years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/50\">",
"     50",
"    </a>",
"    ]. A case control trial comparing 23 women with histologically confirmed FNH to 94 controls estimated the odds ratio of OCP use to be 2.8 (95% CI, 0.8 to 9.4) for those who had ever used OCPs and 4.5 (95% CI, 1.2 to 16.9) for those who had &ge;3 years of use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We generally do not insist that oral contraceptives and other estrogen containing preparations should be discontinued. However, it is reasonable to obtain a follow-up imaging study in 6 to 12 months in women who continue taking these drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of FNH is one of stability and lack of complications. Lesions generally do not change over time, although they occasionally become smaller [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/50,52-55\">",
"     50,52-55",
"    </a>",
"    ]. However, as mentioned above, enlargement of FNH in the setting of OCPs and during pregnancy have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/56\">",
"     56",
"    </a>",
"    ]. There is no evidence for malignant transformation of FNH [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/12,23,57,58\">",
"     12,23,57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who are suspected of having FNH based upon the evaluation described above should be managed conservatively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/23,38,50,52,53,55,59,60\">",
"     23,38,50,52,53,55,59,60",
"    </a>",
"    ]. If a diagnosis remains unclear, a liver biopsy may be helpful, but may also be misleading since only resection will be definitive [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/61\">",
"     61",
"    </a>",
"    ]. Follow-up studies at three and six months will often be sufficient to confirm the stability of the lesion and its benign nature, after which no long-term follow-up is required routinely. Surgery should be reserved for the rare, very symptomatic FNH lesion, and the highly suspicious lesion, which has eluded diagnosis by all other modalities.",
"   </p>",
"   <p>",
"    We generally do not insist that oral contraceptives and other estrogen containing preparations should be discontinued. However, it is reasonable to obtain a follow-up imaging study in 6 to 12 months in women who continue taking these drugs. Small FNH do not appear to pose a significant risk to a successful pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22791/abstract/50,62\">",
"     50,62",
"    </a>",
"    ], although close observation is strongly recommended and resection may be prudent for large (&gt;8 cm) FNH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94740675\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focal nodular hyperplasia (FNH) is the most common non-malignant hepatic tumor that is not of vascular origin. It is now generally accepted to be a hyperplastic (regenerative) response to hyperperfusion by the characteristic anomalous arteries found in the center of these nodules. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      FNH is most often solitary (80 to 95 percent) and usually less than 5 cm in diameter. Only 3 percent are larger than 10 cm. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of reports have found that symptoms or signs directly attributable to FNH are infrequent. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of FNH is usually made by demonstrating its characteristic features on imaging tests and excluding other lesions. The latter can typically be accomplished by assessing the context in which FNH is detected and by obtaining specific radiologic and laboratory testing (",
"      <a class=\"graphic graphic_table graphicRef53705 \" href=\"UTD.htm?36/60/37837\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=see_link\">",
"       \"Approach to the patient with a focal liver lesion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The natural history of FNH is one of stability and a lack of complications. Thus, we suggest that patients who are suspected of having FNH based upon the evaluation described above be managed conservatively (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      FNH may be responsive to exogenous estrogens. We generally do not insist that oral contraceptives and other estrogen-containing preparations should be discontinued. However, it is reasonable to obtain a follow-up imaging study in 6 to 12 months in women who continue taking these drugs. (See",
"      <a class=\"local\" href=\"#H94740971\">",
"       'Role of oral contraceptives'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Craig J, Peters R, Edmundson H. Tumors of the Liver and Intrahepatic Bile Ducts, Fasc 26, 2nd ed, DC Armed Forces Institute of Pathology, Washington, DC 1989. p.6.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/2\">",
"      John TG, Greig JD, Crosbie JL, et al. Superior staging of liver tumors with laparoscopy and laparoscopic ultrasound. Ann Surg 1994; 220:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/3\">",
"      Wanless IR, Mawdsley C, Adams R. On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology 1985; 5:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/4\">",
"      Reymond D, Plaschkes J, L&uuml;thy AR, et al. Focal nodular hyperplasia of the liver in children: review of follow-up and outcome. J Pediatr Surg 1995; 30:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/5\">",
"      Terminology of nodular hepatocellular lesions. International Working Party. Hepatology 1995; 22:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/6\">",
"      Paradis V, Laurent A, Flejou JF, et al. Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of X-chromosome inactivation. Hepatology 1997; 26:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/7\">",
"      Gaffey MJ, Iezzoni JC, Weiss LM. Clonal analysis of focal nodular hyperplasia of the liver. Am J Pathol 1996; 148:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/8\">",
"      Fukukura Y, Nakashima O, Kusaba A, et al. Angioarchitecture and blood circulation in focal nodular hyperplasia of the liver. J Hepatol 1998; 29:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/9\">",
"      Kondo F, Nagao T, Sato T, et al. Etiological analysis of focal nodular hyperplasia of the liver, with emphasis on similar abnormal vasculatures to nodular regenerative hyperplasia and idiopathic portal hypertension. Pathol Res Pract 1998; 194:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/10\">",
"      Nakanuma Y. Non-neoplastic nodular lesions in the liver. Pathol Int 1995; 45:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/11\">",
"      Wanless IR, Gryfe A. Nodular transformation of the liver in hereditary hemorrhagic telangiectasia. Arch Pathol Lab Med 1986; 110:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/12\">",
"      Nguyen BN, Fl&eacute;jou JF, Terris B, et al. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol 1999; 23:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/13\">",
"      Ishak KG, Rabin L. Benign tumors of the liver. Med Clin North Am 1975; 59:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/14\">",
"      Mathieu D, Zafrani ES, Anglade MC, Dhumeaux D. Association of focal nodular hyperplasia and hepatic hemangioma. Gastroenterology 1989; 97:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/15\">",
"      Haber M, Reuben A, Burrell M, et al. Multiple focal nodular hyperplasia of the liver associated with hemihypertrophy and vascular malformations. Gastroenterology 1995; 108:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/16\">",
"      Mindikoglu AL, Regev A, Levi JU, et al. Focal nodular hyperplasia in identical twins. Am J Gastroenterol 2005; 100:1616.",
"     </a>",
"    </li>",
"    <li>",
"     Goodman ZD. Benign Tumors of the Liver. In: Neoplasms of the Liver, Okuda K, Ishak KD (Eds), Springer, Tokyo 1987. p.105.",
"    </li>",
"    <li>",
"     Klatskin G, Conn H. Neoplasms of the Liver and Intrahepatic Bile Ducts. In: Histopathology of the Liver, Oxford University Press, New York 1993. p.367.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/19\">",
"      Wanless IR, Albrecht S, Bilbao J, et al. Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain: a new syndrome. Mod Pathol 1989; 2:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/20\">",
"      Bioulac-Sage P, Rebouissou S, Sa Cunha A, et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology 2005; 128:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/21\">",
"      Brunt EM, Flye MW. Infarction in focal nodular hyperplasia of the liver. A case report. Am J Clin Pathol 1991; 95:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/22\">",
"      Lee MJ, Saini S, Hamm B, et al. Focal nodular hyperplasia of the liver: MR findings in 35 proved cases. AJR Am J Roentgenol 1991; 156:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/23\">",
"      Cherqui D, Rahmouni A, Charlotte F, et al. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology 1995; 22:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/24\">",
"      Shamsi K, De Schepper A, Degryse H, Deckers F. Focal nodular hyperplasia of the liver: radiologic findings. Abdom Imaging 1993; 18:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/25\">",
"      Bartolozzi C, Lencioni R, Paolicchi A, et al. Differentiation of hepatocellular adenoma and focal nodular hyperplasia of the liver: comparison of power Doppler imaging and conventional color Doppler sonography. Eur Radiol 1997; 7:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/26\">",
"      Wang LY, Wang JH, Lin ZY, et al. Hepatic focal nodular hyperplasia: findings on color Doppler ultrasound. Abdom Imaging 1997; 22:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/27\">",
"      Quaia E. The real capabilities of contrast-enhanced ultrasound in the characterization of solid focal liver lesions. Eur Radiol 2011; 21:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/28\">",
"      Kang HS, Kim BK, Shim CS. Focal nodular hyperplasia: with a focus on contrast enhanced ultrasound. Korean J Hepatol 2010; 16:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/29\">",
"      Bernatik T, Seitz K, Blank W, et al. Unclear focal liver lesions in contrast-enhanced ultrasonography--lessons to be learned from the DEGUM multicenter study for the characterization of liver tumors. Ultraschall Med 2010; 31:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/30\">",
"      Seitz K, Bernatik T, Strobel D, et al. Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions in clinical practice (DEGUM Multicenter Trial): CEUS vs. MRI--a prospective comparison in 269 patients. Ultraschall Med 2010; 31:492.",
"     </a>",
"    </li>",
"    <li>",
"     Mergo PJ, Ros PR. Benign Lesions of the Liver. In: The Radiologic Clinics of North America, 2, W.B. Saunders, Philadelphia 1998. Vol 36, p.319.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/32\">",
"      Carlson SK, Johnson CD, Bender CE, Welch TJ. CT of focal nodular hyperplasia of the liver. AJR Am J Roentgenol 2000; 174:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/33\">",
"      Drane WE, Krasicky GA, Johnson DA. Radionuclide imaging of primary tumors and tumor-like conditions of the liver. Clin Nucl Med 1987; 12:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/34\">",
"      Welch TJ, Sheedy PF 2nd, Johnson CM, et al. Focal nodular hyperplasia and hepatic adenoma: comparison of angiography, CT, US, and scintigraphy. Radiology 1985; 156:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/35\">",
"      Rogers JV, Mack LA, Freeny PC, et al. Hepatic focal nodular hyperplasia: angiography, CT, sonography, and scintigraphy. AJR Am J Roentgenol 1981; 137:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/36\">",
"      Boulahdour H, Cherqui D, Charlotte F, et al. The hot spot hepatobiliary scan in focal nodular hyperplasia. J Nucl Med 1993; 34:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/37\">",
"      Mattison GR, Glazer GM, Quint LE, et al. MR imaging of hepatic focal nodular hyperplasia: characterization and distinction from primary malignant hepatic tumors. AJR Am J Roentgenol 1987; 148:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/38\">",
"      Buetow PC, Pantongrag-Brown L, Buck JL, et al. Focal nodular hyperplasia of the liver: radiologic-pathologic correlation. Radiographics 1996; 16:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/39\">",
"      Irie H, Honda H, Kaneko K, et al. MR imaging of focal nodular hyperplasia of the liver: value of contrast-enhanced dynamic study. Radiat Med 1997; 15:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/40\">",
"      Mahfouz AE, Hamm B, Taupitz M, Wolf KJ. Hypervascular liver lesions: differentiation of focal nodular hyperplasia from malignant tumors with dynamic gadolinium-enhanced MR imaging. Radiology 1993; 186:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/41\">",
"      Rummeny E, Weissleder R, Sironi S, et al. Central scars in primary liver tumors: MR features, specificity, and pathologic correlation. Radiology 1989; 171:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/42\">",
"      Mathieu D, Rahmouni A, Anglade MC, et al. Focal nodular hyperplasia of the liver: assessment with contrast-enhanced TurboFLASH MR imaging. Radiology 1991; 180:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/43\">",
"      Fechner RE. Benign hepatic lesions and orally administered contraceptives. A report of seven cases and a critical analysis of the literature. Hum Pathol 1977; 8:255.",
"     </a>",
"    </li>",
"    <li>",
"     Ishak KG. Hepatic Neoplasms Associated with Contraceptive and Anabolic Steroids in Carcinogenic Hormones. In: Recent Results in Cancer Research, Lingeman CH (Ed), Springer-Verlag, New York 1979. p.73.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/45\">",
"      Geders JM, Haque S, Tesi RJ, et al. A young man with a solitary hepatic mass. Hepatology 1995; 22:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/46\">",
"      Nime F, Pickren JW, Vana J, et al. The histology of liver tumors in oral contraceptive users observed during a national survey by the American College of Surgeons Commission on Cancer. Cancer 1979; 44:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/47\">",
"      Aldinger K, Ben-Menachem Y, Whalen G. Focal nodular hyperplasia of the liver associated with high-dosage estrogens. Arch Intern Med 1977; 137:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/48\">",
"      Klatskin G. Hepatic tumors: possible relationship to use of oral contraceptives. Gastroenterology 1977; 73:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/49\">",
"      Shortell CK, Schwartz SI. Hepatic adenoma and focal nodular hyperplasia. Surg Gynecol Obstet 1991; 173:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/50\">",
"      Mathieu D, Kobeiter H, Maison P, et al. Oral contraceptive use and focal nodular hyperplasia of the liver. Gastroenterology 2000; 118:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/51\">",
"      Scalori A, Tavani A, Gallus S, et al. Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study. Am J Obstet Gynecol 2002; 186:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/52\">",
"      Weimann A, Ringe B, Klempnauer J, et al. Benign liver tumors: differential diagnosis and indications for surgery. World J Surg 1997; 21:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/53\">",
"      Heinemann LA, Weimann A, Gerken G, et al. Modern oral contraceptive use and benign liver tumors: the German Benign Liver Tumor Case-Control Study. Eur J Contracept Reprod Health Care 1998; 3:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/54\">",
"      Di Stasi M, Caturelli E, De Sio I, et al. Natural history of focal nodular hyperplasia of the liver: an ultrasound study. J Clin Ultrasound 1996; 24:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/55\">",
"      Leconte I, Van Beers BE, Lacrosse M, et al. Focal nodular hyperplasia: natural course observed with CT and MRI. J Comput Assist Tomogr 2000; 24:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/56\">",
"      Scott LD, Katz AR, Duke JH, et al. Oral contraceptives, pregnancy, and focal nodular hyperplasia of the liver. JAMA 1984; 251:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/57\">",
"      Wanless IR. Nodular regenerative hyperplasia, dysplasia, and hepatocellular carcinoma. Am J Gastroenterol 1996; 91:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/58\">",
"      Rubin RA, Mitchell DG. Evaluation of the solid hepatic mass. Med Clin North Am 1996; 80:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/59\">",
"      Belghiti J, Pateron D, Panis Y, et al. Resection of presumed benign liver tumours. Br J Surg 1993; 80:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/60\">",
"      De Carlis L, Pirotta V, Rondinara GF, et al. Hepatic adenoma and focal nodular hyperplasia: diagnosis and criteria for treatment. Liver Transpl Surg 1997; 3:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/61\">",
"      Fabre A, Audet P, Vilgrain V, et al. Histologic scoring of liver biopsy in focal nodular hyperplasia with atypical presentation. Hepatology 2002; 35:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22791/abstract/62\">",
"      Weimann A, M&ouml;ssinger M, Fronhoff K, et al. Pregnancy in women with observed focal nodular hyperplasia of the liver. Lancet 1998; 351:1251.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3577 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-189.41.172.26-83C8AEB15F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_16_22791=[""].join("\n");
var outline_f22_16_22791=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H94740675\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Non-classical variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Imaging tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H211315113\">",
"      Contrast-enhanced ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - CT scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Technetium sulfur colloid scanning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94740971\">",
"      ROLE OF ORAL CONTRACEPTIVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94740675\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3577\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3577|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/59/1974\" title=\"diagnostic image 1\">",
"      Focal nodula hyperplasia CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/36/42573\" title=\"diagnostic image 2\">",
"      FNH technetium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/45/44759\" title=\"diagnostic image 3\">",
"      FNH MRI T1 weighted",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/30/27119\" title=\"diagnostic image 4\">",
"      FNH MRI T2 weighted",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/3/38960\" title=\"diagnostic image 5\">",
"      FNH Bopta scan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3577|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/7/12404\" title=\"picture 1\">",
"      Focal nodular hyperplasia Gross",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/7/35957\" title=\"picture 2\">",
"      Focal nodular hyperplasia Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/22/32101\" title=\"picture 3\">",
"      FNH trichrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3577|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/60/37837\" title=\"table 1\">",
"      Dx hepatic mass lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=related_link\">",
"      Approach to the patient with a focal liver lesion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_16_22792="Acute interstitial pneumonia (Hamman-Rich syndrome)";
var content_f22_16_22792=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute interstitial pneumonia (Hamman-Rich syndrome)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/16/22792/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/16/22792/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/16/22792/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/16/22792/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/16/22792/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/16/22792/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/16/22792/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute interstitial pneumonia (AIP) is a rare and fulminant form of diffuse lung injury originally described by Hamman and Rich in 1935 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. AIP is classified as an idiopathic interstitial pneumonia (IIP), and among the IIPs, it has the most acute onset and rapidly progressive course [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AIP is similar in presentation to the acute respiratory distress syndrome (ARDS) and probably represents a subset of cases of idiopathic ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical presentation, diagnosis, treatment, and prognosis of AIP will be reviewed here. The other idiopathic interstitial pneumonias and the approach to patients with interstitial lung disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIP generally affects previously healthy individuals without a prior history of lung disease and occurs with roughly equal frequency in men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. It is not associated with cigarette smoking. Most patients are over the age of 40 years, with a mean age of 50 to 55 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/3,5,6,8,9\">",
"     3,5,6,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIP has the histopathologic appearance of diffuse alveolar damage (DAD) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/3\">",
"     3",
"    </a>",
"    ]. DAD is a reaction pattern that occurs in response to a number of known causes of lung injury, but in the case of AIP, it is idiopathic (",
"    <a class=\"graphic graphic_table graphicRef54819 \" href=\"UTD.htm?13/8/13452\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/10\">",
"     10",
"    </a>",
"    ]. DAD has characteristic temporal phases in its evolution &mdash; acute exudative, organizing proliferative, and healed (or fibrotic) phases (",
"    <a class=\"graphic graphic_table graphicRef81916 \" href=\"UTD.htm?13/49/14107\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The histopathologic changes characteristic of the acute \"exudative\" stage are usually not observed on lung biopsy specimens of AIP, as biopsies are frequently obtained later in the clinical course. The most characteristic features of AIP are those found during the organizing, \"proliferative\" stage of DAD and include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Marked thickening of the alveolar septa due to interstitial edema, inflammatory cell infiltration, fibroblast proliferation (within the interstitium and airspaces), and type II cell hyperplasia (",
"      <a class=\"graphic graphic_picture graphicRef63702 graphicRef53033 graphicRef77085 \" href=\"UTD.htm?43/20/44362\">",
"       picture 1A-C",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Collapse and apposition of adjacent alveolar septa",
"     </li>",
"     <li>",
"      Hyaline membranes (most prominent during the acute phase) in focal areas along alveolar septa",
"     </li>",
"     <li>",
"      Thrombi in small arteries",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The healing phase of AIP may show no apparent residue or may reveal variable degrees of interstitial fibrosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    airway scarring (",
"    <a class=\"graphic graphic_picture graphicRef70758 \" href=\"UTD.htm?25/27/26041\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An important feature of AIP is the presence of a",
"    <strong>",
"     temporally uniform",
"    </strong>",
"    lesion, which suggests that an episode of acute lung injury occurred at a single time point [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/4\">",
"     4",
"    </a>",
"    ]. This differs from usual interstitial pneumonia (UIP), in which pathologic lesions are of different ages with alternating areas of normal lung, interstitial inflammation, fibroblast foci, and honeycomb change. However, the clinical course of patients with UIP may be complicated by \"acute exacerbations\" or an \"accelerated phase of rapid clinical decline\" without an identifiable cause. When this occurs, pathologic findings of both AIP and UIP are noted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link&amp;anchor=H3#H3\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\", section on 'Usual interstitial pneumonia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=see_link&amp;anchor=H25#H25\">",
"     \"Treatment of idiopathic pulmonary fibrosis\", section on 'Acute exacerbations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a small autopsy series, marked myofibroblast proliferation was seen in the lungs of all patients with AIP, but was inconsistently seen in patients with infectious causes of ARDS and was mild in patients with ARDS from drug toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/11\">",
"     11",
"    </a>",
"    ]. Pathologic evidence of multiorgan failure was absent in AIP, but uniformly present in patients with infection and inconsistently present in those with drug-induced toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link&amp;anchor=H10#H10\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\", section on 'Multiple organ dysfunction syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact mechanism of the initial injury to the pulmonary endothelium and epithelium in AIP is unknown. Based on studies of animal models and human bronchoalveolar lavage, it is believed that the following sequence of events contributes to the clinical picture of AIP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rapid onset of a widespread injury pattern suggests a single insult as an initiating factor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/5\">",
"     5",
"    </a>",
"    ]. Alveolar epithelial cell damage and death lead to elaboration and release of mediators such as tumor necrosis factor alpha, interleukin 1beta, and monocyte chemoattractant factor. Recruitment of neutrophils into the alveolar spaces and alveolar septae leads to further cellular damage, possibly via release of toxic oxygen radicals and proteases. Undoubtedly, other inflammatory cells contribute to progression of the epithelial cell injury and airspace exudation. The extent of epithelial cell injury and basement membrane damage may modulate the nature and extent of the subsequent fibroblastic response in AIP.",
"   </p>",
"   <p>",
"    Following the acute phase, a stage of organization ensues that is characterized by fibroblast proliferation and connective tissue synthesis. The hyaline membranes are resorbed or incorporated into the alveolar septa and are overgrown by proliferating type II epithelial cells.",
"   </p>",
"   <p>",
"    In patients with a fibrotic response, fibroblast proliferation and differentiation into myofibroblasts leads to production of collagen, widening of the alveolar septae, and organization of the alveolar exudate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/12\">",
"     12",
"    </a>",
"    ]. Alveolar wall collapse and apposition, associated with reepithelization of the fibrotic exudate within the alveolar space, contribute to the severity and extent of the fibrotic process. Resolution of the injury occurs in some patients, others develop a progressive fibrotic response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32378?source=see_link\">",
"     \"Pathogenesis of idiopathic pulmonary fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of AIP is usually rapid, with a prodromal illness that typically lasts 7 to 14 days prior to presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. The most common presenting signs and symptoms are fever, cough, and progressive, severe shortness of breath, affecting 75, 79, and 90 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/3,8,13\">",
"     3,8,13",
"    </a>",
"    ]. The majority will have hypoxemia at presentation and most will require intubation and mechanical ventilation within a few days. Patients may also report prodromal symptoms of myalgias, arthralgias, chills, and malaise [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tachypnea and diffuse crackles are frequently present on lung examination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/3\">",
"     3",
"    </a>",
"    ]. Digital clubbing is typically not seen. The presence of clubbing suggests that the AIP is occurring as an exacerbation of underlying fibrotic disease, such as idiopathic pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link&amp;anchor=H3#H3\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\", section on 'Usual interstitial pneumonia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=see_link&amp;anchor=H25#H25\">",
"     \"Treatment of idiopathic pulmonary fibrosis\", section on 'Acute exacerbations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Careful cardiac, cutaneous, joint, and muscle examinations are performed to exclude heart failure and known causes of acute respiratory distress syndrome (ARDS) or interstitial pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of patients with acute interstitial pneumonia is similar to that for acute lung",
"    <span class=\"nowrap\">",
"     injury/acute",
"    </span>",
"    respiratory distress syndrome",
"    <span class=\"nowrap\">",
"     (ALI/ARDS).",
"    </span>",
"    The possibility of cardiogenic pulmonary edema (heart failure) is excluded (eg, plasma brain natriuretic peptide level, echocardiogram). Known causes of noncardiogenic pulmonary edema and diffuse pulmonary opacities are sought (",
"    <a class=\"graphic graphic_table graphicRef54819 \" href=\"UTD.htm?13/8/13452\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58759 \" href=\"UTD.htm?39/41/40603\">",
"     table 3",
"    </a>",
"    ), using the studies outlined below. If this testing is negative, a lung biopsy is often obtained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory studies are nonspecific and more helpful in identifying alternative diagnoses than in making a diagnosis of AIP. A peripheral leukocytosis is common (mean 12,100",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    range 5,600 to 21,800",
"    <span class=\"nowrap\">",
"     cells/microL).",
"    </span>",
"   </p>",
"   <p>",
"    A",
"    plasma brain natriuretic peptide level and an echocardiogram are often obtained to help exclude cardiogenic pulmonary edema.",
"   </p>",
"   <p>",
"    Tests for connective tissue diseases can help to exclude an acute exacerbation of previously undiagnosed dermatomyositis, polymyositis, rheumatoid arthritis, primary Sj&ouml;gren syndrome, or systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/3,15\">",
"     3,15",
"    </a>",
"    ]. We typically obtain serum muscle enzymes (eg, alanine aminotransferase (ALT), aspartate aminotransferase (AST), aldolase, creatine kinase), an antinuclear antibody test, an anti-Jo-1 antibody, and a rheumatoid factor. If these tests are negative, additional tests for antibodies to RNA synthetases (eg, anti-PR-7, anti-PR-12), signal recognition particle (anti-SRP) or helicase (anti-Mi-2) may be obtained. The laboratory evaluation of the various connective tissue diseases is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=see_link\">",
"     \"Interstitial lung disease in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16906?source=see_link\">",
"     \"Interstitial lung disease associated with Sj&ouml;gren's syndrome: Clinical manifestations, evaluation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=see_link\">",
"     \"Pulmonary manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Arterial blood gases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients develop moderate to severe hypoxemia, often with a",
"    <span class=\"nowrap\">",
"     PaO2/FIO2",
"    </span>",
"    (arterial oxygen",
"    <span class=\"nowrap\">",
"     tension/fraction",
"    </span>",
"    of inspired oxygen) ratio 200 mmHg or less, which is in the range of the acute respiratory distress syndrome (ARDS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link&amp;anchor=H10171195#H10171195\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest imaging findings are similar to those seen in acute respiratory distress syndrome (ARDS). The chest radiograph reveals diffuse, bilateral, air-space opacification (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53486 \" href=\"UTD.htm?43/38/44654\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/3,6,9\">",
"     3,6,9",
"    </a>",
"    ]. High resolution computed tomographic (HRCT) scans typically show bilateral, patchy, symmetric areas of ground glass attenuation, often accompanied by airspace consolidation, septal thickening, and traction bronchiectasis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65227 \" href=\"UTD.htm?12/12/12480\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/9,16-18\">",
"     9,16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other findings that may be seen include a predominantly subpleural distribution of disease, and sparse honeycombing (less than 5 percent of the lung) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=see_link\">",
"     \"Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Microbiologic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A key component of the evaluation of patients with suspected AIP is the exclusion of underlying infection, beginning with a careful history regarding potential exposures. Microbiologic investigation typically includes nasopharyngeal aspirates for influenza testing, induced sputum for Pneumocystis jirovecii immunofluorescence, serologic tests for atypical pneumonias (eg, Coccidioides, Chlamydophila, coronavirus), and urinary antigen tests (eg, Streptococcus pneumoniae and Legionella), as indicated by the history and physical examination.",
"   </p>",
"   <p>",
"    Most patients with AIP have a nonproductive cough, so sputum cultures are usually not available. Bronchoalveolar lavage and bronchial brushing are generally performed to obtain respiratory tract samples for immunofluorescence and culture. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Bronchoscopy and BAL'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Polymerase chain reaction (PCR)-based diagnostic panels that assess multiple respiratory viruses simultaneously on serologic or bronchoalveolar lavage samples can be performed in two to three hours in some hospital laboratories. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\", section on 'Hospitalized patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5528?source=see_link&amp;anchor=H1018262449#H1018262449\">",
"     \"Diagnosis of seasonal influenza in adults\", section on 'Laboratory testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bronchoscopy and BAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main role of bronchoscopy and bronchoalveolar lavage (BAL) is to exclude other diseases in the differential of AIP, such as alveolar hemorrhage, eosinophilia, infection, and diffuse infiltration by cancer or lymphoma. The majority of patients will undergo bronchoscopy with bronchoalveolar lavage. Depending on whether the oxygen saturation can be adequately maintained with supplemental oxygen by nasal cannula, this may require intubation and supportive ventilation.",
"   </p>",
"   <p>",
"    Samples from the BAL are sent for cell counts, cultures (eg, bacterial, mycobacterial, fungal, viral), enzyme immunoassay, direct immunofluorescence, and cytologic analysis (eg, viral inclusion bodies, malignant cells). Samples from bronchial brushings are also sent for cytologic evaluation for viral inclusion bodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link&amp;anchor=H12#H12\">",
"     \"The diffuse alveolar hemorrhage syndromes\", section on 'Bronchoalveolar lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The BAL cellular profile in acute interstitial pneumonia may show a marked increase in neutrophils and atypical epithelial cells, although these findings are nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the initial minimally invasive tests do not yield an alternate diagnosis, a clinical decision must be made regarding whether to perform transbronchial, video-assisted (VATS), or open lung biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/21\">",
"     21",
"    </a>",
"    ]. We favor obtaining a video-assisted lung biopsy early in the course, in the hopes of identifying a treatable process.",
"   </p>",
"   <p>",
"    Some clinicians may choose to perform a transbronchial biopsy first to assess for sarcoidosis, lymphangitic carcinomatosis, acute eosinophilic pneumonia, and alveolar proteinosis, prior to proceeding to VATS or open biopsy. For patients with early, milder disease this may allow a less invasive evaluation. On the other hand, when respiratory impairment is progressing rapidly, VATS or open lung biopsy will lead to a diagnosis more expeditiously. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lung biopsy specimens are also examined for evidence of other specific causes of ARDS. As an example, areas of necrosis are typically not seen in AIP and suggest possible infection, infarct, or vasculitis. Well-formed granulomas, viral inclusions, and neutrophilic abscesses may suggest infection, while poorly formed granulomas suggest hypersensitivity pneumonitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute interstitial pneumonia (AIP) is based upon two findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of a clinical syndrome of idiopathic acute respiratory distress syndrome (ARDS)",
"      <br/>",
"      <br/>",
"      AND",
"     </li>",
"     <li>",
"      Pathologic confirmation of diffuse alveolar damage (DAD).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, after an initial clinical, laboratory, and microbiologic evaluation, an open or thoracoscopic lung biopsy is necessary to confirm the diagnosis. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For those patients whose lung function is not adequate to safely allow a lung biopsy, a presumptive diagnosis of AIP may be based on the presence of a compatible clinical syndrome and the absence of clinical, serologic, or bronchoalveolar lavage evidence of an alternative diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of AIP includes a number of pulmonary diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/14\">",
"     14",
"    </a>",
"    ]. Many of the disorders with a similar presentation to AIP are identified on the basis of laboratory, microbiologic, and bronchoalveolar lavage testing, including heart failure, the diffuse alveolar hemorrhage syndromes, acute eosinophilic pneumonia, cryptogenic organizing pneumonia (also known as idiopathic bronchiolitis obliterans organizing pneumonia), and hypersensitivity pneumonitis. Others may become apparent after examination of the lung biopsy. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Lung biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Once the diagnosis of diffuse alveolar damage (DAD) is confirmed by lung biopsy, we ensure that known causes of DAD have been excluded (eg, connective tissue disease, drug-induced toxicity, radiation pneumonitis, toxin-exposure, or viral infection) (",
"    <a class=\"graphic graphic_table graphicRef54819 \" href=\"UTD.htm?13/8/13452\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58759 \" href=\"UTD.htm?39/41/40603\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Laboratory'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As DAD can be the initial presentation of connective tissue disease, most often rheumatoid arthritis, amyopathic dermatomyositis, or polymyositis, these disorders are evaluated by careful examination for cutaneous and joint manifestations and by laboratory testing [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Laboratory'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AIP should be distinguished from two other forms of idiopathic interstitial pneumonia: usual interstitial pneumonia (UIP) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80665 graphicRef82237 graphicRef75204 \" href=\"UTD.htm?33/56/34696\">",
"     image 3A-C",
"    </a>",
"    ) and desquamative interstitial pneumonia (DIP). Distinguishing features among these clinicopathologic entities include the types of prodromal illness, radiographic and histopathologic findings, the clinical course, and the response to therapy (",
"    <a class=\"graphic graphic_table graphicRef63326 \" href=\"UTD.htm?19/27/19900\">",
"     table 4",
"    </a>",
"    ). The major clinical difference at presentation is disease duration: AIP is an acute disease of abrupt onset, whereas DIP has a subacute course over weeks to months, and UIP has a chronic course over more than one year [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Also in the differential diagnosis of AIP is an \"acute exacerbation\" or an \"accelerated phase of rapid clinical decline\" complicating the clinical course of another interstitial pneumonia, whether idiopathic (eg, idiopathic pulmonary fibrosis [IPF], nonspecific interstitial pneumonia [NSIP]), or due to a connective tissue disease (eg, rheumatoid arthritis, scleroderma) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/23\">",
"     23",
"    </a>",
"    ]. Histological examination of the lung in these cases reveals a pattern of DAD on the background of usual interstitial pneumonia or NSIP. The evaluation and management of acute exacerbations of IPF are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=see_link&amp;anchor=H25#H25\">",
"     \"Treatment of idiopathic pulmonary fibrosis\", section on 'Acute exacerbations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main treatment for acute interstitial pneumonia (AIP) is supportive care. The benefit of glucocorticoids remains unclear, although these are widely used, as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;General supportive care for patients with acute respiratory failure includes supplemental oxygen, ventilatory support, and prevention of complications (eg, venous thromboembolism, gastrointestinal bleeding, nosocomial pneumonia). Noninvasive or invasive mechanical ventilation is usually required, since most patients develop respiratory failure. Supportive care and ventilator strategies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link&amp;anchor=H17#H17\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\", section on 'Hypoxemic respiratory failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of AIP is made, we typically initiate high dose systemic glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    2 gm per day intravenously in divided doses) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/5\">",
"     5",
"    </a>",
"    ]. Data in support of high dose glucocorticoid therapy are limited to small case series that used a variety of glucocorticoid regimens and reported widely varying results [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/3,8,13,24,25\">",
"     3,8,13,24,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest series of 29 patients, survival was 45 percent among patients treated with glucocorticoids and 33 percent among those not treated with glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/3\">",
"       3",
"      </a>",
"      ]. The dose of glucocorticoids was not provided.",
"     </li>",
"     <li>",
"      In a series of eight patients, early administration of pulse dose glucocorticoids was associated with survival in seven [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Seven of eight patients survived in another series in which a mean dose of 240 mg per day of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      was used [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Six of eight patients treated with an unknown dose of glucocorticoids survived the initial hospitalization [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mortality was 100 percent in a series of 12 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We usually initiate empiric broad-spectrum antibiotics at the same time as glucocorticoids, given the difficulty of completely excluding infection. The choice of antibiotics is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\", section on 'Admitted to an ICU'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High-dose glucocorticoid therapy is continued for several days and then tapered slowly over several weeks to months, as tolerated.",
"   </p>",
"   <p>",
"    Surveillance for glucocorticoid-induced side effects (eg, hyperglycemia, increased susceptibility to infection, gastritis, and critical illness myopathy) is appropriate. In patients receiving high-dose, systemic glucocorticoids, the use of neuromuscular blockade during mechanical ventilation increases the risk of post-paralytic critical illness myopathy and is avoided whenever possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=see_link&amp;anchor=H15#H15\">",
"     \"Use of neuromuscular blocking medications in critically ill patients\", section on 'Administration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative immunosuppressive therapies (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) have been reported in case reports of AIP, although success was limited [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/7,8,26,27\">",
"     7,8,26,27",
"    </a>",
"    ]. In a patient who underwent single lung transplantation for AIP, the combination of cyclosporine, azathioprine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    to suppress rejection led to partial improvement in the native lung [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lung transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplantation has been reported in at least three patients with progressive interstitial lung disease thought to be due to AIP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/8,26\">",
"     8,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The in-hospital mortality from AIP is high (greater than 50 percent), and the majority of those who survive the initial hospitalization die within six months of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/3,6,9,24\">",
"     3,6,9,24",
"    </a>",
"    ]. Those who recover may have substantial or complete recovery of lung function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. However, recurrence of AIP and the development of chronic interstitial lung disease have been reported among a substantial fraction of those who survive the initial hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22792/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]. No known factors predict the course of disease among AIP survivors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute interstitial pneumonia (AIP) is a rare and fulminant form of diffuse lung injury that generally occurs in previously healthy individuals. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The onset of AIP is usually rapid, with a prodromal illness of 7 to 14 days. The most common clinical signs and symptoms are fever, cough, and shortness of breath. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of AIP includes heart failure, the diffuse alveolar hemorrhage syndromes, acute eosinophilic pneumonia, cryptogenic organizing pneumonia (also known as idiopathic bronchiolitis obliterans organizing pneumonia), hypersensitivity pneumonitis, and diffuse alveolar damage of known cause (",
"      <a class=\"graphic graphic_table graphicRef54819 \" href=\"UTD.htm?13/8/13452\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of AIP is based upon the presence of a clinical syndrome of idiopathic acute respiratory distress syndrome (ARDS) AND histologic confirmation of diffuse alveolar damage. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main treatment of AIP is supportive care. Noninvasive or invasive mechanical ventilation is often required, as most patients develop respiratory failure. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a diagnosis of AIP, we suggest initiating high dose systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The usual dose of glucocorticoids is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      2 gm per day intravenously in divided doses for the first several days. We typically administer empiric broad-spectrum antibiotics simultaneously. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The in-hospital mortality from AIP is high (greater than 50 percent). Those who survive the initial illness may have substantial or complete recovery of lung function or may experience recurrence of AIP or the progression of chronic interstitial lung disease. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/1\">",
"      Hamman L, Rich AR. Fulminating Diffuse Interstitial Fibrosis of the Lungs. Trans Am Clin Climatol Assoc 1935; 51:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/2\">",
"      Hamman, L, Rich, AR. Acute diffuse interstitial fibrosis of the lungs. Bull Johns Hopkins Hosp 1944; 74:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/3\">",
"      Olson J, Colby TV, Elliott CG. Hamman-Rich syndrome revisited. Mayo Clin Proc 1990; 65:1538.",
"     </a>",
"    </li>",
"    <li>",
"     Fulmer JD, Katzenstein ALA. The interstitial lung diseases. In: Pulmonary and Critical Care Medicine, Bone RC (Ed), Mosby Year Book, St. Louis 1993. p.M1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/5\">",
"      Vourlekis JS. Acute interstitial pneumonia. Clin Chest Med 2004; 25:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/6\">",
"      Katzenstein AL, Myers JL, Mazur MT. Acute interstitial pneumonia. A clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol 1986; 10:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/7\">",
"      Bouros D, Nicholson AC, Polychronopoulos V, du Bois RM. Acute interstitial pneumonia. Eur Respir J 2000; 15:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/8\">",
"      Vourlekis JS, Brown KK, Cool CD, et al. Acute interstitial pneumonitis. Case series and review of the literature. Medicine (Baltimore) 2000; 79:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/9\">",
"      Primack SL, Hartman TE, Ikezoe J, et al. Acute interstitial pneumonia: radiographic and CT findings in nine patients. Radiology 1993; 188:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/10\">",
"      American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/11\">",
"      Kang D, Nakayama T, Togashi M, et al. Two forms of diffuse alveolar damage in the lungs of patients with acute respiratory distress syndrome. Hum Pathol 2009; 40:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/12\">",
"      Pache JC, Christakos PG, Gannon DE, et al. Myofibroblasts in diffuse alveolar damage of the lung. Mod Pathol 1998; 11:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/13\">",
"      Suh GY, Kang EH, Chung MP, et al. Early intervention can improve clinical outcome of acute interstitial pneumonia. Chest 2006; 129:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/14\">",
"      Parambil JG, Myers JL, Aubry MC, Ryu JH. Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy. Chest 2007; 132:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/15\">",
"      Suda T, Kaida Y, Nakamura Y, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med 2009; 103:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/16\">",
"      Johkoh T, M&uuml;ller NL, Taniguchi H, et al. Acute interstitial pneumonia: thin-section CT findings in 36 patients. Radiology 1999; 211:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/17\">",
"      Mihara N, Johkoh T, Ichikado K, et al. Can acute interstitial pneumonia be differentiated from bronchiolitis obliterans organizing pneumonia by high-resolution CT? Radiat Med 2000; 18:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/18\">",
"      Tomiyama N, M&uuml;ller NL, Johkoh T, et al. Acute respiratory distress syndrome and acute interstitial pneumonia: comparison of thin-section CT findings. J Comput Assist Tomogr 2001; 25:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/19\">",
"      Ichikado K, Suga M, M&uuml;ller NL, et al. Acute interstitial pneumonia: comparison of high-resolution computed tomography findings between survivors and nonsurvivors. Am J Respir Crit Care Med 2002; 165:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/20\">",
"      Bonaccorsi A, Cancellieri A, Chilosi M, et al. Acute interstitial pneumonia: report of a series. Eur Respir J 2003; 21:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/21\">",
"      Lim SY, Suh GY, Choi JC, et al. Usefulness of open lung biopsy in mechanically ventilated patients with undiagnosed diffuse pulmonary infiltrates: influence of comorbidities and organ dysfunction. Crit Care 2007; 11:R93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/22\">",
"      Parambil JG, Myers JL, Ryu JH. Diffuse alveolar damage: uncommon manifestation of pulmonary involvement in patients with connective tissue diseases. Chest 2006; 130:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/23\">",
"      Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 2007; 132:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/24\">",
"      Avnon LS, Pikovsky O, Sion-Vardy N, Almog Y. Acute interstitial pneumonia-Hamman-Rich syndrome: clinical characteristics and diagnostic and therapeutic considerations. Anesth Analg 2009; 108:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/25\">",
"      Quefatieh A, Stone CH, DiGiovine B, et al. Low hospital mortality in patients with acute interstitial pneumonia. Chest 2003; 124:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/26\">",
"      Robinson DS, Geddes DM, Hansell DM, et al. Partial resolution of acute interstitial pneumonia in native lung after single lung transplantation. Thorax 1996; 51:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22792/abstract/27\">",
"      Ogawa D, Hashimoto H, Wada J, et al. Successful use of cyclosporin A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis. Rheumatology (Oxford) 2000; 39:1422.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4369 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_16_22792=[""].join("\n");
var outline_f22_16_22792=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Microbiologic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bronchoscopy and BAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4369\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4369|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/38/44654\" title=\"diagnostic image 1\">",
"      Acute interstitial pneumCXR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/12/12480\" title=\"diagnostic image 2\">",
"      Acute interstitial pneum CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/16/18689\" title=\"diagnostic image 3A\">",
"      Usual interstitial pneumonia CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/60/26560\" title=\"diagnostic image 3B\">",
"      Honeycomb cysts in IPF CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/35/42544\" title=\"diagnostic image 3C\">",
"      Marked honeycombing in IPF CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4369|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/23/38264\" title=\"picture 1A\">",
"      Hamman Rich Low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/18/14633\" title=\"picture 1B\">",
"      Hamman Rich High",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/44/28361\" title=\"picture 1C\">",
"      Diffuse alveolar damage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/27/26041\" title=\"picture 2\">",
"      DAD histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4369|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/8/13452\" title=\"table 1\">",
"      Causes of diffuse alveolar damage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/49/14107\" title=\"table 2\">",
"      Histologic features of diffuse alveolar damage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/41/40603\" title=\"table 3\">",
"      Conditions associated with ARDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/27/19900\" title=\"table 4\">",
"      Features of idiopathic interstitial pneumonias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=related_link\">",
"      Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5528?source=related_link\">",
"      Diagnosis of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16906?source=related_link\">",
"      Interstitial lung disease associated with Sj&ouml;gren's syndrome: Clinical manifestations, evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=related_link\">",
"      Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=related_link\">",
"      Interstitial lung disease in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32378?source=related_link\">",
"      Pathogenesis of idiopathic pulmonary fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=related_link\">",
"      Treatment of idiopathic pulmonary fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=related_link\">",
"      Use of neuromuscular blocking medications in critically ill patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_16_22793="Prevention and treatment of measles";
var content_f22_16_22793=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and treatment of measles",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/16/22793/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/16/22793/contributors\">",
"     Jorge L Barinaga, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/16/22793/contributors\">",
"     Paul R Skolnik, MD, FACP, FIDSA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/16/22793/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/16/22793/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/16/22793/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/16/22793/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/16/22793/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measles is a highly contagious viral infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/1\">",
"     1",
"    </a>",
"    ]. Mathematical models have estimated that the average number of secondary infections that follow a single introduction of measles into a susceptible population ranges from 12 to 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/2\">",
"     2",
"    </a>",
"    ]. Infection with measles is highly preventable.",
"   </p>",
"   <p>",
"    Control measures for the prevention and spread of measles and treatment modalities for the virus will be reviewed here. The epidemiology, aims for global eradication, clinical manifestations, and diagnosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42246?source=see_link\">",
"     \"Epidemiology and transmission of measles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=see_link\">",
"     \"Clinical presentation and diagnosis of measles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONTROLLING SPREAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control of outbreaks is of paramount importance in the prevention of measles. The Centers for Disease Control and Prevention (CDC) defines a measles outbreak as &ldquo;a chain of transmission with three or more confirmed cases&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/3\">",
"     3",
"    </a>",
"    ]. Suspected cases of measles should be reported immediately to the local or the state health department, and all such reports should be investigated promptly. Control measures should not be delayed while waiting for laboratory confirmation of the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Outbreak control measures'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Case definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case definitions have been established to standardize the approach to measles outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suspected case &mdash; A suspected case is defined as a febrile illness accompanied by rash.",
"     </li>",
"     <li>",
"      Clinical case &mdash; A clinical case is defined as an illness characterized by cough, coryza, or conjunctivitis, a generalized rash lasting for more than three days, and a temperature &gt;38.3&ordm;C (&gt;101&ordm;F).",
"     </li>",
"     <li>",
"      Probable case &mdash; A probable case meets the clinical case definition, but is not linked epidemiologically to a confirmed case and lacks serologic or virologic proof of disease.",
"     </li>",
"     <li>",
"      Confirmed case &mdash; A confirmed case meets the laboratory criteria for measles (independent of clinical features) or meets the clinical case definition and is epidemiologically linked to a confirmed case.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Outbreak control measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of spread in the setting of an outbreak depends upon prompt administration of vaccine to all susceptible persons. All individuals should provide documentation of measles immunity, which includes one of the following (See",
"    <a class=\"local\" href=\"#H2455568\">",
"     'Establishing evidence of measles immunity'",
"    </a>",
"    below.):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Birth before the year 1957",
"     </li>",
"     <li>",
"      Clinical measles diagnosis by a physician",
"     </li>",
"     <li>",
"      Laboratory evidence of immunity",
"     </li>",
"     <li>",
"      Documentation of receipt of two doses of live measles virus-containing vaccine from a physician or healthcare facility",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individuals unable to produce documentation of measles immunity should be excluded from the outbreak setting until they have complied with vaccination requirements. Those who are exempt from vaccination for medical, religious, or other reasons should be excluded from the outbreak setting for a minimum of three weeks after the onset of rash in the last measles case. Quarantine measures are not otherwise routinely recommended in outbreak control [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Schools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schools are particularly vulnerable to measles outbreaks. In a number of college and secondary school outbreaks in the United States, some individuals who had received one dose of vaccine still developed infection, suggesting that immunity to measles in such individuals can wane. In 1989, the United States adopted a two-dose strategy; revaccination with measles-mumps-rubella (MMR) vaccine is recommended for all children prior to school entry (age four to six years), their siblings, and school personnel who are unable to provide documentation of measles immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/6\">",
"     6",
"    </a>",
"    ]. Furthermore, in order for vaccination to be considered adequate for school outbreaks, two doses of measles vaccine must have been administered after the age of 12 months and separated by at least 28 days.",
"   </p>",
"   <p>",
"    The Advisory Committee on Immunization Practices (ACIP) also recommends that vaccination efforts be considered at unaffected schools that may be at risk during an outbreak. Those who are properly vaccinated may reenter the school immediately after vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Healthcare facilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of a measles diagnosis in a healthcare facility, all employees must provide documentation of measles immunity as outlined above [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/7\">",
"     7",
"    </a>",
"    ]. Any employee who cannot produce such documentation must be excluded from work and administered MMR vaccine promptly. The ACIP recommends that vaccination of those born before 1957 who do not have laboratory evidence of measles immunity also be considered, since some individuals with these characteristics have acquired and transmitted measles in the healthcare setting. (See",
"    <a class=\"local\" href=\"#H2455590\">",
"     'Birth before the year 1957'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Susceptible healthcare workers with measles exposure should be vaccinated within 72 hours of exposure. Previous recommendations indicated that if vaccination occurred within 72 hours of exposure, then exclusion from the workplace was not mandatory except in high-risk settings; subsequent guidelines suggest exclusion of all susceptible exposed persons [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/8\">",
"     8",
"    </a>",
"    ]. Any individual who develops a prodromal illness consistent with measles must be excluded from the facility until four days after the appearance of rash; this interval is the period of infectiousness for measles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Isolation is discussed below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Case isolation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Outbreaks among infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among infants with measles exposure, those aged 6 to 11 months can receive live measles vaccine, although they must be reimmunized at age 12 to 15 months and again prior to school entry. For infants exposed to measles within the household, immunoglobulin administration may be preferable since the risk for acquiring infection is higher than for other types of exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Case isolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a case of measles is suspected in a healthcare facility, respiratory isolation should be initiated. Specifically, private rooms with negative pressure air ventilation (minimum of six air changes per hour) and the use of masks at all times should be required. Data are insufficient to determine the optimal type of mask or respirator [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/9\">",
"     9",
"    </a>",
"    ]. Susceptible healthcare workers should not enter the room of infected patients. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Healthcare facilities'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The ACIP does not make any specific recommendations about isolation of suspected or confirmed cases of measles in the community. Strict respiratory isolation techniques have been demonstrated to decrease transmission rates in an outbreak situation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/10\">",
"     10",
"    </a>",
"    ]. Precautions should include respiratory isolation since the transmission of measles virus occurs via aerosol [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Use of immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intramuscular immune serum globulin can prevent or diminish the severity of disease if administered to susceptible individuals within six days of exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. Administration of immune serum globulin may be especially warranted in exposed individuals for whom the risk of complications of measles is increased, such as pregnant women, individuals less than one year of age, and immunocompromised hosts. Immunocompromised individuals with prior history of vaccination should also receive IG following exposure.",
"   </p>",
"   <p>",
"    Dosing consists of 0.25",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of body weight to a maximum dose of 15 mL intramuscularly [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. In immunocompromised hosts dosing is 0.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    body weight to a maximum dose of 15 mL. Individuals receiving immune serum globulin should receive live vaccination no earlier than five to six months later, so long as the individual is at least 12 months of age at that time and there is no contraindication to vaccination. The passively-acquired measles antibodies from the immune serum globulin should have been cleared by five to six months. For contacts not belonging to these high-risk groups, the administration of live measles vaccine within 72 hours of the exposure is preferable to immune serum globulin administration.(See",
"    <a class=\"local\" href=\"#H22\">",
"     'Contraindications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Administration of immune serum globulin should",
"    <strong>",
"     not",
"    </strong>",
"    be used for outbreak control [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MEASLES VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measles vaccination has markedly reduced the incidence of measles throughout the developed world. However, measles cases still occur in low-incidence countries via importation by travelers. Therefore, maintenance of immunity is important even in countries with a low incidence of measles, since a single imported case can result in large measles outbreaks in the setting of waning immunity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42246?source=see_link\">",
"     \"Epidemiology and transmission of measles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measles vaccine is recommended for all children and for certain high-risk adolescents and adults. Factors to be considered when determining the need for measles vaccination include the age of the recipient, the date of administration of the first dose of vaccine (if any), and local measles epidemiology, including the potential risk of exposure, the type of measles vaccine administered previously, contraindications to vaccination, travel plans, and evidence of prior measles infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14822?source=see_link\">",
"     \"Measles-mumps-rubella vaccination in high risk adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of maintenance of immunity was underscored by a Centers for Disease Control and Prevention (CDC) analysis of United States measles cases reported in 2011, which found that the majority of cases could have been prevented by vaccination; 89 percent of 118 measles cases occurred in unvaccinated individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/13\">",
"     13",
"    </a>",
"    ]. Immunization is also important for preventing severe sequelae of measles infection, including subacute sclerosing panencephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=see_link\">",
"     \"Clinical presentation and diagnosis of measles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Strategies to update immunizations in foreign-born adults are an important component of a comprehensive vaccine program. This is supported by a serologic study of recently arrived immigrants and refugees to Canada, in which 36 percent of participants were nonimmune to at least one of three vaccine-preventable diseases (eg, measles, mumps, or rubella) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42246?source=see_link\">",
"     \"Epidemiology and transmission of measles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Types of measles vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vaccine strain currently in use in the United States is the Enders-Edmonston strain. This live attenuated vaccine was licensed for use in 1968. It is available in combination as a measles-mumps-rubella (MMR) vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/5\">",
"     5",
"    </a>",
"    ], and as the quadrivalent MMRV vaccine (measles, mumps, rubella, and varicella). Several other vaccines, also derived from attenuated measles virus, are in use in other parts of the world.",
"   </p>",
"   <p>",
"    Previously used measles vaccines include an inactivated Edmonston B strain vaccine distributed in the United States from 1963 to 1967, a live attenuated Edmonston B strain vaccine from 1963 to 1975, and a different live attenuated Schwarz strain vaccine introduced in 1965, which is no longer available in the United States. The inactivated vaccine was associated with severe atypical measles in those exposed to live measles after vaccination.",
"   </p>",
"   <p>",
"    Management of patients previously vaccinated with prior vaccine types is discussed below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Prior vaccination with other strains'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23756242\">",
"    <span class=\"h3\">",
"     MMRV",
"    </span>",
"    &nbsp;&mdash;&nbsp;MMRV vaccine was approved by the United States Food and Drug administration in 2005 for individuals aged 12 months to 12 years. MMRV has comparable immunogenicity to simultaneous MMR and varicella vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/16\">",
"     16",
"    </a>",
"    ]. In postlicensure studies MMRV was associated with a small increased risk for febrile seizures; this risk was present at the typical age of receipt for the first dose of vaccine, but not at the age of receipt for the second dose [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/16\">",
"     16",
"    </a>",
"    ]. The Advisory Committee on Immunization Practices (ACIP) reviewed the risks and benefits of MMRV compared to simultaneous MMR and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    and issued recommendations for use as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the first dose of measles, mumps, rubella, and varicella vaccines at age 12 to 47 months, either separate MMR and varicella vaccines or MMRV vaccine may be used. Providers considering administration of MMRV vaccine should discuss the benefits and risks of both vaccination options with the parents or caregivers. Unless the parent or caregiver expresses a preference for MMRV vaccine, the CDC recommends that separate MMR and varicella vaccines be administered for the first dose in this age group.",
"     </li>",
"     <li>",
"      For the second dose of measles, mumps, rubella, and varicella vaccines at any age (15 months to 12 years) and for the first dose at age &ge;48 months, use of MMRV vaccine generally is preferred over separate injections of its equivalent component vaccines (ie, MMR vaccine and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      ). Considerations should include provider assessment, patient preference, and the potential for adverse events. Provider assessment denotes consideration of &ldquo;the number of injections, vaccine availability, likelihood of improved coverage, likelihood of patient return, and storage and cost considerations.&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vaccine effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, anti-measles antibody develops in 95 percent of individuals vaccinated at age 12 months, and 98 percent of individuals vaccinated at age 15 months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ]. Measles vaccination usually leads to long-term immunity; more than 90 percent of recipients develop anti-measles antibody if the first dose of the two-dose series is given no sooner than 12 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/18\">",
"     18",
"    </a>",
"    ]. Waning of immunity after vaccination, known as secondary vaccine failure, has been reported but is relatively rare [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many countries outside the United States, measles vaccination is performed at age nine. Estimates vary for the effectiveness of vaccination at this age; it may be approximately 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/19-23\">",
"     19-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     General recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;For prevention of measles infection in the United States, we agree with the ACIP, which recommends one dose of MMR at age 12 to 15 months, followed by a second dose administered no sooner than 28 days later [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4,16,17\">",
"     4,16,17",
"    </a>",
"    ]. The American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), and the ACIP all recommend that the second dose of vaccine be given prior to school entry (ages four to six years). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H22#H22\">",
"     \"Standard immunizations for children and adolescents\", section on 'MMR vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of contraindication, MMR is the vaccine of choice for protection against measles, mumps, and rubella. Doses of MMR and other measles-containing vaccines administered before the first birthday should not be counted when determining the adequacy of measles vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To achieve the goal of administering two doses of MMR to all children from kindergarten to grade 12, the ACIP has recommended that children without evidence of measles immunity not be admitted to school until the first dose of MMR has been administered. The ACIP, AAP, and AAFP all recommend a health maintenance visit for children 11 to 12 years old; this visit can be used to update vaccinations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    International travelers aged 6 to 11 months should have one MMR dose before departure. MMRV is not licensed for children &lt;12 months of age and therefore should not be considered in this setting. Children who receive a dose of measles vaccine before their first birthday should be revaccinated with two doses of MMR vaccine, the first of which should be administered when the child is aged 12 to 15 months (12 months if the child remains in a high risk area) and the second at least 28 days later [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/24\">",
"     24",
"    </a>",
"    ]. Other international travelers should have documentation of two doses of live measles vaccine.",
"   </p>",
"   <p>",
"    It is safe to administer most vaccines with MMR during the same visit including [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diphtheria",
"      <span class=\"nowrap\">",
"       toxoid/tetanus",
"      </span>",
"      <span class=\"nowrap\">",
"       toxoid/acellular",
"      </span>",
"      pertussis vaccine (DTaP) or diphtheria",
"      <span class=\"nowrap\">",
"       toxoid/tetanus",
"      </span>",
"      <span class=\"nowrap\">",
"       toxoid/whole-cell",
"      </span>",
"      pertussis vaccine (DTP)",
"     </li>",
"     <li>",
"      Haemophilus influenzae type b vaccine (Hib)",
"     </li>",
"     <li>",
"      Inactivated polio vaccine (IPV) or oral polio vaccine (OPV) &mdash; current recommendations are to use IPV instead of OPV in most countries [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       Hepatitis B vaccine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"       Varicella vaccine",
"      </a>",
"      (See",
"      <a class=\"local\" href=\"#H23756242\">",
"       'MMRV'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Live measles and yellow fever vaccines can be administered simultaneously at separate anatomical sites in separate syringes. Limited data exist regarding interactions between MMR and Japanese encephalitis vaccine, meningococcal vaccine, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/7/25718?source=see_link\">",
"     typhoid vaccine",
"    </a>",
"    , but a significant interaction is not expected to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Approach in high risk areas",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, high risk regions are defined by the ACIP as counties with a large inner-city population, counties with a recent measles outbreak among unvaccinated preschool children, and counties with more than five cases of measles among preschool-aged children during the preceding five years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ]. In such regions, the first dose of measles vaccine should be given at age 12 months rather than 15 months. The benefit of preventing measles cases among children aged 12 to 15 months outweighs the risk of slightly reduced vaccine efficacy at this age. Individuals with inadequate response to the first vaccination are likely to develop sufficient immunity with the second vaccination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801740294\">",
"    <span class=\"h2\">",
"     Timing of vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) recommends that in high-prevalence settings, the first dose of MMR be administered at age nine months (given high risk of transmission), whereas in low-prevalence areas it can be given at 12 months (given higher likelihood of seroconversion as discussed below) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children are at risk for measles following clearance of transplacentally-acquired maternal antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Lower levels of measles antibodies have been observed among vaccinated mothers than mothers who had had natural infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/30\">",
"     30",
"    </a>",
"    ]. Maternal antibody levels correlated with neonatal antibody levels at birth (r=0.93), and the median time to loss of immunity was shorter for infants of vaccinated women than for infants of naturally immune women (0.97 months versus 3.78 months, respectively). At six months of age, immunity waned in more than 99 percent of neonates born to vaccinated mothers and 95 percent of neonates born to naturally immune mothers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/30\">",
"     30",
"    </a>",
"    ]. This suggests that by age six months, children are at risk for becoming infected with measles, and that the number of children at risk may grow as vaccination reduces the number of mothers with natural immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such observations have led to the suggestion that an early two-dose vaccination program may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. An interim analysis of a randomized trial of measles vaccine at age 4.5 months found that, in a coincidental outbreak, the monthly incidence of measles was 0.7 percent in the early-vaccination group versus 3.1 percent in the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/31\">",
"     31",
"    </a>",
"    ]. The investigators cautioned that the results likely only applied to the measles vaccine used in the study (Edmonston-Zagreb), and an accompanying editorial recommended that early vaccination not replace vaccine doses given at age 9 to 15 months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other research shows that children vaccinated at a younger age are less likely to respond to measles vaccine. The 2009 World Health Organization (WHO) vaccination guidelines estimate that at age 8 to 9 months, a median 89.6 percent of infants seroconvert after one dose of measles vaccine (interquartile range (IQR): 82 to 95 percent), and at age 11 to 12 months a median 99 percent of infants seroconvert (IQR: 93 to 100 percent). A review on vaccine effectiveness noted that the median effectiveness for a single dose of measles vaccine was higher when given at age &gt;12 months than at age 9 to 11 months; 92.5 percent (IQR: 85 to 97 percent) versus 84 percent (IQR: 72 to 95 percent), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, among Canadian teenagers who developed measles in spite of two doses of childhood measles vaccine, the susceptibility to measles was two- to fourfold higher among those who received the first dose at age 12 months compared with those who received the at age &gt;15 months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In regions with high prevalence of HIV, rapid waning of measles antibody in HIV-infected children suggests that measles vaccination campaigns may need to be repeated more frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/36\">",
"     36",
"    </a>",
"    ]. In a prospective study of 696 children, antibody titers 27 months after vaccination were detectable less frequently in the HIV-infected group than the HIV-negative group (50 percent versus 89 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/37\">",
"     37",
"    </a>",
"    ]. A subset of 12 children with HIV infection incidentally received repeat vaccination; antibody titers were detectable in 92 percent of these children, although the durability of this response was not assessed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link&amp;anchor=H22#H22\">",
"     \"Immunizations in HIV-infected patients\", section on 'Measles, mumps, and rubella vaccine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=see_link\">",
"     \"Clinical presentation and diagnosis of measles\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Prior vaccination with other strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previous vaccination with live attenuated Edmonston B measles vaccine (1963 to 1975) is considered an effective first dose of vaccine if given at age 12 months or older. If indicated, a second dose of MMR vaccine should be administered.",
"   </p>",
"   <p>",
"    All other individuals are considered unvaccinated including: those receiving a further attenuated strain (Schwarz or Moraten), especially if coadministered with IG or a high-titer measles immune globulin (no longer available in the United States); those vaccinated with an unknown strain with or without globulin coadministration; and those receiving inactivated measles vaccine or vaccine of unknown type between 1963 and 1967.",
"   </p>",
"   <p>",
"    These persons should receive two doses of live vaccine separated by at least 28 days. Those who received inactivated vaccine followed within three months by live vaccine should also be revaccinated with two doses of live vaccine separated by at least 28 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Lack of association with autism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concern has been raised periodically about a possible link between receipt of MMR and autism. Several studies have now been performed which fail to demonstrate any such association. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26857?source=see_link\">",
"     \"Autism and chronic disease: Little evidence for vaccines as a contributing factor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2455568\">",
"    <span class=\"h1\">",
"     ESTABLISHING EVIDENCE OF MEASLES IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence for measles immunity is important to establish whether subsequent vaccination is needed. The criteria below are accepted by the Advisory Committee on Immunization Practices (ACIP) as presumptive evidence of measles immunity. Nonetheless, transmission of infection can occur even among individuals who meet criteria for presumptive immunity. Local criteria may differ from those listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2455590\">",
"    <span class=\"h2\">",
"     Birth before the year 1957",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals born before 1957 have had natural measles infection, given the widespread measles epidemics in the United States before the introduction of measles vaccine. Among hospital workers born before 1957, 5 to 9 percent do not have serologic evidence of immunity to measles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the risk of occupational exposure to measles and the risk that healthcare workers with measles may transmit infection to others in a healthcare setting, in a provisional update to its guidelines the Centers for Disease Control and Prevention (CDC) recommend that healthcare facilities consider administration of two doses of measles-mumps-rubella (MMR) vaccine to healthcare workers born prior to 1957 (in the absence of other evidence for measles immunity) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/39\">",
"     39",
"    </a>",
"    ]. Public health authorities should be contacted to determine local vaccination policies for healthcare workers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2455612\">",
"    <span class=\"h2\">",
"     Clinical measles diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical diagnosis of measles documented by a physician is considered acceptable presumptive evidence for immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4,39\">",
"     4,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2455619\">",
"    <span class=\"h2\">",
"     Laboratory evidence of immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-measles antibody unequivocally detected by any serologic test is considered evidence for measles immunity. A negative serology should prompt vaccination except in individuals who are pregnant or have other contraindications (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Contraindications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Screening in non-outbreak situations is most effective when follow up is assured (eg, hiring of new healthcare workers). If follow-up for reporting results and administering vaccine is not possible, screening should not be performed. Screening is not advised during an outbreak situation; vaccination should be administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2455626\">",
"    <span class=\"h2\">",
"     Documentation of vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only written documentation of vaccination is considered valid; a self report or parent report of measles vaccination is inadequate. The definitions of adequate measles vaccination differ by group.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Students in kindergarten through twelfth grade should have documentation of receipt of two doses of vaccine.",
"     </li>",
"     <li>",
"      One dose of vaccine administered on or after the first birthday is considered adequate immunization for preschool-aged children, and for persons who (1) are considered at low risk for measles infection; (2) were born 1957 or later; (3) are eighteen or over. Adults at high risk for measles infection and transmission include international travelers, persons attending colleges and other post-high school educational institutions, and persons who work at healthcare facilities.",
"     </li>",
"     <li>",
"      Students at post high school educational institutions (including colleges, universities, vocational schools, and technical schools) and persons working in healthcare facilities (including volunteers, students, non-medical workers, part time workers, and persons without patient care responsibilities) should have documentation of two doses of live measles vaccine, preferably with MMR, separated by at least 28 days.",
"     </li>",
"     <li>",
"      International travelers aged 6 to 11 months should have documentation of one MMR dose before departure. Children who receive a dose of measles vaccine before their first birthday should be revaccinated with two doses of MMR vaccine, the first of which should be administered when the child is aged 12 to 15 months (12 months if the child remains in a high risk area) and the second at least 28 days later [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/24\">",
"       24",
"      </a>",
"      ]. Other international travelers should have documentation of two doses of live measles vaccine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to measles vaccination are summarized below. In the setting of measles exposure, individuals with contraindications to vaccination should receive immune globulin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Use of immune globulin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a theoretical risk of birth defects among children born to mothers who receive live measles or measles-mumps-rubella (MMR) vaccine during pregnancy. Thus, the vaccine is considered contraindicated in pregnant women. Women of childbearing age should be counseled to avoid pregnancy for 30 days after vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2455889\">",
"    <span class=\"h2\">",
"     Immunocompromised patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Live measles vaccine or MMR should be used with caution in severely immunocompromised individuals. Issues related to immunizations in patients with immune suppression due to various causes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link&amp;anchor=H22#H22\">",
"     \"Immunizations in HIV-infected patients\", section on 'Measles, mumps, and rubella vaccine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link&amp;anchor=H14#H14\">",
"     \"Immunizations in patients with cancer\", section on 'Measles, mumps, and rubella vaccines'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link&amp;anchor=H19#H19\">",
"     \"Immunizations after hematopoietic cell transplantation\", section on 'Measles, mumps, and rubella'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link&amp;anchor=H18#H18\">",
"     \"Immunizations in solid organ transplant candidates and recipients\", section on 'Measles, mumps, and rubella'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    MMR or live measles vaccination should be postponed in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (&gt;2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 20 mg daily or every other day for more than 14 days). Vaccine should not be administered until at least one month after the cessation of treatment.",
"   </p>",
"   <p>",
"    Close contacts of immunocompromised patients should receive routine measles vaccination; secondary transmission associated with vaccination has not been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2456735\">",
"    <span class=\"h2\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with a history of thrombocytopenia are at increased risk of developing significant thrombocytopenia after MMR vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the benefits of primary vaccination usually outweigh the risks. It may be prudent to avoid a second dose of MMR in individuals with history of thrombocytopenia within six weeks of initial vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2456743\">",
"    <span class=\"h2\">",
"     Recent blood products or immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccine efficacy is diminished significantly by prior passive administration of antibody. Vaccination should be delayed for 3 to 11 months after antibody administration; the length of time varies depending upon the amount of antibody in the preparation. The interval is six months for those who have received packed red blood cells (unwashed) or whole blood, and seven months for",
"    <span class=\"nowrap\">",
"     plasma/platelet",
"    </span>",
"    preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2456807\">",
"    <span class=\"h2\">",
"     Allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of anaphylaxis after ingestion of gelatin is associated with an increased risk of anaphylaxis from the MMR or measles vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ]. This history should warrant a skin test for gelatin allergy. Individuals with anaphylaxis (not contact dermatitis) due to neomycin also should not receive these vaccines because they contain a small amount of this antibiotic. In contrast, a history of anaphylaxis after egg ingestion is not a contraindication to measles immunization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link\">",
"     \"Allergic reactions to vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2456861\">",
"    <span class=\"h2\">",
"     Concurrent illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination should be delayed in persons with moderate to severe febrile illnesses until resolution of the acute phase of the illness, as long as the vaccine is not being administered for an exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ]. However, mild febrile or nonfebrile illnesses do not mandate delay of vaccination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of adverse reactions have been reported following measles and measles-mumps-rubella (MMR) vaccine administration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/24\">",
"     24",
"    </a>",
"    ]. Transient fever (39.4&ordm;C or higher occurring one to two weeks after vaccination) develops in 5 to 15 percent of vaccinees. Transient rash occurs in approximately 5 percent. Most hypersensitivity reactions to the vaccine are minor. Anaphylaxis can occur, but is extremely rare. Epinephrine should be available for use at any site that administers the vaccine.",
"   </p>",
"   <p>",
"    Thrombocytopenia has been observed in prospective studies (1 case in 25,000 to 40,000 vaccine doses) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ]. In general, it is transient and occurs within two months of the receipt of vaccine, most commonly at two to three weeks. The risk may be higher in individuals who experienced thrombocytopenia following previous vaccination with MMR. (See",
"    <a class=\"local\" href=\"#H2456735\">",
"     'Thrombocytopenia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Administration of MMR has been associated with febrile seizures, anaphylaxis, and measles inclusion body encephalitis in immunodeficient individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/41\">",
"     41",
"    </a>",
"    ]. The incidence of vaccine-associated seizures has been estimated to be 1 in 3000 MMR doses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ], but is increased in vaccinees with a history of seizures or with a family history in first degree relatives. Most are simple febrile seizures. In most cases, the benefits of vaccination outweigh the risk of seizures. The incidence of anaphylaxis is unknown but is estimated by the Centers for Disease Control and Prevention (CDC) to be less than one per every one million MMR doses distributed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     TREATMENT OF MEASLES INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of measles is largely supportive; there is a role for vitamin A in certain settings, discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The World Health Organization (WHO) has published a comprehensive guide to the treatment of measles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/44\">",
"     44",
"    </a>",
"    ]. Supportive therapy includes antipyretics, fluids, and treatment of bacterial superinfections, such as bacterial pneumonia and otitis. Treatment of other complications, such as seizures and respiratory failure, may also be necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=see_link\">",
"     \"Clinical presentation and diagnosis of measles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Vitamin A",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of vitamin A for treatment of measles was suggested in 1932 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/45\">",
"     45",
"    </a>",
"    ]. The mechanism of action is not known; it may correct a viral-induced state of hyporetinemia. The WHO and UNICEF recommend that vitamin A (100,000 to 200,000 IU orally) be administered to all children with measles in areas where vitamin A deficiency is prevalent or where the mortality from measles exceeds one percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/24\">",
"     24",
"    </a>",
"    ]. This dose recommendation is lower than the 400,000 IU dose (200,000 IU given on successive days) used in the trials below [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one randomized trial including 180 Tanzanian children hospitalized with measles, mortality was reduced in patients treated with vitamin A (7 versus 13 percent); statistical significance was observed in the subgroup of patients under the age of two years [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another randomized trial including 189 South African children hospitalized with measles complications, including pneumonia, diarrhea, and croup, vitamin A was beneficial with respect to recovery time from pneumonia (mean of 6 versus 12 days), diarrhea (mean of 5 versus 8 days), incidence of croup (13 versus 27 cases), hospital stay (mean 10 versus 14 days), and overall mortality (2 versus 10 deaths) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/47\">",
"       47",
"      </a>",
"      ]. The risk of death or a major complication in the control group was twice that of the treated group. Among 156 infected patients in the study, 143 were found to have markedly depressed serum retinol levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A Cochrane review of randomized trials on the use of vitamin A for measles concluded that there was no overall significant reduction in mortality with vitamin A therapy for children with measles, but there was evidence that two doses were associated with a reduced risk of mortality and pneumonia-specific mortality in children under the age of two years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of vitamin A for treatment of measles in developed countries has not been evaluated in a clinical trial. The American Academy of Pediatrics recommends that vitamin A supplementation be considered for children with measles in developed countries in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children (6 months to 12 years) hospitalized with measles or its complications (eg, croup, pneumonia, or diarrhea).",
"     </li>",
"     <li>",
"      Children (older than six months of age) with measles and any of the following risk factors: immunodeficiency, ophthalmologic evidence of vitamin A deficiency, impaired intestinal absorption, moderate to severe malnutrition, and recent immigration from areas where high mortality rates from measles have been observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommended regimens for vitamin A supplementation are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children 6 to 12 months &mdash; 100,000 IU (50,000",
"      <span class=\"nowrap\">",
"       IU/mL)",
"      </span>",
"      as a single oral dose.",
"     </li>",
"     <li>",
"      Children older than 12 months &mdash; 200,000 IU (50,000",
"      <span class=\"nowrap\">",
"       IU/mL)",
"      </span>",
"      as a single oral dose.",
"     </li>",
"     <li>",
"      For children with ophthalmologic evidence of vitamin A deficiency, repeat doses should be administered on day 2 and day 28.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measles virus is susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in vitro; there have been no randomized controlled trials to assess its clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/24\">",
"     24",
"    </a>",
"    ]. Data on use of ribavirin are limited to case reports.",
"   </p>",
"   <p>",
"    In one case report of three HIV-infected children with measles who received aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , two of the three survived initially, but died within the subsequent three months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/50\">",
"     50",
"    </a>",
"    ]. Another case series reported a favorable outcome in five of six adults with severe measles pneumonitis who received intravenous ribavirin. Those who recovered received the drug on day two to day five of illness; the patient who died of progressive respiratory failure received the drug on day 22 of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22793/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/56/2947?source=see_link\">",
"       \"Patient information: Measles (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2457008\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measles is a highly contagious viral infection. Control of outbreaks is of paramount importance in the prevention of measles. Prevention of spread depends upon prompt administration of vaccine to all susceptible persons. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Controlling spread'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Susceptible individuals consist of those who are unable to produce evidence of measles immunity. Acceptable documentation includes one of the following: birth before the year 1957, clinical measles diagnosis by a physician, laboratory evidence of immunity,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      documentation of measles vaccination from a physician or healthcare facility. (See",
"      <a class=\"local\" href=\"#H2455568\">",
"       'Establishing evidence of measles immunity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measles vaccination has markedly reduced the incidence of measles throughout the developed world. However, measles cases still occur in low-incidence countries via importation by travelers. Therefore, maintenance of immunity is important even in countries with a low incidence of measles. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Measles vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For prevention of measles infection in the United States, we recommend measles vaccination as outlined by the Advisory Committee on Immunization Practices (ACIP): one dose of measles-mumps-rubella (MMR) vaccine at age 12 to 15 months, followed by a second dose administered no sooner than 28 days later (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The second dose of vaccine is generally administered prior to school entry (ages four to six years). Worldwide, some nations with high measles prevalence use the World Health Organization (WHO) strategy of administering the first dose of MMR at age 9 months rather than 12 months (See",
"      <a class=\"local\" href=\"#H18\">",
"       'General recommendations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Approach in high risk areas'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      There are several contraindications to measles vaccination, including pregnancy, immunocompromise, and others outlined above. Adverse events include fever, rash, and others outlined above. In rare cases, transient thrombocytopenia has been observed. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Contraindications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H38\">",
"       'Adverse events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of measles is largely supportive. Supportive therapy includes antipyretics, fluids, and treatment of bacterial superinfections and other complications. (See",
"      <a class=\"local\" href=\"#H44\">",
"       'Treatment of measles infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vitamin A may be of some benefit in the setting of measles infection; data are limited. In areas where vitamin A deficiency is prevalent or where the mortality from measles exceeds one percent, we suggest administering vitamin A (100,000 to 200,000 IU orally) to all children with measles (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In developed countries, we suggest administering vitamin A for children with measles complications or at risk for complications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H45\">",
"       'Vitamin A'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/1\">",
"      Moss WJ, Griffin DE. Measles. Lancet 2012; 379:153.",
"     </a>",
"    </li>",
"    <li>",
"     Fine P. Community immunity. In: Vaccines, 4th ed, Plotkin S, Orenstein W (Eds), Elsevier, Philadelphia 2004. p.1443.",
"    </li>",
"    <li>",
"     Measles &mdash; United States, January-May 20, 2011 file://www.cdc.gov/mmwr/pdf/wk/mm6020.pdf (Accessed on November 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/4\">",
"      Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/5\">",
"      Centers for Disease Control (CDC). Measles prevention. MMWR Morb Mortal Wkly Rep 1989; 38 Suppl 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/6\">",
"      Hinman AR, Orenstein WA, Papania MJ. Evolution of measles elimination strategies in the United States. J Infect Dis 2004; 189 Suppl 1:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/7\">",
"      Steingart KR, Thomas AR, Dykewicz CA, Redd SC. Transmission of measles virus in healthcare settings during a communitywide outbreak. Infect Control Hosp Epidemiol 1999; 20:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/8\">",
"      Bolyard EA, Tablan OC, Williams WW, et al. Hospital Infection Control Advisory Committee. Guidelines for infection control in health-care personnel. Am J Infect Control 1998; 26:289.",
"     </a>",
"    </li>",
"    <li>",
"     2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings file://www.cdc.gov/hicpac/pdf/isolation/Isolation2007.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/10\">",
"      Raad II, Sherertz RJ, Rains CS, et al. The importance of nosocomial transmission of measles in the propagation of a community outbreak. Infect Control Hosp Epidemiol 1989; 10:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/11\">",
"      Angel JB, Walpita P, Lerch RA, et al. Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med 1998; 129:104.",
"     </a>",
"    </li>",
"    <li>",
"     Measles: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook - 12th Edition (April 2011) file://www.cdc.gov/vaccines/pubs/pinkbook/meas.html (Accessed on November 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/13\">",
"      Centers for Disease Control and Prevention (CDC). Measles: United States, January--May 20, 2011. MMWR Morb Mortal Wkly Rep 2011; 60:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/14\">",
"      Bellini WJ, Rota JS, Lowe LE, et al. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis 2005; 192:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/15\">",
"      Greenaway C, Dongier P, Boivin JF, et al. Susceptibility to measles, mumps, and rubella in newly arrived adult immigrants and refugees. Ann Intern Med 2007; 146:20.",
"     </a>",
"    </li>",
"    <li>",
"     Use of Combination Measles, Mumps, Rubella, and Varicella Vaccine: Recommendations of the Advisory Committee on Immuniation Practices file://www.cdc.gov/mmwr/pdf/rr/rr5903.pdf.",
"    </li>",
"    <li>",
"     file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5903a1.htm?s_cid=rr5903a1_e#box (Accessed on October 26, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/18\">",
"      Fowlkes A, Witte D, Beeler J, et al. Persistence of vaccine-induced measles antibody beyond age 12 months: a comparison of response to one and two doses of Edmonston-Zagreb measles vaccine among HIV-infected and uninfected children in Malawi. J Infect Dis 2011; 204 Suppl 1:S149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/19\">",
"      Wolfson LJ, Strebel PM, Gacic-Dobo M, et al. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 2007; 369:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/20\">",
"      Talley L, Salama P. Short report: assessing field vaccine efficacy for measles in famine-affected rural Ethiopia. Am J Trop Med Hyg 2003; 68:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/21\">",
"      Kaninda AV, Legros D, Jataou IM, et al. Measles vaccine effectiveness in standard and early immunization strategies, Niger, 1995. Pediatr Infect Dis J 1998; 17:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/22\">",
"      Akramuzzaman SM, Cutts FT, Hossain MJ, et al. Measles vaccine effectiveness and risk factors for measles in Dhaka, Bangladesh. Bull World Health Organ 2002; 80:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/23\">",
"      Cutts FT, Grabowsky M, Markowitz LE. The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. Biologicals 1995; 23:95.",
"     </a>",
"    </li>",
"    <li>",
"     Measles. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, Illinois 2012. p.444.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/25\">",
"      Centers for Disease Control and Prevention (CDC). Recommendations of the Advisory Committee on Immunization Practices: revised recommendations for routine poliomyelitis vaccination. MMWR Morb Mortal Wkly Rep 1999; 48:590.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Weekly epidemiological record: Measles vaccines: WHO position paper. 2009; 35(84):349. www.who.int/wer/2009/wer8435.pdfSimilar (Accessed on February 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/27\">",
"      Papania M, Baughman AL, Lee S, et al. Increased susceptibility to measles in infants in the United States. Pediatrics 1999; 104:e59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/28\">",
"      Maldonado YA, Lawrence EC, DeHovitz R, et al. Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity. Pediatrics 1995; 96:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/29\">",
"      Markowitz LE, Albrecht P, Rhodes P, et al. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser Permanente Measles Vaccine Trial Team. Pediatrics 1996; 97:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/30\">",
"      Leuridan E, Hens N, Hutse V, et al. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. BMJ 2010; 340:c1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/31\">",
"      Martins CL, Garly ML, Bal&eacute; C, et al. Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial. BMJ 2008; 337:a661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/32\">",
"      Kim JJ. Human papillomavirus vaccination in the UK. BMJ 2008; 337:a842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/33\">",
"      Gans HA, Yasukawa LL, Sung P, et al. Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age. J Infect Dis 2013; 207:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/34\">",
"      Uzicanin A, Zimmerman L. Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. J Infect Dis 2011; 204 Suppl 1:S133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/35\">",
"      De Serres G, Boulianne N, Defay F, et al. Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12-14 months versus 15 months of age. Clin Infect Dis 2012; 55:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/36\">",
"      Abzug MJ, Qin M, Levin MJ, et al. Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis 2012; 206:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/37\">",
"      Moss WJ, Scott S, Mugala N, et al. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. J Infect Dis 2007; 196:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/38\">",
"      Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1997; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     ACIP Provisional Recommendations for Measles-Mumps-Rubella (MMR) 'Evidence of Immunity' Requirements for Healthcare Personnel file://www.cdc.gov/vaccines/recs/provisional/downloads/mmr-evidence-immunity-Aug2009-508.pdf (Accessed on November 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/40\">",
"      Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp Epidemiol 2007; 28:702.",
"     </a>",
"    </li>",
"    <li>",
"     Adverse Effects of Vaccines: Evidence and Causality, Stratton K, Ford A, Rusch E, Clayton EW (Eds), Institute of Medicine, 2011.",
"    </li>",
"    <li>",
"     Gershon AA. Measles Virus. In: Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 4th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 1995. p.1519.",
"    </li>",
"    <li>",
"     Bernstein DI, Schiff GM. Measles. In: Infectious Diseases, 2nd ed, Gorbach SL, Bartlett JG, Blacklow NR (Eds), WB Saunders Company, 1998. p.1296.",
"    </li>",
"    <li>",
"     Treating measles in children. World Health Organization, Geneva, 2004 updated. file://www.measlesinitiative.org/mi-files/Reports/Treatment/Treating%20Measles%20in%20Children.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/45\">",
"      Ellison JB. INTENSIVE VITAMIN THERAPY IN MEASLES. Br Med J 1932; 2:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/46\">",
"      Barclay AJ, Foster A, Sommer A. Vitamin A supplements and mortality related to measles: a randomised clinical trial. Br Med J (Clin Res Ed) 1987; 294:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/47\">",
"      Hussey GD, Klein M. A randomized, controlled trial of vitamin A in children with severe measles. N Engl J Med 1990; 323:160.",
"     </a>",
"    </li>",
"    <li>",
"     Vitamin A for treating measles in chidlren (Review) file://www.measlesinitiative.org/mi-files/Reports/Treatment/Huiming%20Cochrane%20Database%20Syst%20Rev%20Vit%20A%20Measles%202005%20Issue%204%20CD001479.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/49\">",
"      American Academy of Pediatrics Committee on Infectious Diseases: Vitamin A treatment of measles. Pediatrics 1993; 91:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/50\">",
"      Krasinski K, Borkowsky W. Measles and measles immunity in children infected with human immunodeficiency virus. JAMA 1989; 261:2512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22793/abstract/51\">",
"      Forni AL, Schluger NW, Roberts RB. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin Infect Dis 1994; 19:454.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3020 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_16_22793=[""].join("\n");
var outline_f22_16_22793=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2457008\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONTROLLING SPREAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Case definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Outbreak control measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Schools",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Healthcare facilities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Outbreaks among infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Case isolation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MEASLES VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Types of measles vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23756242\">",
"      - MMRV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vaccine effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      General recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Approach in high risk areas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801740294\">",
"      Timing of vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Prior vaccination with other strains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Lack of association with autism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2455568\">",
"      ESTABLISHING EVIDENCE OF MEASLES IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2455590\">",
"      Birth before the year 1957",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2455612\">",
"      Clinical measles diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2455619\">",
"      Laboratory evidence of immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2455626\">",
"      Documentation of vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2455889\">",
"      Immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2456735\">",
"      Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2456743\">",
"      Recent blood products or immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2456807\">",
"      Allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2456861\">",
"      Concurrent illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      TREATMENT OF MEASLES INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Vitamin A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Ribavirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2457008\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=related_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26857?source=related_link\">",
"      Autism and chronic disease: Little evidence for vaccines as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=related_link\">",
"      Clinical presentation and diagnosis of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42246?source=related_link\">",
"      Epidemiology and transmission of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=related_link\">",
"      Immunizations after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14822?source=related_link\">",
"      Measles-mumps-rubella vaccination in high risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/56/2947?source=related_link\">",
"      Patient information: Measles (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_16_22794="Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2";
var content_f22_16_22794=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/16/22794/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/16/22794/contributors\">",
"     Cornelis J Lips, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/16/22794/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/16/22794/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/16/22794/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/16/22794/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/16/22794/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple endocrine neoplasia type 2 (MEN2) is subclassified into three distinct syndromes: MEN2A, MEN2B, and familial medullary thyroid cancer (FMTC). The genetic defect in these disorders involves the RET proto-oncogene on chromosome 10. In all three syndromes, there is an occurrence of multicentric tumor formation in all organs where the RET proto-oncogene is expressed. Both thyroid lobes, parathyroid and adrenal glands, and accessory adrenals are at risk for developing tumors that may reduce life expectancy and quality of life. The excellent prognosis for medullary thyroid cancer diagnosed at its earliest stage underscores the importance of early diagnosis for sporadic and hereditary MTC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/1\">",
"     1",
"    </a>",
"    ]. This topic will review the clinical manifestations and diagnosis of MEN2. The genetics of this disorder, its distinction from MEN1, and its treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=see_link\">",
"     \"Classification and genetics of multiple endocrine neoplasia type 2\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8872?source=see_link\">",
"     \"Approach to therapy in multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sporadic medullary thyroid cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9560?source=see_link\">",
"     \"Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38263?source=see_link\">",
"     \"Medullary thyroid cancer: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23288?source=see_link\">",
"     \"Chemotherapy and immunotherapy for medullary thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3038677\">",
"    <span class=\"h1\">",
"     MEN2A",
"    </span>",
"    &nbsp;&mdash;&nbsp;MEN2A is characterized by medullary thyroid cancer (MTC), pheochromocytoma (PC), and primary parathyroid hyperplasia associated with a germline RET mutation. As expected from its autosomal dominant inheritance pattern, men and women are affected in equal proportions. While the penetrance of MTC is nearly 100 percent, there is much inter- and intra-family variability in the other manifestations of MEN2A. In a patient with only one or two of the clinical features, identification of a germline RET mutation or the identification of the clinical features of MEN2A in other first degree relatives is required to make the diagnosis of MEN2A [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/2\">",
"     2",
"    </a>",
"    ]. There are rare families with clinical features of MEN2A in the absence of an identifiable RET mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/2\">",
"     2",
"    </a>",
"    ]. In the absence of an autosomal dominant inheritance pattern or RET mutation, at least two of the classical clinical features of MEN2A are required to make the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Medullary thyroid cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medullary thyroid cancer (MTC), a neuroendocrine tumor of the parafollicular or C cells of the thyroid gland, accounts for approximately 3 to 5 percent of thyroid cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/2\">",
"     2",
"    </a>",
"    ]. C cells are neuroendocrine cells derived from the ultimobranchial bodies (transient embryonic structures), which fuse with the posterior lobes of the thyroid. C cells make up only about 0.1 percent of the thyroid mass. C cells produce calcitonin, a 32-amino-acid peptide, which plays an important role in regulating blood calcium in fish and, in a rat model, it inhibits osteoclast-mediated bone resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the physiological role of calcitonin in humans is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multicentric C cell hyperplasia is the hallmark of MEN2, with a penetrance approaching 100 percent. C cell hyperplasia precedes the development of medullary thyroid cancer, and 90 percent of patients develop clinically apparent MTC, often early in life [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. MTCs in patients with MEN2 or familial medullary thyroid cancer (FMTC) are multicentric and concentrated in the upper third of the thyroid gland reflecting the normal distribution of parafollicular cells (",
"    <a class=\"graphic graphic_picture graphicRef86206 \" href=\"UTD.htm?25/2/25634\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most cases of MTC (75 percent) are sporadic, but as many as 25 percent of all MTCs are considered to be familial (",
"    <a class=\"graphic graphic_table graphicRef85653 \" href=\"UTD.htm?23/5/23643\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/5\">",
"     5",
"    </a>",
"    ]. The staging of medullary thyroid cancer, whether sporadic or familial, is based upon the pathological tumor, node, metastases system (pTMN). Staging is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9560?source=see_link&amp;anchor=H10#H10\">",
"     \"Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;If diagnosed as an index case, the clinical presentation and manifestations of MEN2-associated MTC are similar to those of sporadic MTC. The most common presentation is that of a solitary thyroid nodule or cervical lymphadenopathy. In MEN2A and familial medullary thyroid cancer (FMTC), the peak incidence of index cases is in the third decade of life, and it is usually earlier in MEN2B. However, there is substantial interpatient variability. The typical age of presentation of sporadic medullary thyroid cancer is in the fifth or sixth decade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9560?source=see_link&amp;anchor=H2#H2\">",
"     \"Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less common presentations specific to MEN2-associated MTC include recognition during a search initiated after an associated disease such as pheochromocytoma or hyperparathyroidism becomes apparent, diarrhea caused by gastrointestinal secretion of fluid and electrolytes, and flushing due to the secretion of other peptides by the tumor. In rare cases, MTC causes Cushing's syndrome due to ectopic production of corticotropin (ACTH). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26489?source=see_link\">",
"     \"Causes and pathophysiology of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Basal serum calcitonin concentrations usually correlate with tumor mass and are almost always high in patients with a palpable tumor. In patients with small tumors and those with C cell hyperplasia, the values may be normal but rise excessively after calcium or pentagastrin infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3039235\">",
"     'Biochemical testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H962026\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the index patient, the diagnosis of MTC is usually made based upon the cytological findings after fine needle aspiration biopsy of a thyroid nodule. In some countries, serum basal and stimulated calcitonin levels are also used to make the diagnosis of MTC.",
"   </p>",
"   <p>",
"    In family members of the index patient, the diagnosis of MTC is usually made based upon genetic screening or biochemical testing. The screening of family members is discussed below. (See",
"    <a class=\"local\" href=\"#H1589724\">",
"     'Screening of family members in MEN2 kindreds'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13656953\">",
"    <span class=\"h4\">",
"     Fine needle aspiration cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the index patient who presents with a thyroid nodule, the diagnosis of MTC is usually made after fine needle aspiration biopsy. In retrospective studies, the accuracy of fine needle aspiration ranges from 50 to 80 percent, although higher accuracy can be obtained by the addition of immunohistochemical staining for calcitonin (",
"    <a class=\"graphic graphic_picture graphicRef56242 \" href=\"UTD.htm?30/6/30831\">",
"     picture 2",
"    </a>",
"    ) or by measurement of calcitonin (where available) in needle washings from repeat FNA specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of C cell hyperplasia (CCH) is based upon microscopy criteria: the presence of an increased number of diffusely scattered C cells (&ge;7 per thyroid follicle), clusters of C cells, or 50 or more C cells in at least one low power field (x 100) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. CCH occurs in a reactive (secondary) form or a neoplastic form (precursor to MTC in MEN2). Reactive CCH is considered to be caused by a stimulus from outside the C cell and probably is not premalignant (",
"    <a class=\"graphic graphic_picture graphicRef85628 \" href=\"UTD.htm?4/63/5108\">",
"     picture 3",
"    </a>",
"    ). Hypercalcemia, hyperparathyroidism, chronic lymphocytic thyroiditis or follicular tumors have been associated with reactive CCH [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/12\">",
"     12",
"    </a>",
"    ]. Neoplastic C cell hyperplasia is diagnosed when nests of C cells appear to extend beyond the basement membrane and to infiltrate and destroy thyroid follicles (",
"    <a class=\"graphic graphic_picture graphicRef86205 \" href=\"UTD.htm?19/55/20343\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13656946\">",
"    <span class=\"h4\">",
"     Serum calcitonin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of serum calcitonin to complement FNA in making the diagnosis of MTC is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/14\">",
"     14",
"    </a>",
"    ]. Measurement of serum calcitonin has not been a part of the routine evaluation of patients with thyroid nodules in the United States. The high frequency of falsely high serum calcitonin values, the inability to confirm the high calcitonin by pentagastrin stimulation in the United States, and the accuracy of fine needle aspiration biopsy would argue against a change in this recommendation. Further, occasional patients with locoregional metastases or locally invasive MTC will have normal unstimulated serum calcitonin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/15\">",
"     15",
"    </a>",
"    ]. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Serum calcitonin concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the basal serum calcitonin (CT) level is measured and exceeds 10",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    the CT measurement should be repeated after calcium or, when available, pentagastrin (after renal insufficiency and use of proton pump inhibitor medication have been ruled out) stimulation testing [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1624290\">",
"     'Pentagastrin stimulation test'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3039577\">",
"     'Calcium stimulation test'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1590908\">",
"    <span class=\"h3\">",
"     Evaluation after diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients diagnosed with MTC or C cell hyperplasia on the basis of cytologic evaluation of a thyroid nodule, evaluation is the same as in sporadic medullary thyroid cancer and should include measurement of serum calcitonin, carcinoembryonic antigen (CEA), ultrasonography of the neck (if not already performed), genetic testing for germline RET mutations, and evaluation for coexisting tumors. The evaluation is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9560?source=see_link&amp;anchor=H6#H6\">",
"     \"Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1590678\">",
"     'Indications for genetic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When the diagnosis of MTC is established, preoperative testing should include measurement of serum calcium (to rule out hyperparathyroidism requiring concomitant surgical intervention) and testing for pheochromocytoma. If the index patient has a germline RET mutation and the initial screening tests are negative, it is important to evaluate for pheochromocytoma and hyperparathyroidism regularly (",
"    <a class=\"graphic graphic_table graphicRef77855 \" href=\"UTD.htm?30/60/31691\">",
"     table 2",
"    </a>",
"    ). In addition, family members should undergo genetic testing and assessment for medullary thyroid cancer. (See",
"    <a class=\"local\" href=\"#H1590765\">",
"     'Genetic screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pheochromocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pheochromocytoma occurs in approximately 40 percent of patients with MEN2A and probably a similar percentage in MEN2B [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/5,17\">",
"     5,17",
"    </a>",
"    ]. There is, however, large variability in the penetrance of pheochromocytoma among different reported kindreds, depending upon the specific RET germline mutation. These findings may help guide screening and therapy for MEN2 patients (",
"    <a class=\"graphic graphic_table graphicRef77855 \" href=\"UTD.htm?30/60/31691\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. As an example, compared with families with mutations in codons 634 and 918, pheochromocytomas are rare in families with mutations in codon 533, 609, 611, 618, 620, 630, 633, 666, 768, 790, 791, 804, and 891, but they do still occur. Thus, screening for pheochromocytoma is mandatory in all patients with familial medullary thyroid cancer syndromes. Pheochromocytomas in MEN2A and MEN2B occur earlier than sporadic forms. Due to screening programs, pheochromocytomas may be diagnosed at a young age and before symptoms are present. (See",
"    <a class=\"local\" href=\"#H1589724\">",
"     'Screening of family members in MEN2 kindreds'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Sporadic pheochromocytomas are almost always unilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In contrast, pheochromocytomas in MEN2A have been reported to be bilateral in approximately 30 to 100 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Extraadrenal pheochromocytoma is rare in MEN2, but does occur, especially in accessory adrenal glands (",
"    <a class=\"graphic graphic_picture graphicRef85629 \" href=\"UTD.htm?31/55/32629\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef86207 \" href=\"UTD.htm?5/21/5457\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most studies the percentage of MEN2A-associated pheochromocytomas that are malignant is considerably less than the 10 percent rate of malignancy reported for sporadic pheochromocytomas [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/5,26\">",
"     5,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unusual for pheochromocytoma to precede the development of MTC and be the initial manifestation of MEN2. In patients who have undergone regular screening, pheochromocytomas have usually become evident about 10 years later than C cell hyperplasia or MTC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/28\">",
"     28",
"    </a>",
"    ]. Thus, pheochromocytomas in MEN2 are usually identified during screening or through heightened vigilance for symptoms in patients with known or suspected MEN2. Rarely, pheochromocytoma may be the first manifestation of MEN2 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In such patients, symptoms are similar to those in patients with sporadic pheochromocytomas and may include attacks (paroxysms) of anxiety, headache, diaphoresis, palpitations or tachycardia. However, in one report, only about one-third had hypertension at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13657053\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biochemical diagnosis of pheochromocytoma is confirmed, as it is in patients with sporadic pheochromocytoma, by measurement of plasma fractionated metanephrines or urinary catecholamines. Biochemical screening for pheochromocytoma should be performed yearly in MEN2 patients (",
"    <a class=\"graphic graphic_table graphicRef77855 \" href=\"UTD.htm?30/60/31691\">",
"     table 2",
"    </a>",
"    ). The risk of developing pheochromocytoma is variable depending upon genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. In patients with a high index of suspicion for pheochromocytoma, such as a patient with MTC and classical symptoms of pheochromocytoma or known MEN2 syndrome, plasma fractionated metanephrines is the first-line test. Details of biochemical screening to detect pheochromocytomas, including in MEN2 patients, is reviewed elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because undiagnosed pheochromocytoma could cause substantial morbidity or even death during thyroid or parathyroid surgery, it is important to consider this diagnosis as a component of possible MEN2A and, if present, to remove the tumor",
"    <strong>",
"     before",
"    </strong>",
"    removing the other endocrine tumors. Once the diagnosis of pheochromocytoma in MEN2A is established, the possibility of bilateral disease must be carefully evaluated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8872?source=see_link\">",
"     \"Approach to therapy in multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     RET mutation in sporadic pheochromocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important question is whether patients with apparently sporadic pheochromocytoma, ie, with unilateral disease and without a positive family history, should undergo routine RET mutation testing for the detection of unsuspected heritable MEN2. Combined data from five studies failed to demonstrate even one example (yield",
"    <span class=\"nowrap\">",
"     0/156",
"    </span>",
"    cases) of an unsuspected germline RET mutation among unselected patients with apparently sporadic pheochromocytoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, in large series of young patients screened for the five susceptibility genes (RET, VHL, SDHB, SDHC and SDHD), 11 to 32 percent were found to harbor a germline mutation in these genes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. The frequency depended upon family history and clinical presentation.",
"   </p>",
"   <p>",
"    The discrepant findings in these studies could be due in part to differences in the populations studied and perhaps to ascertainment bias toward inherited disease in registry-based cases. In the United States, it appears that the yield of RET testing in patients with apparently sporadic pheochromocytoma, defined by unilateral disease, a negative family history, and no signs or symptoms of MEN2, is exceedingly low. In comparison, RET testing may be indicated in patients with pheochromocytoma who do not meet all three criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. The topic of genetic testing in patients with apparently sporadic pheochromocytomas is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21351?source=see_link\">",
"     \"Pheochromocytoma in genetic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Other causes of familial pheochromocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of familial pheochromocytoma has been as high as 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/23\">",
"     23",
"    </a>",
"    ]. This is probably an overestimate because of selection bias; a more likely figure is 10 percent. Other heritable syndromes associated with pheochromocytoma include von Hippel-Lindau (vHL) syndrome, neurofibromatosis type 1, and paraganglioma syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/23,41,42\">",
"     23,41,42",
"    </a>",
"    ]. The characteristic features of these syndromes are usually present in affected patients with pheochromocytomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/43/695?source=see_link\">",
"     \"Hemangioblastoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=see_link\">",
"     \"Paragangliomas of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Phenotype of MEN2 versus vHL syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pheochromocytomas due to MEN2 syndrome are more symptomatic than those with von Hippel-Lindau syndrome, which can be explained by differences in their biochemical phenotype. MEN2 patients, due to the higher tyrosine hydroxylase (TH) and phenylethanolamine N-methyltransferase (PNMT) expression, have an adrenergic phenotype with higher rates of epinephrine biosynthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. This topic is reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21351?source=see_link&amp;anchor=H4#H4\">",
"     \"Pheochromocytoma in genetic disorders\", section on 'Phenotype of MEN2 versus VHL syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Primary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperparathyroidism in MEN2A is almost always multiglandular. It has been reported in 10 to 25 percent of patients with MEN2A (our impression is that the lower figure may be more accurate) and rarely in patients with MEN2B [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/2,5,46\">",
"     2,5,46",
"    </a>",
"    ]. The penetrance of hyperparathyroidism depends upon the specific RET germline mutation (",
"    <a class=\"graphic graphic_table graphicRef77855 \" href=\"UTD.htm?30/60/31691\">",
"     table 2",
"    </a>",
"    ). The recurrence rate after apparently successful subtotal parathyroidectomy is less than that in MEN1 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/47,48\">",
"     47,48",
"    </a>",
"    ], being similar to the excellent long-term results seen in patients with nonfamilial primary hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38871?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Etiology and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been a suggestion that parathyroid disease in MEN2A may somehow be a consequence of the C cell abnormalities, based upon a low reported incidence of parathyroid disease in patients in whom C cell hyperplasia was detected early and treated by total thyroidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. In one report, as an example, none of 22 patients who underwent thyroidectomy developed hyperparathyroidism after more than 10 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/49\">",
"     49",
"    </a>",
"    ]. Why this might occur, and whether the risk is indeed lower after thyroidectomy, is not clear. It seems unlikely that hypercalcitoninemia per se is the stimulus for the parathyroid tumors for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperparathyroidism is not associated with MEN2B, FMTC, or sporadic MTC, all of which can be characterized by sustained hypercalcitoninemia.",
"     </li>",
"     <li>",
"      The RET gene is expressed in MEN2A-associated parathyroid tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A particular RET mutation, Cys to Arg at codon 634, may be preferentially found in MEN2 families that have hyperparathyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/52,53\">",
"       52,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Primary hyperparathyroidism may be the first manifestation of MEN2 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data imply that the initial stimulus to parathyroid cell proliferation in MEN2A, while often mild, is probably related to expression of the mutant RET protein within parathyroid tissue. It is interesting in this context, although not of direct clinical importance, that calcium suppression testing in normocalcemic patients has suggested that mild abnormalities in parathyroid function may be common in MEN2A [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hyperparathyroidism in MEN2A is often clinically occult. The diagnosis is established by finding high (or inappropriately normal) serum parathyroid hormone concentrations in the presence of hypercalcemia. Biochemical screening for hyperparathyroidism should be performed yearly or biennially in MEN2 patients (depending upon the specific RET mutation) (",
"    <a class=\"graphic graphic_table graphicRef77855 \" href=\"UTD.htm?30/60/31691\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1589672\">",
"    <span class=\"h2\">",
"     Other associated diseases",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Cutaneous lichen amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous lichen amyloidosis (CLA), also termed lichen planus amyloidosis (LPA), is a rare skin condition and can occur both sporadically and as a familial disease. The hereditary forms are transmitted in an autosomal dominant fashion, and an association between CLA and MEN2A has been established in some families [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The skin lesion is usually described as pruritic, scaly, papular, and pigmented, and located in the interscapular region or on the extensor surfaces of the extremities (",
"    <a class=\"graphic graphic_picture graphicRef65753 graphicRef69450 \" href=\"UTD.htm?35/27/36277\">",
"     picture 7A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/55\">",
"     55",
"    </a>",
"    ]. Amyloid deposition has been documented histologically [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Keratin-like peptides have been found in the amyloid deposits, but not calcitonin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/56\">",
"     56",
"    </a>",
"    ]. The presumed \"friction amyloidosis\" in CLA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/59\">",
"     59",
"    </a>",
"    ] is now thought to result from a primary neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/58,60\">",
"     58,60",
"    </a>",
"    ]. This is an attractive hypothesis with respect to CLA being a rare manifestation of MEN2A, since RET is expressed in the peripheral and central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/61-63\">",
"     61-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several different RET codon 634 mutations have been described in",
"    <span class=\"nowrap\">",
"     MEN2A/CLA",
"    </span>",
"    families [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/64,65\">",
"     64,65",
"    </a>",
"    ], and both dermal and non-dermal manifestations segregate with the mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/64\">",
"     64",
"    </a>",
"    ]. These same RET mutations are also found in MEN2A families without evidence of CLA, suggesting the influence of \"modifying genes\" or other factors, cooperating with the RET mutation, in the expression of the CLA phenotype. One exception was found in a patient with CLA associated with FMTC and a RET 804 mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/66\">",
"     66",
"    </a>",
"    ]. CLA kindreds without MEN2A have not had demonstrable germ-line RET mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hirschsprung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hirschsprung disease (HD) is characterized by the absence of autonomic ganglion cells within the distal colonic parasympathetic plexus resulting in chronic obstruction and megacolon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In humans, inactivating mutations of the RET proto-oncogene have been associated with HD. HD is a heterogenic disorder, occurring both in a familial and in a sporadic form. In about 50 percent of familial and 15 to 35 percent of sporadic HD patients, mutations in the RET gene are involved. Most HD cases arise from loss of function mutations, RET haploinsufficiency, RET polymorphisms or haplotypes of the RET promotor region. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=see_link&amp;anchor=H9#H9\">",
"     \"Classification and genetics of multiple endocrine neoplasia type 2\", section on 'Germline mutations in the intracellular tyrosine kinase domains'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hirschsprung disease (HD) was found in 50 percent of children in a family with a C620 mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RET proto-oncogene testing in infants presenting with Hirschsprung disease may identify new multiple endocrine neoplasia 2A kindreds [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/68\">",
"     68",
"    </a>",
"    ]. RET proto-oncogene testing in infants presenting with Hirschsprung disease is useful and may identify new multiple endocrine neoplasia 2A kindreds [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23352631\">",
"    <span class=\"h1\">",
"     MEN2B",
"    </span>",
"    &nbsp;&mdash;&nbsp;MEN2B is an autosomal dominant disorder characterized by MTC and PC, but not hyperparathyroidism. MTC occurs in almost all patients. The tumor develops at an earlier age and is more aggressive than in MEN2A [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/5\">",
"     5",
"    </a>",
"    ]; as a result, early diagnosis and prevention are crucial. The syndrome also includes mucosal neuromas, typically involving the lips and tongue, and intestinal ganglioneuromas. Patients with MEN2B also have development abnormalities, a decreased",
"    <span class=\"nowrap\">",
"     upper/lower",
"    </span>",
"    body ratio, skeletal deformations (kyphoscoliosis or lordosis), joint laxity, Marfanoid habitus, and myelinated corneal nerves. Disturbances of colonic function are common, including chronic constipation and megacolon [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/17\">",
"     17",
"    </a>",
"    ]. Unlike patients with Marfan's syndrome, MEN2B patients do not have ectopia lentis or aortic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MTC in MEN2B tends to be more aggressive as well as earlier in onset than in MEN2A and FMTC, and surgery is often not curative [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/17,70\">",
"     17,70",
"    </a>",
"    ]. In one large study, death from MTC occurred in 50 percent of patients with MEN2B versus 9.7 percent of those with MEN2A [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/70\">",
"     70",
"    </a>",
"    ]. Thus, thyroidectomy as early as the neonatal period may be indicated in patients with MEN2B identified by genetic screening (see",
"    <a class=\"local\" href=\"#H30\">",
"     'Timing of surgery'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23352513\">",
"    <span class=\"h1\">",
"     FAMILIAL MEDULLARY THYROID CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;FMTC is a variant of MEN2A in which there is a strong predisposition to MTC but not the other clinical manifestations of MEN2A (or 2B). Distinguishing FMTC from MEN2A may be difficult in small families and, therefore, rigorous criteria for FMTC should be used in order not to miss a pheochromocytoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/71\">",
"     71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      More than 10 carriers in the kindred",
"     </li>",
"     <li>",
"      Multiple carriers or affected members over the age of 50 years",
"     </li>",
"     <li>",
"      An adequate medical history, particularly in older family members",
"     </li>",
"     <li>",
"      Identification of a RET mutation only associated with FMTC",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Why pheochromocytomas and hyperparathyroidism do not develop in these families is still unknown, since many FMTC and MEN2A families carry identical RET mutation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=see_link&amp;anchor=H5#H5\">",
"     \"Classification and genetics of multiple endocrine neoplasia type 2\", section on 'Familial medullary thyroid cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1590678\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR GENETIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in the molecular genetics underlying the MEN2 syndromes have resulted in DNA testing becoming the optimal test for their detection. The role of RET DNA testing in MEN2 kindreds is better established than testing for MEN1 mutations in MEN1 families. This is because identification of specific RET mutations predicts particular phenotypes (age of onset, aggressiveness of medullary thyroid cancer (MTC), and presence or absence of other endocrine neoplasms) and thus guides surveillance and management (",
"    <a class=\"graphic graphic_table graphicRef77855 \" href=\"UTD.htm?30/60/31691\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58578 \" href=\"UTD.htm?0/38/620\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef71392 \" href=\"UTD.htm?32/12/32972\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In observational studies, the 10-year survival of MTC ranges from 61 to 76 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/2,72,73\">",
"     2,72,73",
"    </a>",
"    ]. The important prognostic factors that predict adverse outcome include older age at diagnosis, extent of primary tumor, nodal disease, and distant metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. Early diagnosis by screening of &ldquo;at risk&rdquo; family members is important because MTC can be cured or prevented by early thyroidectomy.",
"   </p>",
"   <p>",
"    Based upon these observations, we suggest germline RET mutation analysis in patients with the following (",
"    <a class=\"graphic graphic_table graphicRef65295 \" href=\"UTD.htm?40/12/41163\">",
"     table 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinically proven MEN2 syndrome",
"     </li>",
"     <li>",
"      MTC or pheochromocytoma and a family member with MTC or pheochromocytoma",
"     </li>",
"     <li>",
"      Apparently sporadic MEN2-related tumors and young age (&lt;35 years), multicentric tumors in one organ,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      two different organs affected; it can be considered in all patients with sporadic MTC",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    RET mutation analysis should also be performed in first and second degree family members of MEN2 patients. (See",
"    <a class=\"local\" href=\"#H1589724\">",
"     'Screening of family members in MEN2 kindreds'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For the index patient, all exons should be sequenced, starting with exons 10, 11, 13, 14, 15, and 16. If no germline mutation is found, only a small risk of hereditary MTC remains. In this case, tumor DNA can be analyzed. In sporadic MTC, somatic mutations (within the tumor cells) in codon 883 or 918 occur relatively frequently and identification of one of these mutations argues against, but does not exclude, hereditary disease. Conversely, mutations in cysteine codons in exon 10 or 11 are uncommon in sporadic MTC and are suggestive of hereditary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1589724\">",
"    <span class=\"h1\">",
"     SCREENING OF FAMILY MEMBERS IN MEN2 KINDREDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, pentagastrin and calcium stimulation tests were used to stimulate calcitonin secretion by thyroid C cells, and assess for the diagnosis of MTC in family members. However, RET-mutation screening is available for MEN2 and, therefore, these tests have lost their clinical significance with respect to diagnosis of MEN2 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/76\">",
"     76",
"    </a>",
"    ]. Genetic testing in known MEN2 families has several clinically important advantages over the pentagastrin or calcium tests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It provides clinical benefit that should accrue from earlier surgery for known MEN2 gene carriers, as the genotype correlates with the age at initial diagnosis of MTC (",
"      <a class=\"graphic graphic_table graphicRef58578 \" href=\"UTD.htm?0/38/620\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38871?source=see_link\">",
"       \"Multiple endocrine neoplasia type 1: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It definitively establishes that an individual does not carry the MEN2 mutation and eliminates the need for biochemical testing.",
"     </li>",
"     <li>",
"      It avoids unnecessary thyroidectomy in genetically normal subjects in MEN2 families. It is now clear, from retrospective DNA testing, that such subjects can have falsely positive pentagastrin tests [",
"      <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/77,78\">",
"       77,78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, biochemical tests are still used in family members with particular RET mutations that confer a lower risk of developing MTC in childhood. In patients with low risk mutations, prophylactic thyroidectomy is performed after an abnormal stimulation test result is observed. (See",
"    <a class=\"local\" href=\"#H3039235\">",
"     'Biochemical testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1590765\">",
"    <span class=\"h2\">",
"     Genetic screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family members of patients with germline RET mutations require genetic testing and assessment for medullary thyroid cancer. In general, the primary and most compelling purpose of such screening in human tumor predisposition syndromes is to prevent disease-related morbidity and mortality that would otherwise occur [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/1,2,72,73\">",
"     1,2,72,73",
"    </a>",
"    ]. A family member who has not inherited the specific RET mutation that causes that family&rsquo;s MTC needs no further evaluation. For those with RET mutations, prophylactic thyroidectomy in family members is timed based upon the specific DNA mutation in the RET proto-oncogene occurring in the family. The risk-benefit equation is strengthened by the ease of thyroid hormone replacement after thyroidectomy, and the relatively low morbidity of the surgery, even in children, when performed by high-volume surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/79\">",
"     79",
"    </a>",
"    ]. The timing of prophylactic thyroidectomy is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8872?source=see_link&amp;anchor=H6#H6\">",
"     \"Approach to therapy in multiple endocrine neoplasia type 2\", section on 'Prophylactic thyroidectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an MEN2 family, a sample from one subject already known to be affected should be tested in order to determine the specific RET mutation for that family. All subjects of unknown status in that family should then be definitively genotyped. RET genotyping requires only a small blood sample, and can therefore be performed at birth or soon thereafter. At the latest, genotyping should be done before the time at which prophylactic thyroidectomy would be performed in the event of a positive result. However, there is no universal agreement as to the optimal time for thyroidectomy in a child with a positive RET DNA test [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/28,77\">",
"     28,77",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Timing of surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Thus far, family screening efforts appear to be suboptimal, as a high proportion of patients continue to receive less than optimal initial surgical treatment. According to the population-based Surveillance, Epidemiology, and End Results (SEER) registry, there has been no change in stage at diagnosis or significant improvement in survival noted over the last 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Although the SEER registry does not contain information regarding hereditary or biochemical results, an estimated 50 percent had a familial form of MTC. This suggests that many",
"    <span class=\"nowrap\">",
"     MEN2/FMTC",
"    </span>",
"    patients underwent surgery that was less than optimal for stage of the disease. Summary information concerning MEN2 may be useful for counseling patients and affected families. Family alliances can provide such information:",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    or",
"    <a class=\"external\" href=\"file://www.endocrineweb.com/MEN/MEN2.html\">",
"     www.endocrineweb.com/MEN/MEN2.html",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Sensitivity/specificity",
"    </span>",
"    &nbsp;&mdash;&nbsp;One potential problem relates to the rare MEN2 families with no detectable RET mutation. In addition, as with any genetic test, other potential sources of error exist such as sample mix-up, cross contamination of the polymerase chain reactions used in the tests, and DNA polymorphisms that would prevent amplification of one RET allele, a situation that could result in a false-negative screening test. To date, however, neither false-negative nor false-positive RET tests have been described in MEN2 families in which a specific RET mutation was detected in an index case.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Availability of genetic diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic diagnosis of MEN2A, FMTC, and MEN2B is readily available commercially. A list of testing laboratories is available at the MD Anderson Cancer Center web site (",
"    <a class=\"external\" href=\"file://www.mdanderson.org/\">",
"     www.mdanderson.org",
"    </a>",
"    ), and through the Genetic Testing Resource (",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    ). In Europe, a listing of commercial laboratories can be found at",
"    <a class=\"external\" href=\"file://www.eddnal.com/\">",
"     www.eddnal.com",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Clinicians should inquire as to the protocol and methodology of the offered RET DNA test. One important issue is whether all relevant exons (exons 10, 11, and 16, and, if those are negative, exons 8, 13, 14, and 15) will be sequenced if the RET mutation in that family is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before blood samples are taken for DNA analysis, detailed information about the consequences of DNA analysis must be provided to the family. Psychological support may well be needed before DNA test results are disclosed and during follow-up after diagnosis. Written consent must be obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/82\">",
"     82",
"    </a>",
"    ]. Given the rarity of this disease and the potential complications of a total thyroidectomy in young children, all patients should be referred to academic centers with expertise in MEN2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Reproductive options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MEN2 and a known familial RET mutation should be counseled that prenatal testing and preimplantation genetic testing are available options if they choose to pursue fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/2\">",
"     2",
"    </a>",
"    ]. Prenatal testing is performed in the first or second trimester via chorionic villus sampling or amniocentesis, respectively. Preimplantation genetic diagnosis (PGD) is done as part of in vitro fertilization; single embryonic cells are tested for the RET mutation. Only embryos without a RET mutation are then transferred to the uterus. The various reproductive options available to prospective parents require thoughtful discussion and genetic counseling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Timing of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is not universal agreement, one suggested approach for timing of prophylactic thyroidectomy in children with a RET germline mutation (which is in general agreement with American Thyroid Association guidelines), is based upon the specific DNA mutation in the RET proto-oncogene occurring in the family (",
"    <a class=\"graphic graphic_table graphicRef71392 \" href=\"UTD.htm?32/12/32972\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/2,82-84\">",
"     2,82-84",
"    </a>",
"    ]. These RET mutations can be categorized as highest, high, intermediate, and low risk, referring to the potential risk for local and distant metastases at an early age. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8872?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to therapy in multiple endocrine neoplasia type 2\", section on 'Timing of surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3039235\">",
"    <span class=\"h2\">",
"     Biochemical testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increasing availability of DNA analysis for the detection of mutations in the RET gene (eg, by nucleotide sequence analysis or single-strand conformation polymorphism [SSCP] analysis) is a highly specific method for the identification of subjects with familial MTC. DNA testing has made biochemical screening largely obsolete [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The C cell has specific but different receptors for gastrin and calcium on its surface (GR and CSR). In the past, biochemical screening was traditionally performed using intravenous pentagastrin (no longer available in many countries) or calcium, which stimulate calcitonin secretion from malignant or hyperplastic parafollicular C cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are, however, problems with relying on biochemical testing. False-positive tests can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/77,78,87\">",
"     77,78,87",
"    </a>",
"    ]. Because stimulation testing has been traditionally used for prospective screening in MEN2 families, some subjects have had \"false-positive\" tests that were mistakenly interpreted to indicate that they had MEN2 and that led to inappropriate thyroidectomy. In addition, a negative biochemical test in a child at risk for MEN2 reflects only that disease is not currently detectable; the child might still have inherited the mutant MEN2 gene. Modern screening with molecular methods for the RET proto-oncogene should obviate these problems, permitting specific diagnosis in patients in whom biochemical tests might be equivocal and identify individuals with pre-clinical disease (see",
"    <a class=\"local\" href=\"#H1590678\">",
"     'Indications for genetic testing'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, for closely related MEN2 or FMTC family members who refuse DNA analysis for themselves or their children, biochemical testing is an alternative option. If biochemical testing is used, yearly testing until at least age 35 years (or until a positive test occurs) is necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/5\">",
"     5",
"    </a>",
"    ]. Where available, pentagastrin is the preferred stimulation test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1624290\">",
"    <span class=\"h3\">",
"     Pentagastrin stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pentagastrin stimulation test uses a slow intravenous injection of pentagastrin (0.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    body weight) over three minutes. Blood samples for calcitonin are obtained at baseline and two and five minutes after pentagastrin infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. If stimulated CT values are &ge;200",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    MTC is likely and thyroidectomy and lymphadenectomy is required. If values are &lt;100",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    the risk of MTC is low and periodic monitoring of basal and stimulated serum calcitonin levels is recommended. If the stimulated calcitonin values are between 100 and 200",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    the risk is uncertain. Such values could be indicative of C cell hyperplasia or micro MTC. Some advise surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/90,91\">",
"     90,91",
"    </a>",
"    ], others observation (following CT levels) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects of pentagastrin include abdominal cramping, extremity paresthesia, and feeling of warmth, lasting up to one to two minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/89\">",
"     89",
"    </a>",
"    ]. Pentagastrin is not available in many countries, including the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3039577\">",
"    <span class=\"h3\">",
"     Calcium stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcium stimulation test uses an infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    (2.5 mg elemental",
"    <span class=\"nowrap\">",
"     calcium/kg",
"    </span>",
"    body weight over 30 seconds) administered in a fasting state (no food after midnight) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/77,89\">",
"     77,89",
"    </a>",
"    ]. Blood samples for calcitonin are obtained at baseline and two and five minutes after the stimulus. The most common side effects are temporary flushing and feeling of warmth (98 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/89\">",
"     89",
"    </a>",
"    ]. Facial paresthesias are less common (20 percent).",
"   </p>",
"   <p>",
"    Owing to the unavailability of pentagastrin in many countries, there is growing interest in the calcium stimulation test. However, there are few data using the calcium stimulation as a confirmatory test in patients with elevated basal calcitonin levels, and cut points for the discrimination of normal, C cell hyperplasia, and MTC have not been standardized [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/92\">",
"     92",
"    </a>",
"    ]. In one study, basal and stimulated calcitonin levels were measured in over 100 patients with thyroid disease (MTC in remission or persistence, RET gene mutation carriers, nodular goiter) and in 16 healthy volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/93\">",
"     93",
"    </a>",
"    ]. In all groups, the levels of calcitonin (CT) stimulated by either pentagastrin or calcium were significantly correlated. In this study, calcium stimulated calcitonin levels above 32.6",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (females) and 192",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (males) had the best accuracy to differentiate normal subjects from patients with C cell hyperplasia or MTC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/16/22794/abstract/93\">",
"     93",
"    </a>",
"    ]. Criteria for abnormal calcitonin values may vary in local or commercial laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple endocrine neoplasia type 2 (MEN2) is subclassified into three distinct syndromes: MEN2A, MEN2B, and familial medullary thyroid cancer (FMTC). The genetic defect in these disorders involves the RET proto-oncogene on chromosome 10.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MEN2A is an autosomal dominant disorder characterized by medullary thyroid cancer (MTC), pheochromocytoma, and primary parathyroid hyperplasia. As expected from its autosomal dominant inheritance pattern, men and women are affected in equal proportions. In a patient with only one or two of the clinical features, identification of a germline RET mutation or the identification of the clinical features of MEN2A in other first degree relatives is required to make the diagnosis of MEN2A. (See",
"      <a class=\"local\" href=\"#H3038677\">",
"       'MEN2A'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While the penetrance of MTC is nearly 100 percent, there is much inter- and intra-family variability in the other manifestations of MEN2A. For the index patient with MTC, preoperative testing should include measurement of serum calcium (to rule out hyperparathyroidism requiring concomitant surgical intervention) and testing for pheochromocytoma. If the initial testing is negative, it is important to evaluate the index patient for pheochromocytoma and hyperparathyroidism regularly (",
"      <a class=\"graphic graphic_table graphicRef77855 \" href=\"UTD.htm?30/60/31691\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Medullary thyroid cancer'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Pheochromocytoma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Primary hyperparathyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MEN2B is also an autosomal dominant disorder characterized by MTC and pheochromocytoma, but not hyperparathyroidism. MTC occurs in almost all patients. The tumor develops at an earlier age and is more aggressive than in MEN2A; as a result, early diagnosis and prevention are crucial. The syndrome also includes mucosal neuromas, typically involving the lips and tongue, intestinal ganglioneuromas, and a Marfanoid habitus. Disturbances of colonic function are common, including chronic constipation and megacolon. Unlike patients with Marfan's syndrome, MEN2B patients do not have ectopia lentis or aortic abnormalities. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Medullary thyroid cancer'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Pheochromocytoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      FMTC is a variant of MEN2A in which there is a strong predisposition to MTC but not the other clinical manifestations of MEN2A (or 2B). Distinguishing FMTC from MEN2A may be difficult in small families and, therefore, rigorous criteria for FMTC should be used in order not to miss a pheochromocytoma (see",
"      <a class=\"local\" href=\"#H23352513\">",
"       'Familial medullary thyroid cancer'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Advances in the molecular genetics underlying the MEN2 syndromes have resulted in DNA testing becoming the optimal test for their detection (",
"      <a class=\"graphic graphic_table graphicRef65295 \" href=\"UTD.htm?40/12/41163\">",
"       table 5",
"      </a>",
"      ). In contrast to MEN1, in which the long-term benefit of early diagnosis by genetic screening is not well established, early diagnosis by screening of \"at-risk\" family members in MEN2 kindreds is important because identification of specific RET mutations predicts particular phenotypes (age of onset, aggressiveness of medullary thyroid cancer [MTC], and presence or absence of other endocrine neoplasms) and thus guides surveillance and management (",
"      <a class=\"graphic graphic_table graphicRef77855 \" href=\"UTD.htm?30/60/31691\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef58578 \" href=\"UTD.htm?0/38/620\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef71392 \" href=\"UTD.htm?32/12/32972\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1590678\">",
"       'Indications for genetic testing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8872?source=see_link\">",
"       \"Approach to therapy in multiple endocrine neoplasia type 2\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In an MEN2 family, a sample from one subject already known to be affected should be tested in order to determine the specific RET mutation for that family. When (as is usually the case) a germline RET mutation is found, all subjects of unknown status in that family should then be definitively genotyped. RET genotyping requires only a small blood sample, and can therefore be performed at birth or soon thereafter. At the latest, genotyping should be done before the time at which prophylactic thyroidectomy would be performed in the event of a positive result (",
"      <a class=\"graphic graphic_table graphicRef71392 \" href=\"UTD.htm?32/12/32972\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1589724\">",
"       'Screening of family members in MEN2 kindreds'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One approach for timing of prophylactic thyroidectomy in children with MEN2A and FMTC is based upon the specific DNA mutation in the RET proto-oncogene occurring in the family (",
"      <a class=\"graphic graphic_table graphicRef71392 \" href=\"UTD.htm?32/12/32972\">",
"       table 4",
"      </a>",
"      ). These mutations may be categorized as high, intermediate, and low risk, referring to the potential risk for local and distant metastases at an early age. This is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8872?source=see_link&amp;anchor=H7#H7\">",
"       \"Approach to therapy in multiple endocrine neoplasia type 2\", section on 'Timing of surgery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Periodic clinical monitoring of carriers of an MEN2 mutation for pheochromocytoma and hyperparathyroidism depends upon the specific mutation in the RET gene (",
"      <a class=\"graphic graphic_table graphicRef77855 \" href=\"UTD.htm?30/60/31691\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pheochromocytoma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Primary hyperparathyroidism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/1\">",
"      Frank-Raue K, Rondot S, Raue F. Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC. Mol Cell Endocrinol 2010; 322:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/2\">",
"      American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/3\">",
"      Hoff AO, Catala-Lehnen P, Thomas PM, et al. Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest 2002; 110:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/4\">",
"      Tiegs RD, Body JJ, Barta JM, Heath H 3rd. Plasma calcitonin in primary hyperparathyroidism: failure of C-cell response to sustained hypercalcemia. J Clin Endocrinol Metab 1986; 63:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/5\">",
"      Raue F, Frank-Raue K, Grauer A. Multiple endocrine neoplasia type 2. Clinical features and screening. Endocrinol Metab Clin North Am 1994; 23:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/6\">",
"      Parthemore JG, Bronzert D, Roberts G, Deftos LJ. A short calcium infusion in the diagnosis of medullary thyroid carcinoma. J Clin Endocrinol Metab 1974; 39:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/7\">",
"      Bugalho MJ, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol 2005; 91:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/8\">",
"      Bhanot P, Yang J, Schnadig VJ, Logro&ntilde;o R. Role of FNA cytology and immunochemistry in the diagnosis and management of medullary thyroid carcinoma: report of six cases and review of the literature. Diagn Cytopathol 2007; 35:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/9\">",
"      Kudo T, Miyauchi A, Ito Y, et al. Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens. Thyroid 2007; 17:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/10\">",
"      LiVolsi VA. C cell hyperplasia/neoplasia. J Clin Endocrinol Metab 1997; 82:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/11\">",
"      Verga U, Ferrero S, Vicentini L, et al. Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia? Endocr Relat Cancer 2007; 14:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/12\">",
"      Albores-Saavedra JA, Krueger JE. C-cell hyperplasia and medullary thyroid microcarcinoma. Endocr Pathol 2001; 12:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/13\">",
"      Wolfe HJ, Delellis RA. Familial medullary thyroid carcinoma and C cell hyperplasia. Clin Endocrinol Metab 1981; 10:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/14\">",
"      Costante G, Filetti S. Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease? Oncologist 2011; 16:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/15\">",
"      Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 1984; 63:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/16\">",
"      Karges W, Dralle H, Raue F, et al. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 2004; 112:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/17\">",
"      O'Riordain DS, O'Brien T, Crotty TB, et al. Multiple endocrine neoplasia type 2B: more than an endocrine disorder. Surgery 1995; 118:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/18\">",
"      Quayle FJ, Fialkowski EA, Benveniste R, Moley JF. Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 2007; 142:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/19\">",
"      Peppa M, Boutati E, Kamakari S, et al. Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene. Eur J Endocrinol 2008; 159:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/20\">",
"      Bethanis S, Koutsodontis G, Palouka T, et al. A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A. Hormones (Athens) 2007; 6:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/21\">",
"      Mian C, Barollo S, Zambonin L, et al. Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation. Fam Cancer 2009; 8:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/22\">",
"      Pinna G, Ghiani M, Mariotti S. Asymptomatic bilateral adrenal pheochromocytoma in a patient with a germline V804M mutation in the RET proto-oncogene. Clin Endocrinol (Oxf) 2008; 68:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/23\">",
"      Neumann HP, Berger DP, Sigmund G, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993; 329:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/24\">",
"      Webb TA, Sheps SG, Carney JA. Differences between sporadic pheochromocytoma and pheochromocytoma in multiple endocrime neoplasia, type 2. Am J Surg Pathol 1980; 4:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/25\">",
"      Pomares FJ, Ca&ntilde;as R, Rodriguez JM, et al. Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma. Clin Endocrinol (Oxf) 1998; 48:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/26\">",
"      Evans DB, Lee JE, Merrell RC, Hickey RC. Adrenal medullary disease in multiple endocrine neoplasia type 2. Appropriate management. Endocrinol Metab Clin North Am 1994; 23:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/27\">",
"      Lips CJ, Minder WH, Leo JR, et al. Evidence of multicentric origin of the multiple endocrine neoplasia syndrome type 2a (Sipple's syndrome) in a large family in the Netherlands. Diagnostic and therapeutic implications. Am J Med 1978; 64:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/28\">",
"      Utiger RD. Medullary thyroid carcinoma, genes, and the prevention of cancer. N Engl J Med 1994; 331:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/29\">",
"      Kinlaw WB, Scott SM, Maue RA, et al. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2005; 63:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/30\">",
"      Pigny P, Cardot-Bauters C, Do Cao C, et al. Should genetic testing be performed in each patient with sporadic pheochromocytoma at presentation? Eur J Endocrinol 2009; 160:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/31\">",
"      Bae SJ, Kim DJ, Kim JY, et al. A rare extracellular D631Y germline mutation of the RET proto-oncogene in two Korean families with multiple endocrine neoplasia 2A. Thyroid 2006; 16:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/32\">",
"      Dourisboure RJ, Belli S, Domenichini E, et al. Penetrance and clinical manifestations of non-hotspot germline RET mutation, C630R, in a family with medullary thyroid carcinoma. Thyroid 2005; 15:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/33\">",
"      Learoyd DL, Gosnell J, Elston MS, et al. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations. Clin Endocrinol (Oxf) 2005; 63:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/34\">",
"      Eisenhofer G, Lenders JW, Linehan WM, et al. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 1999; 340:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/35\">",
"      Arnold A. RET mutation screening in sporadic pheochromocytoma. J Clin Endocrinol Metab 1996; 81:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/36\">",
"      Brauch H, Hoeppner W, J&auml;hnig H, et al. Sporadic pheochromocytomas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret protooncogene. J Clin Endocrinol Metab 1997; 82:4101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/37\">",
"      Bar M, Friedman E, Jakobovitz O, et al. Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Hippel-Lindau and RET genes. Clin Endocrinol (Oxf) 1997; 47:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/38\">",
"      Jim&eacute;nez C, Cote G, Arnold A, Gagel RF. Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab 2006; 91:2851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/39\">",
"      Casc&oacute;n A, L&oacute;pez-Jim&eacute;nez E, Landa I, et al. Rationalization of genetic testing in patients with apparently sporadic pheochromocytoma/paraganglioma. Horm Metab Res 2009; 41:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/40\">",
"      Mannelli M, Castellano M, Schiavi F, et al. Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab 2009; 94:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/41\">",
"      Maher ER, Yates JR, Harries R, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990; 77:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/42\">",
"      Walther MM, Herring J, Enquist E, et al. von Recklinghausen's disease and pheochromocytomas. J Urol 1999; 162:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/43\">",
"      Eisenhofer G, Walther MM, Huynh TT, et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 2001; 86:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/44\">",
"      Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003; 88:2656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/45\">",
"      Unger N, Pitt C, Schmidt IL, et al. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol 2006; 154:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/46\">",
"      Schuffenecker I, Virally-Monod M, Brohet R, et al. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs &agrave; Calcitonine. J Clin Endocrinol Metab 1998; 83:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/47\">",
"      O'Riordain DS, O'Brien T, Grant CS, et al. Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery 1993; 114:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/48\">",
"      Raue F, Kraimps JL, Dralle H, et al. Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 1995; 238:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/49\">",
"      Gagel RF, Tashjian AH Jr, Cummings T, et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 1988; 318:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/50\">",
"      Snow KJ, Boyd AE 3rd. Management of individual tumor syndromes. Medullary thyroid carcinoma and hyperparathyroidism. Endocrinol Metab Clin North Am 1994; 23:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/51\">",
"      Pausova Z, Soliman E, Amizuka N, et al. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 1996; 81:2711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/52\">",
"      Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994; 6:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/53\">",
"      Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996; 276:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/54\">",
"      Vierhapper H, Rondot S, Schulze E, et al. Primary hyperparathyroidism as the leading symptom in a patient with a Y791F RET mutation. Thyroid 2005; 15:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/55\">",
"      Heath H 3rd, Sizemore GW, Carney JA. Preoperative diagnosis of occult parathyroid hyperplasia by calcium infusion in patients with multiple endocrine neoplasia, type 2a. J Clin Endocrinol Metab 1976; 43:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/56\">",
"      Gagel RF, Levy ML, Donovan DT, et al. Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med 1989; 111:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/57\">",
"      Kousseff BG, Espinoza C, Zamore GA. Sipple syndrome with lichen amyloidosis as a paracrinopathy: pleiotropy, heterogeneity, or a contiguous gene? J Am Acad Dermatol 1991; 25:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/58\">",
"      Wong CK, Lin CS. Friction amyloidosis. Int J Dermatol 1988; 27:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/59\">",
"      Robinson, MF, Furst, EJ, Nunziata, V, et al. Evidence for a neurological defect in the MEN 2A/cutaneous lichen amyloidosis syndrome. Bone Mineral 1992; 17(Suppl 1):91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/60\">",
"      Verga U, Fugazzola L, Cambiaghi S, et al. Frequent association between MEN 2A and cutaneous lichen amyloidosis. Clin Endocrinol (Oxf) 2003; 59:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/61\">",
"      Schuchardt A, D'Agati V, Larsson-Blomberg L, et al. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 1994; 367:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/62\">",
"      Pachnis V, Mankoo B, Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 1993; 119:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/63\">",
"      Avantaggiato V, Dathan NA, Grieco M, et al. Developmental expression of the RET protooncogene. Cell Growth Differ 1994; 5:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/64\">",
"      Ceccherini I, Romei C, Barone V, et al. Identification of the Cys634--&gt;Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis. J Endocrinol Invest 1994; 17:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/65\">",
"      Hofstra, R, Stelwagen, T, Stulp, R, et al. RET mutations in MEN 2 associated diseases. Am J Hum Genet 1994; 55:A60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/66\">",
"      Rothberg AE, Raymond VM, Gruber SB, Sisson J. Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis. Thyroid 2009; 19:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/67\">",
"      B&uuml;tter A, Gagn&eacute; J, Al-Jazaeri A, et al. Prophylactic thyroidectomy in pediatric carriers of multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma: mutation in C620 is associated with Hirschsprung's disease. J Pediatr Surg 2007; 42:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/68\">",
"      Fialkowski EA, DeBenedetti MK, Moley JF, Bachrach B. RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds. J Pediatr Surg 2008; 43:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/69\">",
"      Moore SW, Zaahl M. Familial associations in medullary thyroid carcinoma with Hirschsprung disease: the role of the RET-C620 \"Janus\" genetic variation. J Pediatr Surg 2010; 45:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/70\">",
"      Wells SA Jr, Dilley WG, Farndon JA, et al. Early diagnosis and treatment of medullary thyroid carcinoma. Arch Intern Med 1985; 145:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/71\">",
"      Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/72\">",
"      Cupisti K, Wolf A, Raffel A, et al. Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution's experience over 20 years. Ann Surg 2007; 246:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/73\">",
"      Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'&eacute;tude des tumeurs &agrave; calcitonine. Clin Endocrinol (Oxf) 1998; 48:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/74\">",
"      Miccoli P, Minuto MN, Ugolini C, et al. Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer. Endocr Relat Cancer 2007; 14:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/75\">",
"      Baloch ZW, LiVolsi VA. Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma. Thyroid 2001; 11:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/76\">",
"      Lips CJ, H&ouml;ppener JW, Thijssen JH. Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement. Ann Clin Biochem 2001; 38:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/77\">",
"      Lips CJ, Landsvater RM, H&ouml;ppener JW, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994; 331:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/78\">",
"      Hern&aacute;ndez G, Sim&oacute; R, Oriola J, Mesa J. False-positive results of basal and pentagastrin-stimulated calcitonin in non-gene carriers of multiple endocrine neoplasia type 2A. Thyroid 1997; 7:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/79\">",
"      Sosa JA, Tuggle CT, Wang TS, et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab 2008; 93:3058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/80\">",
"      Kebebew E, Greenspan FS, Clark OH, et al. Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg 2005; 200:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/81\">",
"      Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006; 107:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/82\">",
"      Lips CJ, H&ouml;ppener JW, Van Nesselrooij BP, Van der Luijt RB. Counselling in multiple endocrine neoplasia syndromes: from individual experience to general guidelines. J Intern Med 2005; 257:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/83\">",
"      Marini F, Falchetti A, Del Monte F, et al. Multiple endocrine neoplasia type 2. Orphanet J Rare Dis 2006; 1:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/84\">",
"      Machens A, Dralle H. Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg 2007; 31:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/85\">",
"      Decker RA, Peacock ML, Borst MJ, et al. Progress in genetic screening of multiple endocrine neoplasia type 2A: is calcitonin testing obsolete? Surgery 1995; 118:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/86\">",
"      Mulligan LM, Ponder BA. Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 1995; 80:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/87\">",
"      Marsh DJ, McDowall D, Hyland VJ, et al. The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families. Clin Endocrinol (Oxf) 1996; 44:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/88\">",
"      Herrmann BL, Schmid KW, Goerges R, et al. Calcitonin screening and pentagastrin testing: predictive value for the diagnosis of medullary carcinoma in nodular thyroid disease. Eur J Endocrinol 2010; 162:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/89\">",
"      Doyle P, D&uuml;ren C, Nerlich K, et al. Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults. J Clin Endocrinol Metab 2009; 94:2970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/90\">",
"      Daniels GH. Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada. Thyroid 2011; 21:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/91\">",
"      Milone F, Ramundo V, Chiofalo MG, et al. Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels. Clin Endocrinol (Oxf) 2010; 73:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/92\">",
"      Kudo T, Miyauchi A, Ito Y, et al. Serum calcitonin levels with calcium loading tests before and after total thyroidectomy in patients with thyroid diseases other than medullary thyroid carcinoma. Endocr J 2011; 58:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/16/22794/abstract/93\">",
"      Colombo C, Verga U, Mian C, et al. Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. J Clin Endocrinol Metab 2012; 97:905.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7870 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-D795AC79FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_16_22794=[""].join("\n");
var outline_f22_16_22794=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3038677\">",
"      MEN2A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Medullary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H962026\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13656953\">",
"      Fine needle aspiration cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13656946\">",
"      Serum calcitonin concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1590908\">",
"      - Evaluation after diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13657053\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - RET mutation in sporadic pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Other causes of familial pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Phenotype of MEN2 versus vHL syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Etiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1589672\">",
"      Other associated diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Cutaneous lichen amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hirschsprung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23352631\">",
"      MEN2B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23352513\">",
"      FAMILIAL MEDULLARY THYROID CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1590678\">",
"      INDICATIONS FOR GENETIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1589724\">",
"      SCREENING OF FAMILY MEMBERS IN MEN2 KINDREDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1590765\">",
"      Genetic screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Sensitivity/specificity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Availability of genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Counseling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Reproductive options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Timing of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3039235\">",
"      Biochemical testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1624290\">",
"      - Pentagastrin stimulation test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3039577\">",
"      - Calcium stimulation test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7870\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7870|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/2/25634\" title=\"picture 1\">",
"      MTC surgical specimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/6/30831\" title=\"picture 2\">",
"      Medullary thyroid carcinoma FNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/63/5108\" title=\"picture 3\">",
"      Secondary C cell hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/55/20343\" title=\"picture 4\">",
"      Neoplastic C-cell hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/55/32629\" title=\"picture 5\">",
"      Pheo in adrenal gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/21/5457\" title=\"picture 6\">",
"      Pheo surgical specimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/25/11679\" title=\"picture 7A\">",
"      Cutaneous lichen amyloid general view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/7/25714\" title=\"picture 7B\">",
"      Cutaneous lichen amyloid close-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7870|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/5/23643\" title=\"table 1\">",
"      Classification MTC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/60/31691\" title=\"table 2\">",
"      Monitoring MEN2 FMTC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/38/620\" title=\"table 3\">",
"      MEN2 genotype timing progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/12/32972\" title=\"table 4\">",
"      MEN2 timing thyroidectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/12/41163\" title=\"table 5\">",
"      Indication RET mutation analysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8872?source=related_link\">",
"      Approach to therapy in multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26489?source=related_link\">",
"      Causes and pathophysiology of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23288?source=related_link\">",
"      Chemotherapy and immunotherapy for medullary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=related_link\">",
"      Classification and genetics of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=related_link\">",
"      Congenital aganglionic megacolon (Hirschsprung disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/43/695?source=related_link\">",
"      Hemangioblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9560?source=related_link\">",
"      Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38263?source=related_link\">",
"      Medullary thyroid cancer: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38871?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=related_link\">",
"      Paragangliomas of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21351?source=related_link\">",
"      Pheochromocytoma in genetic disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_16_22795="Scoring system for dysmenorrhea";
var content_f22_16_22795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Verbal multidimensional scoring system for assessment of dysmenorrhea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        Working ability",
"       </td>",
"       <td class=\"subtitle1\">",
"        Systemic symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Analgesics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 0: Menstruation is not painful and daily activity",
"is unaffected",
"       </td>",
"       <td>",
"        Unaffected",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 1: Menstruation is painful but seldom inhibits",
"normal activity; analgesics are seldom required; mild pain",
"       </td>",
"       <td>",
"        Rarely affected",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Rarely required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 2: Daily activity is affected; analgesics",
"required and give sufficient relief so that absence from school is",
"unusual; moderate pain",
"       </td>",
"       <td>",
"        Moderately affected",
"       </td>",
"       <td>",
"        Few",
"       </td>",
"       <td>",
"        Required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 3: Activity clearly inhibited; poor effect of",
"analgesics; vegetative symptoms (headache, fatigue, vomiting, and",
"diarrhea); severe pain",
"       </td>",
"       <td>",
"        Clearly inhibited",
"       </td>",
"       <td>",
"        Apparent",
"       </td>",
"       <td>",
"        Poor effect",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Andersch, B, Milsom, I, Am J Obstet Gynecol 1982; 144:655.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_16_22795=[""].join("\n");
var outline_f22_16_22795=null;
var title_f22_16_22796="Differential diagnosis Cogans";
var content_f22_16_22796=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of Cogan's syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inflammatory eye disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlamydial infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lyme disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes simplex and varicella zoster infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leprosy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycobacterium tuberculosis infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inner ear dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meniere disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune hearing loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebellopontine angle tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perilymphatic fistulas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demyelinating disease (eg, multiple sclerosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Both eye and inner ear disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whipple's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vogt-Koyanagi-Harada syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KID (keratitis, ichthyosis, and deafness) syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sj&ouml;gren's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-phospholipid antibody syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyarteritis nodosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relapsing polychondritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beh&ccedil;et's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcerative colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crohn's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system lymphoma/leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retinocochleocerebral vasculopathy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_16_22796=[""].join("\n");
var outline_f22_16_22796=null;
var title_f22_16_22797="Rx strep endocarditis II";
var content_f22_16_22797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested regimens for therapy of native valve endocarditis due to strains of viridans streptococci and Streptococcus bovis relatively resistant to penicillin G (Minimum Inhibitory Concentration &gt;0.12 &micro;g/mL and &le;0.5 &micro;g/mL)*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        American Heart Association",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        British Society for Antimicrobial Chemotherapy",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        European Society of Cardiology",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Adult (for patients with normal renal function)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pediatric (not to exceed dose of normal adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Either",
"         </strong>",
"         aqueous penicillin G 24 million units per 24 h IV either continuously or in 4 or 6 equally divided doses for 4 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ceftriaxone 2 g per 24 h IV or IM in 1 dose for 4 wks",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &Delta;",
"         </sup>",
"         3 mg/kg per 24 h IV or IM in 1 dose or in 2 to 3 equally divided doses for 2 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         <strong>",
"          Monotherapy with",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         30 mg/kg per 24 h IV in 2 equally divided doses for 4 wks; not to exceed 2 g per 24 h unless concentrations in serum are inappropriately low",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Either",
"         </strong>",
"         aqueous penicillin G 300,000 units/kg per 24 h IV in 4 or 6 equally divided doses for 4 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ceftriaxone 100 mg/kg per 24 h IV or IM in 1 dose for 4 wks",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &Delta;",
"         </sup>",
"         &nbsp;3 mg/kg per 24 h IV or IM in 1 dose or in 3 equally divided doses for 2 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         <strong>",
"          Monotherapy with",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         &nbsp;40 mg/kg per 24 h IV in 2 or 3 equally divided doses for 4 wks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Benzylpenicillin",
"         <sup>",
"          &sect;",
"         </sup>",
"         2.4 g every 4 h IV for 4 to 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin 1 mg/kg every 12 h IV for 2 wks",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Either",
"         </strong>",
"         aqueous penicillin G 24 million units per 24 h IV in 6 equally divided doses for 4 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Amoxicillin 200 mg/kg per 24 h IV in 4 or 6 equally divided doses for 4 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ampicillin 12 g per 24 h (200 mg/kg per 24 h) in 6 equally divided doses for 4 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         &nbsp;30 mg/kg per 24 h IV in 2 equally divided doses for 4 wks",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &Delta;",
"         </sup>",
"         &nbsp;3 mg/kg per 24 h IV or IM in 1 dose for first 2 wks",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     h: hours; IV: intravenously; IM: intramuscularly; wks: weeks.",
"     <br>",
"      * Patients with endocarditis caused by penicillin-resistant (MIC &gt;0.5 &micro;g/mL) strains should be treated with a regimen recommended for enterococcal endocarditis. European society of cardiology (ESC) guideline recommendations are applicable to strains having penicillin MIC 0.125 &micro;g/mL up to 2 &micro;g/mL.",
"      <br>",
"       &bull; Pediatric doses (should not exceed adult doses): aqueous penicillin G 200,000 units/kg per 24 h IV in 4 or 6 divided doses; amoxicillin 300 mg/kg per 24 h IV in 4 or 6 divided doses; ceftriaxone, vancomycin and gentamicin dosing recommendations are same as American Heart Association, pediatric.",
"       <br>",
"        &Delta; Renal function and gentamicin serum concentrations should be monitored at least once per week. Gentamicin dosage adjusted for peak serum concentration 3-4 &micro;g/mL, trough &lt;1 &micro;g/mL when 2-3 divided doses used; when given in a single daily dose, pre-dose (trough) concentrations should be &lt;1 &micro;g/mL and post-dose (peak, one hour after injection) serum concentrations should be approximately 10-12 &micro;g/mL.",
"        <br>",
"         &loz; Vancomycin therapy only recommended for patients allergic to penicillins and cephalosporins; dose adjusted for peak serum concentrations (1 h after infusion completed) of 30-45 &micro;g/mL and pre-dose (trough) concentration of 10-15 &micro;g/mL.",
"         <br>",
"          &sect;Amoxicillin 2 g every 4 to 6 h may be used in place of benzylpenicillin 1.2 to 2.4 g every 4 h.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Circulation 2005; 111:3167; J Antimicrob Chemother 2012; 67:269; Eur Heart J 2009; 30:2369.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_16_22797=[""].join("\n");
var outline_f22_16_22797=null;
var title_f22_16_22798="Regression CAD chol lowering";
var content_f22_16_22798=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Effect of cholesterol lowering therapy on regression of coronary disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 281px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The difference between the change in minimum lumininal diameter (MLD) with drug treatment (DR) compared with placebo (PL) therapy in recent angiographic trials of lipid lowering. Except for HARP, the difference in MLD change between placebo and drug patients is comparable across the range of mean baseline LDL-cholesterol concentrations. All trials were double blind except HARP and all tested an HMG-CoA reductase inhibitor. An additional drug was used in HARP and LCAS.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Herd, JA, Ballantyne, CM, Farmer, JA, et al, for the LCAS Investigators, Am J Cardiol 1997; 80:278",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_16_22798=[""].join("\n");
var outline_f22_16_22798=null;
var title_f22_16_22799="Uncommon fast slow AVNRT";
var content_f22_16_22799=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Uncommon fast-slow variant of atrioventricular nodal reentrant tachycardia (AVNRT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagrammatic representation in the circuit (left panel) and the ladder diagram (right panel) of the uncommon form of AVNRT (fast-slow variant). Antegrade conduction is through the fast (F) pathway and retrograde conduction is through the slow (S) pathway. Because of slow retrograde activation of the atrium, the P wave occurs after the QRS complex with a long RP interval and relatively short PR interval before the next QRS complex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_16_22799=[""].join("\n");
var outline_f22_16_22799=null;
